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Abstract
Role of the host cell in the type III translocation of Pseudomonas aeruginosa
exoenzyme S
Elizabeth A. Rucks
Exoenzyme S (ExoS) is a bifunctional toxin that is directly translocated into eukaryotic
cells by the Pseudomonas aeruginosa (Pa) type III secretory (T3S) process. The Nterminal region of ExoS includes a GTPase activating protein (GAP) activity and the Cterminal region includes an ADP-ribosyltransferase (ADPRT) activity. The T3Stranslocation (T3S-T) of ExoS allows the bacteria to directly manipulate host cell
function, thereby contributing the virulence of Pa. A cell culture model of infection was
developed to study the effects of ExoS on cell function, which differentiates the effects
of ExoS expression from other bacterial effects. Previous studies found that ExoS
inactivates cell function, and this inactivation was largely attributed to the ADPRT
activity. Bacterially translocated ExoS (T3S-T-ExoS) was also found to ADP-ribosylate a
number of low molecular weight G-proteins (LMWG-proteins) within the cell. While the
effects of T3S-T-ExoS on cell function were characterized, the role of the host cell in the
T3S process remained unknown. Studies described in this dissertation characterize
host cell influences in the targeting of ExoS ADPRT activity to specific eukaryotic
substrates, characterize host cell mechanism of resistance to ExoS, and examine
mechanisms associated with differences in host cell influence on T3S-T-ExoS ADPRT
activity. Results from these studies identified two main patterns of T3S-T ExoS ADPribosylation of eukaryotic proteins, a model system to examine the host cell influence on

the Pa T3S-T process, and a method of tracking intracellular ExoS by examining ExoSeukaryotic protein interactions. Combined, these studies expand previous knowledge
about the host cell influence on the Pa T3S-T process and provide methods to
understand host cell mechanisms targeting T3S effector activity.
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Chapter 1: Literature Review
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Pseudomonas aeruginosa: Pseudomonas aeruginosa (Pa) is a gram-negative
rod-shaped bacterium with a single polar flagellum (181). It is a ubiquitous
environmental organism, which inhabits terrestrial, freshwater and marine habitats. Soil
is thought to be primary ecological niche of Pa (83), where it plays a role in decay and
degradation. Despite its association with life-threatening illness, Pa causes disease only
upon gaining access to compromised plants, animals or humans. In the environment,
Pa can colonize plants and healthy animals without disease (83, 118, 181) and is only
overtly cytotoxic to phagocytic amoebae, presumably as a means of self-preservation
(84). The success of Pa as an opportunistic pathogen closely correlates with its
versatility as an environmental organism. Correspondingly, genes encoding regulation
and environmental sensing proteins make up 8.4% of its 6.3 Mbp genome (225).
Additionally, Pa can utilize many different types of compounds as a source of energy,
produce multiple virulence factors, tolerate a wide range of temperatures, and, notably,
is intrinsically resistant to a large number of antibiotics (83, 138, 140, 166, 181, 248).
Since the late 1800’s, Pa had been linked to infections of wounds and surgical
dressings. However, William Osler was the first to observe that the organisms inhabited
previously damaged tissues and were not the primary cause of the infection, thus
characterizing Pa as an opportunistic pathogen (181). In the 1960’s, Pa emerged as a
major human pathogen due to its ability to infect cystic fibrosis and burn patients.
Illustrating the opportunistic nature of Pa infections, Donald D. Stieritz and Ian Alan
Holder developed an experimental burned mouse model (224). Mice were subjected to
a nonlethal burn by ethanol flame, and the LD50 for Pa was determined after
subcutaneous injection at the burn site at various time points from 0 hours to 7 days,
2

after the initial burn. The LD50 of control mice (mice not sustaining burn injury) was 1.3 x
106 organisms. Inoculation of burn sites with fewer than 10 organisms resulted in death
of 50% of the animals tested within the first 18 hours. However, the longer the recovery
period (i.e. 24 hours to 7 days) before the tissue was inoculated with Pa, the closer the
LD50 was to control mice. Interestingly, burned mice inoculated with Pa at nonburned
skin sites were the least susceptible to Pa-associated morbidity and mortality, as
compared to unburned mice (224). These studies validated the notion that Pa causes
infections by gaining direct access to damaged tissues. In recent years, Pa has been
reported to infect neutropenic recipients of chemotherapy, immunosuppressed
individuals with AIDS, or drug addictions. However, Pa infections are primarily
nosocomial and typically associated with severe burn victims, persons with cystic
fibrosis (CF) and persons who wear contact lenses for extended periods of time (49,
145, 181).
Pa pathogenesis: Creating a cohesive model of Pa pathogenicity is complicated by
the fact that there is no clear phenotypic or genetic delineation between environmental
and disease-associated strains (199, 251). It is likely that any Pa residing in the natural
environment has the potential to cause disease in a compromised individual. There are
three stages to Pa pathogenesis (Figure 1): (1) colonization of the compromised tissue,
(2) elaboration of virulence factors, and (3) persistence within the host. Synonymous
with the ability of Pa to colonize compromised tissues is its ability to adhere to
eukaryotic cells (253). Both bacterial and host factors are involved in Pa adherence to
host tissues. Among the bacterial factors implicated in Pa binding to damaged tissue,

3

A. Healthy airway
flow
More
viscous
Less
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B. Compromised airway
flow
Highly
viscous

1. Bacterial adherence

flow

flow
Highly
viscous

2. Elaboration of
virulence factors

Highly
viscous
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Figure 1. Model of Pa pathogenesis.
A. In a healthy, non-compromised airway, Pa may bind to the viscous mucus and be
cleared. In an alternative hypothesis, Pa binds to apical receptors, mainly CFTR, and is
internalized. Infected epithelial cells are then desquamated and removed from the lung
by the mucus (145). B. Within a compromised airway, depicted here as a CF lung, Pa is
drawn to the epithelial cells by the viscous mucus. Bacterial adherence is established,
which leads to the elaboration of virulence factors. Virulence factors are represented by
proteases (yellow crosses), exotoxin A (ETA) (red stars), and T3S effector proteins
(purple triangles). Also depicted are acyl homoserine lactones (AHLs) (small fluorescent
green circles), when the AHLs reach a threshold density, Pa forms a biofilm, where it
persists within the host. Within the biofilm, Pa loses motility as well as the ability to
express virulence factors (103, 145, 146).
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the most thoroughly studied are type IV pili and lipopolysaccharide (LPS) (185, 203,
207, 254, 265). Specifically, type IV pili and LPS were found to bind purified glycolipid
gangliotetraosylceramide (asialo GM1) (85), a receptor found on the apical surface of
epithelial cells. There is much debate within the literature about which specific factors
are necessary for adherence, and suggestions of a redundancy of Pa adherence
mechanisms or lack of receptor specificity required for bacterial binding.
Given the pathopneumonic nature of Pa infections within lungs of CF patients,
distinguishing qualities of these tissues were investigated to try to identify host factors
which facilitate bacterial binding. Affinity of Pa to CF lung tissues has been linked to
increased exposure of asialo GM1 (107, 202), resulting in increased type IV pili
receptors (204). Bolstering this hypothesis, it was found that respiratory epithelial cells
recovering from stress or injury expressed greater amounts of asialo GM1 (41). In 1997,
Pier et al. hypothesized that the CF transmembrane conductance regulator (CFTR) acts
as a receptor that internalizes Pa, thus allowing healthy individuals to clear a Pa
infection by desquamation of infected cells. However, mutant CFTR inhibited both
internalization of Pa and subsequent clearance of Pa, resulting in a persistent infection
in the lung (180). Interestingly, internalization of Pa via CFTR in corneal epithelial cells
has been linked to increased infectivity, while mutant CFTR was protective against Pa
corneal keratitis (266). Additionally, studies have found that Pa binds fibronectin and
vitronectin (135, 187, 195), concordant receptors α5β1 and αvβ5 integrins , as well as
other components of basement membranes (135, 195). Combined, these findings
support an alternative hypothesis that Pa readily infects compromised tissue because of
greater access to tight junctions and basolateral membranes (58, 59, 133).

5

Recent studies indicate that Pa utilizes membrane rafts to facilitate association with
eukaryotic cells. Membrane rafts are distinct domains on the plasma membrane that are
rich in cholesterol and sphingolipids and serve as dynamic platforms to cluster receptors
and connect them to intracellular signaling pathways. Upon purification, membrane rafts
are detergent insoluble and of low density, making them easily isolated from the rest of
the plasma membrane by differential centrifugation (213). While rafts have been
implicated in the pathogenesis of microorganisms (149), it is suggested that the use of
membrane rafts by Pa provides host protection. Studies have shown that Pa bind to
CFTR on membrane rafts and are internalized by epithelial cells. These cells are
subsequently sloughed off and Pa is cleared (82, 121). Other contradictory studies have
illustrated that Pa utilize membrane rafts during infection of type I pneumocytes in lung
alveolar sacs and corneal infection (262, 264). The lack of a consensus about adhesion
strategies used by Pa to associate with eukaryotic cells is likely illustrative of its
versatility and ability to survive in multiple diverse environments.
Once adherence to damaged tissue is established, Pa elaborates an arsenal of
virulence factors to help promote its existence within the new environment. These
virulence factors include hemolysin, elastase, alkaline protease, phospholipases,
alginate, endotoxin, exotoxin A (ETA), and two type III secretory (T3S) effectors
exoenzyme S (ExoS) and exoenzyme U (ExoU) (3, 12, 138, 140, 162-164, 212). In
general, production of these virulence factors promotes the survival of Pa by causing
tissue damage and the release of nutrients, promoting evasion from host immune
defenses, and allowing dissemination within the host (8, 138, 140, 164, 174). ETA,
which is the most toxic Pa virulence factor (138, 140), is an ADP-ribosyltransferase
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(ADPRT) that targets elongation factor-2 (EF-2) (105). Resultant ETA-ADP-ribosylation
of EF-2 inhibits cellular protein synthesis (105).
Environmental queues, such as iron, phosphate, calcium and zinc chloride,
influence the expression of multiple virulence factors, including ETA, alkaline protease,
elastase, hemolysin and the T3S pathway (60, 139, 216). For example, in contrast to
limited iron levels within the mammalian host, the natural environment provides an
abundance of iron, which contributes to the growth and survival of Pa. Therefore, to
survive within the host, Pa must have mechanisms to scavenge iron. In iron-limiting
environments, such as the environment found within the host, Pa produces ETA,
alkaline protease, elastase and siderphores. It is hypothesized that ETA and the
proteases combine to cause cellular damage, thereby releasing iron for uptake by
siderophores (239). To control the release of iron, expression of genes involved in iron
acquisition are tightly regulated. The expression of ETA and siderophores are regulated
in parallel, but independently of each other, by the repressor, Fur. In ETA regulation,
iron-bound Fur negatively regulates the extracytoplasmic sigma factor, PvdS by binding
to the promoter region of pvdS. However, in iron-limiting conditions, no repression of
pvdS transcription by Fur occurs, ultimately resulting in the expression of ETA (23, 239).
While ETA contributes significantly to tissue damage and mortality during Pa
infection, it is recognized that Pa virulence factors act in concert to promote the survival
of the microbe (164). Another virulence mechanism is the T3S pathway, which directly
translocates bacterial effector proteins into mammalian cells to alter cellular function.
Clinical isolates harboring T3S genes are associated with higher mortality and
prolonged infection (52, 200). Genetically altered strains of Pa that no longer express
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components of the T3S pathway have diminished virulence in the mouse burn model
(96). Also in mouse models of infection, immunization against a T3S component, PcrV,
which is required for effector translocation, was found to protect infected mice from
morbidity and mortality (95, 161, 196, 208). To date there are four identified Pa T3S
effector proteins, ExoS, ExoT, ExoU and ExoY (55, 258, 260, 261). Recent studies have
shown that ExoU, an acute cytotoxin and phospholipase (55, 206), is the most cytotoxic
Pa T3S effector protein (212). ExoS, a bifunctional GTPase activating (GAP) and
ADPRT protein (77, 106), interferes with clearance from the initial site of infection, and
aids in dissemination of the organism (212). Interestingly, clinical and environmental
isolates commonly harbor either the exoU or exoS gene, but not both, indicating a
mutually exclusive relationship, with exoS being more predominant than exoU (52, 54).
While the production of virulence factors is advantageous for establishing infection,
persisting within the host requires a different microbial strategy. Pa strains isolated from
chronic infections of the CF lung are notably non-motile and T3S- negative (108, 144,
148). When strains isolated from chronic infection were tested for virulence in mouse
models of infection, the majority were found to be avirulent (143). Further examination
of characteristics of clinical isolates from chronic infections revealed that microbes exist
in chronic infections as biofilms and express the rhl quorum sensing system (214).
These studies indicate a selective pressure from the host for Pa to alter its lifestyle to
persist after establishing an infection.
Biofilms are complex differentiated microbial communities. They originate from
planktonic bacteria, which adhere as a monolayer to a substratum. These bacteria
divide to form microcolonies that combine and differentiate to form fluid-filled
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macrocolonies surrounded by a matrix of polysaccharide and proteins. Pa biofilms are
resistant to phagocytosis, host antibodies and antibiotics, and contribute to chronic
infections in CF lung and cornea. In addition, biofilms can contribute to Pa
dissemination by regularly shedding single planktonic bacterium (201). The initiation of
biofilm formation requires flagella, type IV pili and twitching motility (171). The
differentiation of biofilms requires quorum sensing (247). Quorum sensing allows
microbes to communicate with one another via diffusible extracellular signals which, in
Pa, are acylated-homoserine lactones (AHLs). When cell density is high, the increased
concentration of AHLs induces a downstream signaling cascade that leads to the
expression of genes responsible for the formation of biofilms (179). While there is
evidence that quorum sensing may play a more direct role in the virulence of Pa (175,
201), it ultimately controls expression of components of a persistant infection, including
biofilm formation and alginate, which is the polysaccharide component of biofilms (11,
214, 247).
Recent studies have indicated that the inverse relationship between a virulent state
and a persistent state is genetically regulated through two main pathways. RetS, which
is a hybrid sensor kinase/response regulator, controls signaling pathways involved in
increasing the expression of the T3S pathway, type IV pili and ETA (78). In addition,
RetS activity inhibits the expression of exopolysaccharide genes involved in biofilm
matrix. Mutation of RetS results in hyperadhesion and loss of virulence mechanisms,
such as expression of the T3S pathway or type IV pili (78). Acting in opposition to RetS
is the GacS/GacA two-component regulatory system, which downregulates expression
of virulence factors, such as the T3S pathway and type IV pili, and upregulates
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components essential for biofilm formation (78, 173). Also, mutation of genes controlling
expression of quorum sensing and biofilm maturation results in an up-regulation of T3Spathway expression (16, 125). The environmental signals that control the switch
between factors favoring virulence to factors favoring biofilm formation are not yet clear.
However, it is a common supposition that the environment created by Pa after initial
infection requires further adaptation to support persistence within the host.
Our studies have focused on the T3S effector, ExoS in Pa pathogenesis. Pa is not
an overt pathogen and will only infect compromised tissues, which indicates that a
compromised host environment allows or signals the initiation of an infection. Given the
intimate interaction between the bacterium and host cell, which allows the T3Smediated translocation (T3S-T) of ExoS into the eukaryotic cell, we are interested in
understanding how the host cell influences not only the translocation of ExoS, but also
the intracellular targeting of its activity.
Characterization of ExoS: Classical bacterial toxins are classified by their AB
structure and their mechanism of action. The A portion of a toxin includes the enzymatic
activity (A subunit), and the B portion includes the cell binding and translocation
functions (B subunit). Three main AB toxin structures have been described. 1 AB toxins
are synthesized as a single polypeptide, which includes an A (active) subunit and a B
(binding) subunit. Connecting the amino-terminal A subunit to the carboxy-terminal B
subunit is translocation or T domain. Once the toxin has bound and been translocated
into the cells, the A subunit must be cleaved from the B subunit to express full catalytic
activity. 2 In ABn toxins, the B subunit is synthesized as a separate polypeptide and
forms an oligomer which binds to target host cells. The A polypeptide has a high affinity
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for the oligomer and becomes enzymatically active when an internal site is cleaved. In
these toxins, the translocation function has not yet been fully described. 3 Bipartite
toxins are comprised of two distinct soluble proteins. One of the proteins is responsible
for cell binding and membrane translocation, and the other confers enzymatic activity.
Many toxins affect host cell function by targeting and modifying eukaryotic proteins,
thereby altering their function (23).
ETA is a classical AB toxin. The single polypeptide is a 71.5 kDa proenzyme that
when denatured or proteolytically cleaved produces a 27 kDa enzymatically active
fragment (A domain) and a 45 kDa enzymatically inactive fragment (B domain) (238).
Further analysis identified 3 distinct structural domains: domains I and II for the B
domain, while domain III is the enzymatically active, A domain (4). Domain I, within the
N-terminal half of the molecule, forms an antiparallel β-structure (4) which binds to the
eukaryotic cell receptor α2-macroglobulin receptor/low density lipoprotein receptorrelated protein (α2MR/LRP) (120). The ETA proenzyme is internalized by the host cell
through receptor-mediated endocytosis (57). Once inside a vesicle, domain II, which is
composed of mainly alpha helices (4), acts to translocate the processed A-subunit into
the cytosol (109). Four sequentially formed disulfide bonds must be cleaved or
denatured to form a catalytically active ETA molecule (4, 238). Domain III, within the
carboxy-terminus, includes the ADPRT activity of ETA (4). Upon translocation to the
cytosol, ETA’s ADPRT activity targets EF-2, thereby inhibiting host cell protein synthesis
(105). ETA illustrates the efficient design of bacterial toxins, each distinct domain
confers a distinct function that contributes to the action of the molecule as a whole.
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ExoS was first identified as an ADP-ribosyltransferase distinct from ETA when more
radioactive ADP-ribose was transferred in partially purified EF-2 preparation than could
be accounted for by the calculated amount of available EF-2. ExoS was characterized in
Pa strain 388, which does not produce ETA (106). Comparisons of the ADPRT activity
of ETA to that of ExoS defined unique characteristics of ExoS. Activity was not
neutralized by anti-ETA antibody and was destroyed by pretreatment with urea (ETA
activity is promoted by urea treatment). In addition, ExoS was found to be more heatstable than ETA and did not target EF-2 (106). ExoS was found not to have one
preferred eukaryotic substrate, but to ADP-ribosylate several different targets in wheat
germ extract and reticulocyte lysates (106). In in vitro reactions, the preferential
eukaryotic target proteins of ExoS were found to belong to the Ras family of low
molecular weight G-proteins (LMWG-proteins) (10, 28, 30, 63, 65, 89, 153, 190), and
ExoS was also found to target vimentin (26). In vivo analysis of ExoS ADPRT activity
confirmed that ExoS targeted LMWG-proteins, as well as, cyclophilin A and ezrin,
radixin and moesin proteins (ERMs) within the eukaryotic cell (44, 63, 65, 89, 150, 153).
In order to ADP-ribosylate target proteins, ExoS requires a eukaryotic cofactor from the
14-3-3 protein family, for catalytic activity (29, 68, 92).
ExoS purified from culture supernatants of strain 388 was an aggregate of two
proteins of 49 and 53 kDa (106, 127, 165). Originally it was hypothesized that the 53
kDa protein was a proenzyme form of ExoS, since the 49 and 53 kDa proteins were
immunologically cross-reactive (127, 165), shared a common amino-terminus (25), and
produced common peptides following cleavage with cyanogen bromide and proteases
(104). In support of this hypothesis and consistent with toxin structure/function models,
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after extraction from an SDS-polyacrylamide gel only the 49 kDa form displayed ADPRT
activity (29, 128, 165). The common origin of the 49 kDa and 53 kDa proteins was
supported by their highly regulated coordinate expression. The production of both the
49 kDa and 53 kDa proteins by the bacterium increased or decreased in parallel with
changes in the culture medium (25, 104). Medium promoting maximal production
contained a chelator, nitrilotriacetic acid (NTA), ethylenediamine tetraacetic acid (EDTA)
(231) or ethyleneglycol tetraacetic acid (EGTA) (60). The production of both proteins
was inhibited by the addition of calcium or zinc chloride salts (60).
The cumulative data indicated that the 49 kDa and 53 kDa proteins were related,
but confirmation of their being two forms of the same protein was lacking. A genetic
approach was employed to explore if the proteins were produced by the same gene. For
this, Pa strain PA103, which produced the 53 kDa protein, but not the enzymatically
active 49 kDa protein (62) was transformed with the 49 kDa structural gene cloned from
strain 388 and cultured under inducing conditions. Both the 49 kDa and 53 kDa proteins
were produced in response to NTA (126). In addition, the allelic exchange of the 49 kDa
ExoS gene with a tetracycline gene cartridge in strain 388 (forming strain
388∆exoS::Tc), eliminated the production of 49 kDa ExoS, but the production of the 53
kDa protein was unaffected (126). This was the first data that supported that 49 kDa
ExoS and the 53 kDa protein were encoded by separate genes. An open reading frame,
termed exoT, was identified by Southern blot analysis of 388∆exoS::Tc, using exoS to
probe chromosomal digests (256). The exoT gene product was identified as the 53 kDa
protein, first known as Exo53, then later as ExoT. While ExoT shares 75% amino acid
identity to ExoS, the recombinant form of this protein displayed only 0.2% ADPRT
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activity (256, 260). Together, these studies confirmed that 49 kDa ExoS and 53 kDa
ExoT were distinct proteins, and that the 53 kDa protein was not a proenzyme form of
ExoS.
In determining the role of ExoS during the Pa infection process, a transposon Tn1
mutant of strain 388, lacking ADP-ribosyltransferase activity, was generated and found
to be 2,000-fold less virulent than the parent strain 388 (165). In an experimental mouse
burn wound model, using strain 388 and the null ExoS strain (388exs1::Tn1), the
production of ExoS did not alter the ability of Pa to colonize the site of the wound.
However, without ExoS, the organism was compromised in the ability to disseminate,
implicating ExoS at this stage of the infection process (162, 165). Yet, conflicting with
evidence that ExoS played a role in the virulence of Pa was the fact that purified ExoS
was not toxic to animals (162, 163) nor to cultured eukaryotic cells (25, 170).
Additionally, culture supernatants obtained from ExoS-producing bacteria were nontoxic
to cultured cells (7, 170). These data suggested that ExoS did not have a structural B
domain that allowed its binding or translocation into eukaryotic cells. During the mid1990’s a common conclusion was that delivery of ExoS to eukaryotic cells was by a
unique mechanism, not yet described for other toxins.
Bacterial secretion systems: To date, there are five main processes described for
a Gram-negative bacterium to secrete or transport a protein from the bacterial
cytoplasm and across the inner membrane, periplasmic space and outer membrane
(Figure 2) (88). These processes are grouped based on their dependence on the Sec
pathway of protein export. The Sec pathway, also known as the general secretory

14

Sec independent

Sec dependent

Type III

Type I

Type II

Type IV Type V

OM
P
IM
ATP

ATP
ADP

ADP

N

N

N

Sec

ATP ATP
ADP
ADP

N

ATP
ADP

Sec

C
C
C

C

Figure 2. Bacterial secretion systems.
Grouped by their dependence on Sec proteins for translocation of proteins into the
periplasmic space, types I and III secretion pathways involve the one-step secretion of
proteins, driven by inner membrane ATPases. Uncleaved signal sequences are found in
the C-terminal end of proteins destined for the type I pathway, while signal sequences
within the N-terminus identify proteins for secretion by the type III pathway. The type III
pathway also differs in that it translocates bacterial proteins across eukaryotic cell
membranes. Proteins destined for type II and V pathways contain cleavable N-terminal
consensus sequences. The proteins are processed in the periplasmic space before final
translocation across the outer membrane. Type V secreted proteins are known as
autotransporters and they oligomerize to form a pore, allowing self-translocation across
the outer bacterial membrane. Type IV secretion uses a Sec-dependent process to
translocate DNA-protein complexes and large protein complexes either outside the
bacterial cell or, via a pilus-like structure, inside the eukaryotic cell. The figure is based
on text by Stathopoulus et al., 2000 (219) and Henderson et al., 2004 (88). OM, outer
membrane; P, periplasmic space; IM, inner membrane.
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pathway, exports proteins from the bacterial cytoplasm into the periplasmic space,
utilizing an inner membrane ATPase and a chaperone protein that binds the
presecretory protein. Sec-dependent transport processes are types II, IV and V, while
Sec-independent transport processes are types I and III. All pathways are highly
conserved among Gram-negative bacterium (88, 205).
Type II secretion (T2S) occurs in two steps and requires that the secreted proteins
have a concensus signal sequence within the first 30 amino-terminal amino acids, which
targets proteins for Sec inner membrane transport. This signal sequence is then
cleaved within the periplasmic space and the protein becomes partially folded.
Transport across the outer membrane requires a multimeric outer membrane
component termed secretin (88, 102, 205). T2S was first described as the secretion
mechanism that Klebsiella aerogenes used to transport pullulanase (113, 230).
Homologous systems were later identified for other Gram-negative bacteria (205). ETA
is an example of a Pa virulence factor secreted via the type II secretory pathway (249).
The type IV secretion pathway (T4SP) is the least understood of the secretory
processes, but appears to be closely related to ancestral bacterial conjugation systems.
The T4SP allows the transfer of DNA/protein macromolecular complexes (T-DNA) from
the bacterium to the host cell (22, 88, 249). In this regard, the best characterized T4SP
is in Agrobacterium tumefaciens which utilizes membrane transport protein VirB to
secrete a single-stranded DNA molecule across bacterial membranes and into plant
cells, where the DNA integrates into the genome, ultimately resulting in tumor growth
(269). T4SP also allows the secretion of large oligomeric protein complexes, such as
the large A-B5 pertussis toxin (243). It is now thought that secretion of T-DNA occurs in
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one step, while the transfer of protein complexes occurs in two steps and utilizes the
Sec inner membrane secretion system (22, 88). The two seemingly divergent transport
pathways are classified together because the related transporters share architectural
similarities to VirB (183).
The type V secretion pathway (T5SP) describes the secretion mechanism of a
group of proteins known as autotransporters. Proteins secreted by this pathway exhibit
an extended N-terminal signal sequence that identifies the proprotein for secretion by
the Sec inner membrane translocation machinery. Once in the periplasmic space, the
signal sequence is cleaved and the remaining N-terminal portion of the molecule forms
a β-barrel structure that inserts into the bacterial outer membrane to form a pore. The Cterminal active portion of the molecule either remains attached to the pore by the linker
region or is cleaved upon secretion. It is thought that the folding of the β-barrel pore
structure provides the energy to translocate the active portion from the periplasmic
space across the outer membrane (88).
Type I secretion (T1S) is Sec-independent and is a single-step continuous process
from the bacterial cytoplasm across both inner and outer membranes. Proteins secreted
by this pathway are not processed nor do they have a periplasmic intermediate. The
secretion signal sequence is located within the C-terminal 60 amino acids. The type I
secretion complex includes an inner membrane ATPase, a channel forming membrane
fusion protein and an outer membrane pore. Examples of proteins secreted by this
process include E. coli alpha-hemolysin and Pa alkaline protease (88, 102, 205, 219).
T3S, which is also Sec-independent, displays similarities to both types I and II
secretion. T3S was recognized in the early 1990’s in association with pathogenicity
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determinates of Yersinia enterocolitica termed Yersinia outer proteins (Yops) (156).
Effector proteins secreted by this pathway do not require processing, but include a
signal for secretion within the first 10 to 15 residues (5, 88, 102, 142, 205). The T3S
secretion apparatus forms a needle-like syringe, termed the injectisome, which
translocates bacterial effector proteins in one continuous step from the bacterial
cytoplasm across the inner and outer membranes, followed by the eukaryotic host cell
membrane into the cytosol. Proteins that form the injectisome are conserved among
Gram-negative bacteria and are thought to have common evolutionary origins with
flagella (102, 147, 155, 205). T3S-effector proteins are bacterium specific, thus allowing
different bacteria to manipulate the host cell according to its unique survival needs.
Characterization of Pa ExoS secretory mechanism: Since its discovery in the
late 1970’s, the biochemical properties of ExoS have been well studied, but how ExoS
ADPRT affected eukaryotic cells remained a mystery, because the purified protein was
not toxic when added to cultured cells or administered to animals (25, 162, 163, 170).
Comparison of genes affecting ExoS production with those involved in Yersinia Yops
production helped to understand how ExoS might be affecting host cells. ExoS did not
include an N-terminal consensus signal or N-terminal processing sequences (128, 256),
indicating that the secretion of ExoS was Sec-independent. Mutations within the
carboxy-terminus and internal sequence of ExoS, that would be predicted to alter T1S,
did not alter ExoS secretion (258). However, the first nine amino-terminal residues were
necessary for ExoS secretion. The activation of a gene encoding the ExsA protein was
also absolutely required for ExoS expression. ExsA acts as a trans-regulatory protein
and contains a DNA-binding helix-turn-helix motif (61). ExsA is homologous to AraC of
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Escherichia coli and VirF/LcrF (two terms referring to the same protein) of Yersinia
enterocolitica (61, 99, 257). VirF/LcrF controls the expression of Y. enterocolitica Yops
(93, 130, 155). Dnase I-footprint analysis of promoters controlled by ExsA found the
concensus binding site of ExsA to be similar to the concensus binding sites of VirF (99).
A map depicting the organization of the Pa T3S-regulon in Figure 3 shows the clustering
of genes involved in T3S, ExsA binding sites, and the non-contiguous locations of
genes that encode the effector proteins, ExoS, ExoT, ExoY, ExoU (Figure 3).
The expression of the ExoS operon in vitro requires growth of Pa in a cationdepleted medium, similar to the medium required to promote production of Yops (231),
indicating similarities between the regulation of ExoS and Yops. The amino-terminus of
ExoS displays sequence homology to a secreted effector protein, YopE, indicating that
similarities between the Yops and ExoS systems extended beyond regulation (259). In
addition, a locus containing an ExsA-dependent promoter and encoding gene products
termed PscB-L, was identified and found to be homologous to the YscB-L proteins of
Yersinia (258). Mutations within the pscC gene prevented secretion of ExoS. PscC is
homologous to a Yersinia protein, YscC, which is involved in T3S of Yops (258). The
regulation and homology data suggested that ExoS was secreted by the T3S pathway
(258). Therefore, it was recognized that ExoS can only affect eukaryotic cell function if
translocated into the host cell after bacterial contact.
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Components of the Pseudomonas aeruginosa Type III Secretion System
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Figure 3. Organization of the Pa T3S regulon.
The individual gene products of the Pa T3S system and effector proteins, ExoU,
ExoS, ExoT and ExoY are represented by colored arrows. Different colors identify
operons based on promoter mapping, transcriptional fusion, or DNA-binding analyses.
The effectors and known chaperones (ExoU and SpcU; ExoS and Orf1; ExoT; ExoY)
are located at different sites within the chromosome, and are separate from genes
encoding proteins involved in the regulation and formation of the T3S apparatus. ExsA
consensus and imperfect binding sites are indicated. This figure was published in the
book entitled Bacterial Protein Toxins, (ed. Drusilla L. Burns, Joseph T. Barbieri,
Barbara H. Iglewski and Rino Rappuoli, ASM press, Washington D.C., 2003).
Permission to use the figure was given by ASM press and Dara Frank, who developed
the original figure.
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Structural analysis of the T3S process: The conserved nature of the T3S process
among pathogenic Gram-negative bacteria is consistent with genes encoding the T3S
pathway being obtained either through horizontal gene transfer (HGT) or from a
common ancestor. In support of the HGT hypothesis, genes encoding T3S systems
reside within plasmids or as gene clusters located in pathogenicity islands, bounded by
the remnants of insertion sequences, bacteriophage genes or transposable elements.
Pathogenicity islands are also recognized by differences in G+C content when
compared to the entire bacterial chromosome (70, 102, 249). In contrast to the T3S
regulons of other pathogenic bacteria, the G+C content of the genes encoding the Pa
T3S regulon (67.3%), is similar to the G+C content of the entire Pa genome (69%),
indicating that Pa T3S regulons do not reside on a pathogenicity island (60). This finding
is consistent with the hypothesis that T3S is not just involved in pathogenesis but an
integral Pa survival mechanism.
Translocation of proteins via the T3S pathway requires the bacterium and
eukaryotic cell to be in close contact, allowing insertion of the bacterial T3S-needle-like
apparatus into the host cell membrane (Figure 4 C). The result is the delivery of
bacterial effector proteins directly into the host cell cytosol, allowing the bacteria to
strategically hijack host cell processes (70, 76, 102). Purified T3S complexes from
Salmonella typhimurium and Shigella flexneri resemble needles (18, 124). Similarities
between flagella and the T3S apparatus are evident both structurally and based on
protein homology (Figure 4 A and B) (19, 76, 147). The base of the S. typhimurium
needle complex was observed to be similar to that of a flagellar basal body, with two
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C. T3S injectisome with the host cell

Figure 4. Comparison of flagellar and injectisome structure.
(A) Depicts the dimensions of the flagellar hook-basal body and (B) depicts the T3S
apparatus or injectisome of Salmonella. CM, bacterial cytoplasmic membrane; PG,
peptidoglycan layer; OM, bacterial outer membrane. (C) Depicts a T3S apparatus in
contact with the eukaryotic cell. The needle is drawn based on electron microscopy
images (see inset), with several ring structures spanning the inner and outer
membranes. The needle filament (green protrusion) is thought to engage a bacterial
pore-forming complex (translocator) that becomes lodged in the eukaryotic host cell
membrane. The diagram also depicts effector proteins, awaiting translocation,
associated with their cognate chaperones.
Parts A and B of the figure were originally published in Molecular Microbiology
(2005, 56(2): 303-308) in an article entitled, “Measure for measure in the control of type
III secretion hook and needle length”, authored by Tohru Minamino and Anthony P.
Pugsley. The image appears by permission of Blackwell Publishing. Part C of the figure
was originally published in Nature Reviews Molecular Cell Biology (2003, 4: 738-743) in
an article entitled, “Priming virulence factors for delivery into the host”, authored by C.
Erec Stebbins and Jorge E. Galan. The image appears by permission of Nature
publishing and C. Erec Stebbins.
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upper and two lower rings (124), with the needle portion of the complex resembling the
flagellar hook (19, 76, 147).
Interestingly, the proteins forming the needle base of the T3S process are localized
and positioned within the bacterial inner membrane, periplasmic space and outer
membrane in a Sec-dependent manner (116, 228). Further assembly of the needle
complex requires this basal body structure. Similar to the energy requirements of
functional flagella, treatment with sodium azide, which abolishes oxidative
phosphorylation, also inhibits T3S (17). The protein that makes up the outer membrane
ring of the T3S apparatus differs from the outer membrane ring of flagella. This
component, InvG, initially characterized in S. typhimurium, is a member of the secretin
family of proteins (116) (InvG is labeled OM in Figure 4B and is depicted by the yellow
box in Figure 4C). Secretins usually function alone and are involved in the transport of
large macromolecular structures, including the T2S of type IV pili components (137).
However, InvG serves a different purpose in the T3S process as it is associated with 2
other proteins consisting of the needle complex basal body (116, 228). InvG is
homologous to the Pa T3S protein, PscC, and Yersinia T3S protein YscC (60, 76).
While the exact location of PscC within the Pa T3S apparatus is currently unknown,
YscC has been found to form a stable oligomeric complex, which forms a channel in the
bacterial outer membrane (119). Pa strains lacking a functional pscC structural gene do
not secrete T3S effector proteins (258).
The needle component, first visualized by electron microscopy in S. typhimurium, is
thinner than a flagellar organelle, only 7- to 8- nm wide, and 60 nm long (124). However,
the needle-length was found to be organism specific (76). Much like a component of the
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flagellar hook apparatus, T3S needle complexes have a protein that determines the
length of the needles. These proteins lack sequence homology to the flagellar protein,
FliK, but are functional equivalents in that their mutation or deletion result in T3S
needles of variable length, with only shorter needles found incapable of T3S-T (263). A
recent study of the Y. enterocolitica needle proposes that T3S needle length is related
to the distance between bacterium and host cell created by adhesion molecules
attaching bacteria to the host cell (159).
Once the needle is assembled, certain bacteria, including S. flexneri, Yersinia, and
Pa, secrete proteins termed translocators, which form the end of the needle and insert a
channel into eukaryotic membranes (76). In S. flexneri IpaB and IpaC insert into the
host cell membrane comprising a channel for the translocation of Shigella effector
proteins (17). IpaB and IpaC share structural similarities to Yersinia proteins YopB and
YopD, respectively (17). YopB and YopD direct the translocation of effector proteins
across the host cell membrane and are functionally interchangeable with Pa proteins,
PopB and PopD (67). In Pa T3S, PopD was found to be required for the transport of
ExoS across CHO cell membranes. The lack of PopD resulted in secretion of effector
proteins from the bacterium, without translocation into eukaryotic cells (236). Attempts
at detecting PopD in eukaryotic cell membranes during a Pa infection PopD have been
unsuccessful. However, recently PopD was shown to bind to ghost erythrocyte
membranes and form oligomers and ring structures in cholesterol-rich liposomes,
indicating its potential to form pores in eukaryotic cell membranes (81, 210).
Assembly of the needle structure precedes the translocation of effector proteins.
The signal sequence targeting effectors for T3S is within the amino-terminus. However,
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whether the source of the secretion signal is an amino acid or mRNA sequence remains
controversial. Deletion of the first 15 amino acids of T3S proteins abolishes secretion
(155, 218, 250), which is consistent with either the first 15 amino acids or the mRNA
encoding this region being required for secretion. Analysis of T3S-secretion of Y.
entercolitica effector proteins revealed a role for mRNA sequence in targeting effectors
for T3S. Construction of frameshift mutations, which would alter mRNA codons
translation, but not the actual mRNA sequence in the sequence encoding YopQ, did not
block T3S (6).
Proteins translocated shortly after needle assembly are thought to be translated and
sequestered in the bacterial cytoplasm by a chaperone protein. In Salmonella, it has
been shown that chaperones maintain T3S effector proteins in a partially unfolded
confirmation, while protecting them from aggregation and degradation (220). The ability
of effector proteins to unfold prior to translocation, excludes other cytoplasmic proteins
from T3S transport (51). However, not all effector proteins have known cognate
chaperones. This is true of Pa in which ExoS and ExoU have chaperones Orf1 and
SpcU, respectively, while ExoT and ExoY do not (56, 60). Previous studies have
indicated that T3S effectors have different efficiencies when binding to chaperones,
thereby, allowing for certain effectors to be translocated before others (20). Additionally,
it has been reported that there is a translation hierarchy of T3S effectors. For example,
blockage of the Y. enterocolitica T3S pathway resulted in translation of YopE, but not
YopQ, supporting evidence that YopE is T3S-T earlier than YopQ (6). In summary,
effectors which are T3S-T early after needle assembly seem to rely on interaction with a
chaperone protein, while effectors which are T3S-T later are shuttled to the T3S
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apparatus based on their N-terminal mRNA sequence (19). A hierarchy of secretion
underscores the highly regulated manner in which bacteria can manipulate eukaryotic
cells to their benefit.
Regulation of Pa T3S. Over 40 genes, which encode regulators, apparatusstructure proteins, translocator proteins and effector proteins, are involved in the T3S
pathway (60, 70, 102). Expression of the Pa T3S pathway responds to environmental
factors such as low calcium, presence of serum or contact with the eukaryotic host cell
(60, 236). However, recent work has shown that some components of the Pa T3S
pathway are constitutively expressed at basal levels, but further induced by appropriate
environmental signals (252). Expression of the Pa T3S is also controlled by global
regulators that sense environmental changes, including adenylate cyclase and cyclic
AMP regulators (2, 215, 227, 245, 252),fimL , a member of a chemosensory pathway
(246), and retS, a hybrid sensor kinase/response regulator (78).
At the level of transcription, Pa T3S is controlled by an intricate network of bacterial
cytoplasmic regulators, ExsA, ExsD, ExsC (Figure 5) (40, 61, 152). ExsA is a
transcriptional activator that promotes the expression of Pa T3S genes (60, 61, 257).
Prior to induction of a functional T3S apparatus, ExsA is bound to ExsD, thus repressing
ExsA activity. Deletion of exsD results in constitutive expression of T3S genes. This
occurs even in the presence of a mutation affecting outer membrane protein PscC,
which prevents the formation of a functional T3S apparatus (152). Also indicating
another layer of T3S regulation, mutation of exsC results in very low T3S expression
(40, 79).
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Figure 5. Transcriptional regulation of Pa T3S.
Transcription of Pa T3S is activated by ExsA. In conditions that do not favor T3S,
such as high calcium (depicted in A), ExsD sequesters and prevents ExsA from
activating transcription of T3S genes, such as exoS. In T3S-favorable conditions
(depicted in B), ExsC recruits ExsD from ExsA, freeing ExsA to initiate transcription of
T3S genes. ExsA activity is further regulated by ExsE, which binds to ExsC in T3Sunfavorable conditions, preventing ExsC from recruiting ExsD. ExsE is thought to be the
molecular sensor of T3S-apparatus readiness. T3S-T of ExsE frees ExsC to interact
and recruit ExsD from ExsA. This diagram is based on work by Mark L. Urbanowski,
Guinevere L. Lykken and Timothy L. Yahr in a paper entitled “A secreted regulatory
protein couples transcription to the secretory activity of the Pseudomonas aeruginosa
type III secretion system”, which appeared in Proc. Natl. Acad. Sci. USA in July 2005
(102 (28): 9930-9935.
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Further analysis indicated that overexpression of exsC mimicked the deletion of exsD,
and that ExsC binds to ExsD. These data indicated that in favorable conditions, ExsC
binds to ExsD, thereby freeing ExsA to activate transcription of other T3S genes (40).
ExsC exhibits characteristics of a T3S chaperone in that it has a low molecular mass,
an acidic isoelectric point, and a carboxy-terminal amphipathic alpha-helix (51, 172).
This suggested the possibility that in unfavorable conditions for T3S, ExsC is bound to
another protein, which is secreted or translocated upon favorable T3S conditions,
thereby freeing ExsC to bind ExsD and ultimately free ExsA (40). Interestingly,
immediately downstream of exsC is an open reading frame that encodes an 8.7 kDa
protein, termed ExsE. Recent studies have shown that ExsC binds to ExsE, and ExsE is
secreted from the bacteria in low calcium conditions (191, 234). However, the absence
of ExsE does not have any affect on the regulatory activity of ExsD, indicating that there
are multiple regulatory checkpoints in the induction and expression of Pa T3S (234).
Manipulation of the host cell by T3S effector proteins: The T3S-injection of
effector proteins into the eukaryotic cell provides a mechanism for Gram-negative
bacteria to manipulate host cell function in a manner that promotes their specific lifestyle. While the structure of the T3S-apparatus is conserved among Gram-negative
bacteria, effector proteins are species specific. To evade the immune system, Yersinia
T3S-translocates multiple effector proteins which coordinately inhibit inflammation and
phagocytosis, while inducing macrophage apoptosis (36, 37). In contrast, the T3S-T of
Salmonella effectors promotes bacterial invasion into the host cell, thus allowing
intracellular propagation (37). Underlying the broad effects of T3S-T effectors on
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eukaryotic cells is the intricate manner in which they hijack host cell signaling and mimic
the activities of eukaryotic proteins (221).
One example of eukaryotic cell mimicry involves a group of T3S effectors which
function similarly to eukaryotic Rho GTPase activating proteins (GAPs). G-proteins are
molecular switches, which cycle between active, GTP-bound, and inactive, GDP-bound
states. GAPs control G-proteins by accelerating the hydrolysis of phosphate from GTP,
forming an inactive GDP-bound-G-protein (237). Rho GAP proteins target Rho, Rac and
Cdc42, proteins that control the actin cytoskeleton network (229, 237). T3S effector
proteins that have been found to contain Rho GAP activity include: Yersinia YopE (242),
Pa ExoS and ExoT (77, 122, 178), and Salmonella SptP (69). Consistent with their GAP
activities targeting Rho, Rac and Cdc42, the transfection or T3S-T of YopE, ExoS and
ExoT is associated with cell rounding/actin cytoskeleton rearrangement and
antiphagocytic effects (38, 66, 74, 178, 192, 242).
An example of multiple T3S effectors coordinately manipulating host cell function
was first illustrated with Salmonella typhimurim proteins, SptP and SopE. Epithelial cells
lining the gastrointestinal tract do not normally engulf bacteria. However, Salmonella
must enter these epithelial cells to evade the host immune system and initiate the
infectious process. T3S-T of SopE activates Rac and Cdc42, resulting in localized actin
reorganization and membrane ruffling, which stimulates the host cell to engulf the
organism (45, 86). Following internalization, S. typhymurium resides within a specialized
vacuole. To protect its new niche, the T3S effector SptP acts as a GAP towards Rac
and Cdc42, thereby reversing the effects of SopE and allowing the host cell’s actin
cytoskeleton to recover (45, 69, 221). The sequential action of SopE and SptP activities
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highlights the sophisiticated manner in which bacteria are able to usurp host cell
signaling pathways.
Structure/function relationships of T3S-T-ExoS. While ExoS was characterized
as an ADP-ribosyltransferase in 1978 (106), further examination of the functional
domains revealed that the N-terminal region of ExoS includes a GAP domain, which
targets Rho GTPases (77), while the ADPRT activity resided within the C-terminal
portion of the molecule (117). Arginine at position 146 (R146) was found to be required
for ExoS GAP activity (77). The co-crystal structure of the N-terminal GAP domain of
ExoS with Rac1 revealed that the positioning of the R146 mimics that of catalytic
arginines found in eukaryotic GAP molecules without sharing structural homology (255).
Two glutamic acid residues control ExoS ADPRT activity. In vitro kinetic analysis found
the glutamic acid at position 379 (E379) to modulate the transfer of the ADP-ribose
moiety to the target eukaryotic protein, and the glutamic acid at position 381 (E381) to
confer the NAD glycohydrolase activity (186). In vitro analysis also found that mutation
of the E381 catalytic residue inhibited in vitro ExoS ADPRT activity (186). As previously
indicated, the first nine amino acids are required for T3S-T (258). Additionally, ExoS
contains a membrane localization domain (MLD) between residues 52 and 71 (176).
Studies of Petterson et. al. support that T3S-T-ExoS is processed at a site within the
first 78 residues upon translocation into the eukaryotic cell (177). For maximal ADPRT
activity, ExoS requires interaction between amino acids 420-429 and a eukaryotic cofactor, 14-3-3 protein (90). The functional regions of ExoS are depicted in Figure 6.
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Figure 6. Linear model of ExoS.
ExoS contains 453 amino acids and consists of two separate catalytic domains.
Within the N-terminal region is the GAP activity, which targets Rho, Rac and Cdc42
(77). The ADPRT activity is within the C-terminal region (117). The first nine amino
acids of ExoS are required for T3S-translocation (258), and the region between amino
acids 52 and 71 (MLD), targets ExoS to eukaryotic membranes (176, 188). ExoS binds
its cofactor 14-3-3 between amino acids 420-429 (90).
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Since the effects of ExoS on cell function can only be realized upon T3S-T, a coculture system was developed in which established eukaryotic cell cultures are treated
with ExoS producing bacteria. To differentiate the effects of ExoS from other bacterial
factors, the effects of an ExoS producing strain (388) were compared to the effects of
an isogenic ExoS-deletion mutant strain (388∆S) (170). In co-culture analyses of
epithelial cells, T3S-T-ExoS caused a general inactivation of cell function, including an
inhibition of DNA synthesis, loss of re-adherence and cytoskeletal alterations (169). In
other cell culture models of infection, ExoS has been implicated as a cytotoxin and an
anti-phagocytic or anti-invasive factor (38, 66, 192). The complex effects of ExoS on
eukaryotic cell function are believed to relate to its bi-functional mode of action. The
GAP activity of ExoS has been linked to transient cytoskeletal alterations (178) and
antiphagocytic capabilities (66, 192), while the ADPRT activity of ExoS was found to be
required for the effects of T3S-T-ExoS on human epithelial cell DNA synthesis, readherence and permanent cytoskeletal alterations (64).
T3S-T-ExoS ADPRT activity targets multiple cellular LMWG-proteins (63, 65, 89,
153). Ras was the first cellular protein to be identified as a substrate by T3S-T-ExoS
ADPRT activity. ADP-ribosylation of Ras results in an alteration in protein mobility
detected by SDS-PAGE and two-dimensional electrophoresis (2DE). To confirm that the
alteration in mobility related to the transfer of an ADP-ribose moiety, in vitro reactions,
which included purified ExoS, recombinant Ras, 14-3-3 and NAD were performed, and
the alteration in Ras mobility corresponded to that caused by T3S-T-ExoS. Additionally,
when cellular pools of NAD were radiolabeled, and cells were incubated with ExoS
producing bacteria radiolabeled ADP-ribose was transferred to immunoprecipitated Ras.
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This study confirmed that T3S-T-ExoS ADP-ribosylates cellular Ras (153). Using a
similar strategy to identify other LMWG-proteins ADP-ribosylated by ExoS, in vivo and
in vitro ExoS ADPRT reactions were performed and alterations in protein mobility were
compared by SDS-PAGE and 2DE. These studies led to the identification of RalA,
Rab5, Rab7, Rab8, Rab11 and Rac1, but not Rab4 or Rho as cellular substrates of
T3S-T-ExoS ADPRT activity (Figure 7) (63, 65). Cdc42, a member of the Rho family of
proteins, was also ADP-ribosylated by T3S-T-ExoS, but not as efficiently as other
proteins examined (65). Notably, Rab4 was not ADP-ribosylated by T3S-T-ExoS, but
was ADP-ribosylated by ExoS in vitro (30, 65), indicating that the host cell confers T3ST-ExoS target protein specificity. More recent studies have also identified non-LMWGprotein targets of T3S-ExoS ADPRT activity including ezrin/radixin/moesin proteins,
which help regulate actin cytoskeleton structure, (150), and cyclophilin A, a peptidylprolyl cis-trans isomerase (44).
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Figure 7. Proteins ADP-ribosylated by ExoS.
(A and C) In vivo analysis: HT-29 cells were grown to 50-65% confluency and cocultured with 1 x 107 colony forming units (cfu)/ml of 388 or 388∆S (∆S) for 4 to 5 hours.
To examine Ras modification, cells were lysed and Ras was immunoprecipitated from
cell lysates. To examine other proteins, eukaryotic cells were lysed in Laemmli sample
buffer (129). Samples were resolved by SDS-PAGE and probed for the indicated
LMWG-protein by Western blot analysis. (B) In vitro analysis: 1 µg of purified protein (HRas or Rac1) or 50 µl of HT-29 cell lysates (Rab proteins) were incubated without or
with 0.2 µM purified ExoS, 10 mM NAD and a source of 14-3-3 protein. Reactions were
terminated by the addition of 4X Laemmli sample buffer and heated at 95ºC prior to
resolution by SDS-PAGE and Western blot analysis. Relative molecular mass of the
LMWG-proteins, and ADP-ribosylated (M) and un-ADP-ribosylated (U) proteins are
indicated. The results are representative of multiple independent studies.
This figure originally was originally published in Biochem. Biophys. Res. Commun
(291: 91-100, 2002) in an article entitled, “Eukaryotic cell determination of ExoS ADPribosyltransferase substrate specificity” by J. E. Fraylick, E. A. Rucks, D. M. Greene, T.
S. Vincent and J. C. Olson. The figure and selected text from the original figure legend
appears with permission by Elsevier Science (USA).
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To determine if the cellular localization of the LMWG-proteins influences ADPribosylation by ExoS, HT-29 cells were fractionated into S100, cytosol, and P100
membrane fractions following treatment with ExoS producing bacteria. Proteins that
localize to the plasma membrane fraction, like RalA and Rab5, were the first to be ADPribosylated by T3S-T-ExoS (65). These results are consistent with the notion that the
MLD of ExoS targets ExoS to eukaryotic membranes where its ADPRT activity is
enhanced (176, 188). The cellular fractionation studies revealed a different finding
relative to the ADP-ribosylation of Rac1, which localizes primarily to the cytosol. While
Rac1 was ADP-ribosylated in both the cytosolic and membrane fractions (193), the
majority of T3S-T-ExoS ADP-ribosylated Rac1 was found in the membrane fraction (65,
193).
Since the cellular localization of LMWG-proteins appeared to influence the targeting
ExoS ADPRT activity in the membrane fraction (65, 193). Time course studies were
performed to examine trafficking patterns of ExoS ADPRT activity within HT-29 cells
(Figure 8). After a 3 hour exposure to ExoS-producing bacteria, Ras and RalA, both of
which localize primarily to the plasma membrane, displayed small shifts in mobility, as
did Rab5, which localizes to early endosomes. By 4 hours, Rab8 and Rab11, both of
which localize to recycling endosomes, were ADP-ribosylated. The last proteins to be
modified by T3S-T-ExoS, following a 5 hour exposure to bacteria, were Rab7, which
localizes to late endosomes, and Rac1, which is primarily a cytosolic protein that cycles
to the plasma membrane when GTP-bound (65). Combined, these studies indicate that
features of the host cell determine the specificity and order in which eukaryotic proteins
are targeted by T3S-T-ExoS ADPRT activity.
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Figure 8. Time course analysis of T3S-T-ExoS substrate modification.
HT-29 cells were co-cultured with strain 388 or 388∆S (∆S) for 2 to 5 hours.
Substrate modification was analyzed as described in Figure 7. The results compare
substrate modification on the same samples from one experiment, and are
representative of studies performed three times. The mobilities of ADP-ribosylated
proteins (M) and unmodified proteins (U) are indicated.
This figure originally was originally published in Biochem. Biophys. Res. Commun
(291: 91-100, 2002). The title of the article is, “Eukaryotic cell determination of ExoS
ADP-ribosyltransferase substrate specificity” and authors are J. E. Fraylick, E. A. Rucks,
D. M. Greene, T. S. Vincent and J. C. Olson. The figure and selected text from the
original figure legend appears with permission by Elsevier Science (USA).
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ExoS was found to ADP-ribosylate specific arginine residues within eukaryotic
substrates (30). The arginine residues targeted are often within functional domains of
the LMWG-proteins involved in guanine nucleotide binding. This is the case for Ras,
RalA, and Rac1 (63, 71, 193, 241). In assessing the consequences of ExoS ADPribosylation, Ras modification was linked to the effects of ExoS on DNA synthesis. In
addition, a direct correlation was observed between the severity of the effect of ExoS on
DNA synthesis and the efficiency of Ras ADP-ribosylation (153). In concordance with
this finding, ADP-ribosylation of Ras was found to inhibit its ability to interact with its
guanine nucleotide exchange factor (GEF), which activates G-proteins by exchanging
GTP for GDP. Additionally, T3S-T-ExoS ADP-ribosylation of Ras interfered with its
interaction with downstream effector Raf-1, thereby interfering with activation of the
MAP-kinase, Erk-2 pathway that leads to cellular proliferation (73, 92, 241). However,
mutating R41 in Ras, which prevents T3S-T-ExoS ADP-ribosylation at the site of Ras
that interferes with GEF interaction, did not inhibit the effects of ExoS on DNA synthesis
(J.C. Olson and T.S. Vincent, unpublished observation). These results support that
ExoS ADP-ribosylation of Ras does not alone explain the effects of ExoS on DNA
synthesis.
RalA is involved in signaling processes that affect cell proliferation, vesicular
transport and cytoskeletal structure (50, 158, 226, 229). ADP-ribosylation of RalA by
ExoS was found to inhibit interaction with its downstream effector Ral binding protein 1
(63), implicating modification of RalA in the cellular effects elicited by ExoS. Rab
proteins control distinct pathways in endocytosis and vesicular trafficking that affect
membrane recycling (194). In vitro analysis found the ADP-ribosylation of Rab5 by
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ExoS to interfere with its ability to bind EEA1, retarding endosome-endosome fusion
(10). Thus, T3S-T-ExoS has the potential to interfere with multiple cell signaling
pathways. It has been difficult for investigators to assign a individual target proteins to
each phenotype caused by ExoS ADP-ribosylation since there is cross-talk between
many of these pathways. However, it is likely that the effects of ExoS on proliferation,
cytoskeleton and readherence mechanisms relate to the targeting of multiple eukaryotic
cell substrates.
The examination of multiple human cell lines has identified differences in cellular
sensitivities to T3S-T-ExoS. Normal, confluent, polarized epithelial monolayers were
found to be highly resistant to the effects of T3S-T-ExoS (58, 154). However, when
these cell monolayers were disrupted with EDTA-treatment or tested subconfluently,
cells became sensitive to the effects of T3S-T-ExoS and ADP-ribosylation of Ras was
observed (154). In examining the effects of ExoS producing bacteria on epithelial cell
lines derived from different tissues, it was noted that tumor-derived cell lines were highly
sensitive to the effects of ExoS on cell growth (Figure 9) (154). The detection of cellular
differences in sensitivity to T3S-T-ExoS, along with the finding that alterations in cellular
physiology can affect sensitivity to ExoS, supported the notion that eukaryotic cell
factors can influence the T3S-T and ultimately the toxicity of ExoS. The purpose of the
studies in this dissertation is to examine the host cell role in the T3S-T of ExoS, and
subsequent cellular targeting of T3S-T-ExoS ADPRT activity.
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Figure 9. Differential effects of T3S-T-ExoS on DNA synthesis.
Different cell lines were assayed for the effect of T3S-T-ExoS on DNA synthesis
based on [3H]Thymidine incorporation after a 4 to 5 hour co-culture with strains 388 or
388∆S (170). The difference in inhibition of DNA synthesis between non-ExoS
producing strain, 388∆S, and ExoS producing strain, 388, is attributed to an ExoS
specific effect on DNA synthesis. Data shown is representative of studies performed
multiple times and the mean and standard deviation of [3H]Thymidine incorporation
relative to non-bacterial treated controls are shown.
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Research Objectives:
Hypothesis:
The host cell can influence the T3S-T of effector proteins at the level of
membrane translocation or, once translocated, through the intracellular targeting
of effector protein activity.
Specific Aim 1: To characterize eukaryotic cell differences in the function and substrate
specificity of ExoS ADPRT activity when translocated by Pseudomonas T3S.
Specific Aim 2: To determine the cellular mechanism associated with phorbol esterinduction of sensitivity in T3S-ExoS-resistant HL-60 cells.
Specific Aim 3: To determine the mechanism associated with ExoS substrate specificity
as it may relate to the trafficking, processing or localization of ExoS within the
eukaryotic cell.
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Chapter 2: Cell line differences in bacterially translocated ExoS ADPribosyltransferase substrate specificity

Contents of this chapter were originally published in 2003 in Volume 149 of
Microbiology, pages 319-331 and appear with permission from the Society for General
Microbiology. Authors of the published manuscript are E. A. Rucks, J. M. Fraylick, L. M.
Brandt, T. S. Vincent, and J. C. Olson.
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Abstract
Exoenzyme S (ExoS) is an ADP-ribosyltransferase (ADPRT) directly translocated
into eukaryotic cells by the type III secretory (T3S) process of Pseudomonas aeruginosa
(Pa). Comparisons of the effects of ExoS on human epithelial and murine fibroblastic
cells found that human epithelial cells exhibited an overall increased sensitivity to the
effects of bacterially translocated ExoS on cell proliferation, morphology and readherence. ExoS was also found to ADP-ribosylate a greater number of low molecular
weight G- (LMWG-) proteins in human epithelial cells, as compared to murine
fibroblasts. Examination of the mechanism for differences in ExoS ADPRT substrate
modification found that the more restricted pattern of substrate modification in murine
fibroblasts was not linked to the efficiency of bacterial adherence or to the efficiency of
ExoS internalization by the T3S process. In exploring the nature of patterns of substrate
modification, more extensive substrate modification was detected in human and simian
cell lines, while rodent cell lines, including rat, mouse and hamster, consistently
exhibited the more limited pattern of LMWG-protein ADP-ribosylation. Patterns of
substrate modification were not altered by transformation and occurred independently of
cell type. These studies suggest that properties related to the animal origin of eukaryotic
cells affect the substrate targeting of ExoS ADPRT activity, and that this in turn can
influence the severity of effects of ExoS on host cell function.
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Introduction
Pa is a ubiquitous environmental organism that can thrive in a variety of
environmental niches, including soil, rivers, and biofilms. If it is allowed to transverse
normal physical or immunological barriers, Pa can adapt to become a highly virulent
opportunistic pathogen. The success of Pa as an opportunistic pathogen relates to its
ability to produce a large number of virulence factors and to its high antibiotic
resistance. One virulence factor produced by Pa, ExoS, is an ADPRT that is directly
translocated into eukaryotic cells by the T3S process (258). Although the precise role of
ExoS in Pa virulence is not fully understood, the exoS gene is found in a majority of
clinical isolates (52), and there is a 6-fold greater risk of mortality associated with the
expression of T3S effectors, including ExoS, in Pa lower respiratory and systemic
infections (196). In cell culture models of infection, ExoS has been implicated as an antiphagocytic or anti-invasive factor (38, 66). In analyses of epithelial cells, bacterial
translocation (T3S-T) of ExoS has been associated with a general inactivation of cell
function, including an inhibition of DNA synthesis, loss of re-adherence and cytoskeletal
alterations (169).
The complex effects of ExoS on eukaryotic cell function are believed to relate to its
bi-functional mode of action. ExoS includes a GTPase activating (GAP) function within
its amino-terminus (77), and an ADPRT activity within its carboxy-terminus (117). The
GAP activity of ExoS has been linked to cytoskeletal alterations (178), while the ADPRT
activity of ExoS is required for the effects of T3S-T-ExoS on human epithelial cell DNA
synthesis, re-adherence and long-term cytoskeletal alterations (64). When translocated
by T3S, ExoS ADPRT activity targets multiple cellular LMWG-proteins (63, 65, 153) and
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requires a eukaryotic cofactor, 14-3-3, for catalytic activity (29, 68, 90). ADP-ribosylation
of cellular targets, Ras and RalA, has been found to interfere with their respective signal
transduction pathways (63, 73, 91, 241), thereby linking a cellular mechanism to the
effects of ExoS on eukaryotic cell function. Recent studies have drawn attention to
possible modulatory influences the eukaryotic cell can have on ExoS function. Notably,
ExoS ADPRT activity was found to be enhanced in the membrane compartment of
epithelial cells when T3S-T (64, 188). In addition, an E381A mutant form of ExoS, which
is unable to ADP-ribosylate Ras in vitro, was found to modify Ras when translocated
into cells by the T3S process.
The examination of multiple human epithelial cell lines has identified differences in
cellular sensitivities to T3S-T-ExoS. Normal, confluent, polarized epithelial monolayers
were found to be highly resistant to the effects of T3S-T-ExoS (58, 154). However,
when normal epithelial cell monolayers were disrupted or subconfluent, cells became
sensitive to ExoS (154). In examining the effects of ExoS producing bacteria on
epithelial cell lines derived from different tissues, it was noted that tumor-derived cell
lines were highly sensitive to the effects of ExoS on cell growth (154). The detection of
cellular differences in sensitivity to T3S-T-ExoS, along with the finding that alterations in
cellular physiology can affect sensitivity to ExoS, support the notion that eukaryotic cell
factors can influence the toxicity of ExoS.
To clarify how the eukaryotic cell might contribute to the toxicity of T3S-T-ExoS, we
examined how different cell lines compared in their response to ExoS producing
bacteria. Our studies found murine fibroblasts to be more resistant to the effects of
ExoS than human epithelial cells. The increased resistance of murine fibroblastic cells
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to ExoS was associated with less efficient ADP-ribosylation of cellular substrates by
ExoS, and occurred independently of detectable differences in the efficiency of T3S-T of
ExoS. In examination of a rodent, simian, and human cell lines, distinct patterns of ExoS
ADPRT substrate modification were detected, with human cell lines showing both more
efficient and more extensive LMWG-protein substrate modification. These studies
support that once internalized, host cell properties can influence the substrate specificity
of ExoS ADPRT activity, which corresponds with alterations in the severity of effects of
ExoS on cell function.
Methods and Materials
Bacterial strains and culture conditions. Pa strains used in this study include the
prototype ExoS producing strain 388 (106) and its isogenic mutant, strain 388∆exoS,
which lacks ExoS production due to an allelic exchange of the majority of the exoS
structural gene for a tetracycline resistance gene cartridge (126). Complementation
studies have confirmed that differences in the effects of strains 388 and 388∆S on
eukaryotic cell function relate to the production of ExoS (169). To further rule out the
role of ExoT in our analyses (which is expressed by strains 388 and 388∆S) a
388∆ExoT mutant (256) was included in all experiments as a control. All bacterial
strains used in this study were kindly provided by Dara Frank from the Medical College
of Wisconsin, Milwaukee, WI. Bacteria were grown and prepared for co-culture studies
with eukaryotic cells as previously described (153, 170).
Eukaryotic cell culture. CHO-K1, Cos-1, Detroit 532, HT-1080, HT-29, LNCaP, NIH3T3, Swiss-3T3, TCMK-1, T24 and Vero cells used in this study were obtained from the
American Type Culture Collection (ATCC; Rockville, MD). RHEC cells were provided by
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Carwile LeRoy, and WI-38 and WI-38 SV40 transformed cells were kindly provided by
Daohong Zhou, both from the Medical University of South Carolina, Charleston, SC.
Characteristics of cell lines used in this study are shown in Table 1. Cell lines were
cultured, as described below, in their respective medium containing 10% v/v fetal bovine
serum (FBS) and 100 units/ml penicillin and 100 µg/ml streptomycin (PS) at 37°C in 5%CO2-95% air. All cell culture media and components were purchased from Gibco-BRL
(Gaithersburg, MD).
Epithelial cell lines. CHO-K1 cells (ATCC CCL 61) were cultured in Ham’s F12K
medium and split 1:6 at confluency and passaged. HT-1080 (ATCC CCL-121), RHEC,
TCMK-1 (ATCC CCL 139), and Vero cells (ATCC CCL 81) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM), split 1:6-1:10 at confluency and passaged. HT-29
cells (ATCC HTB 38) were maintained in McCoy’s 5A medium, as previously described
(169). LNCaP cells (ATCC CRL 1740) were cultured in RPMI medium and split 1:4 at
confluency and passaged. T24 cells (ATCC HTB 4) were grown in McCoy’s 5A medium,
split 1:6 at confluency and passaged twice weekly.
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Table 1. LMWG-protein substrate modification by T3S-T-ExoS in different cell
lines.
*Cell type, immortality and tumorgenicity as indicated by the ATCC, except for the
RHEC cell line, which was obtained from Carwile LeRoy. † +, ADP-ribosylation by
ExoS; ++, two ExoS ADP-ribosyl-modified isoforms; -, not ADP-ribosylated by ExoS. ‡
SV-40 transformed.
Fibroblastic cell lines. Detroit 532 cells (ATCC CCL 54) were grown in RPMI medium
and maintained as previously described (170). Cos-1 cells (ATCC CRL 1650), NIH-3T3
cells (ATCC CRL 1658), Swiss-3T3 cells (ATCC CCL 92), WI-38 and WI-38 SV40
transformed (WI-38t) were cultured in DMEM and split 1:6 and passaged twice a week.
Co-culture of eukaryotic cells with bacteria. For bacterial/eukaryotic cell co-culture
studies, eukaryotic cells were detached with 0.05% w/v trypsin-0.53 mM EDTA (trypsinEDTA) and seeded at 1 x 105 cells/ml in 6, 24 or 48-well plates or culture dishes
(Costar; Cambridge, MA). Cells were grown for either 24 hours or 48 hours (depending
on the growth rate of the cell line) to obtain 60-80% confluency prior to co-culture with
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bacteria. Strain 388 or 388∆S bacteria were diluted, based on culture OD590, to 1x107
cfu/ml in medium specific for each eukaryotic cell line containing 0.6% w/v bovine serum
albumin (BSA). A multiplicity of infection (MOI). range of 10 to 100 was used in these
studies, unless otherwise indicated, and bacteria were co-cultured with eukaryotic cells
for 2 to 6 hours. Control cells received the respective medium with no bacteria. Effects
of bacteria on eukaryotic cell function were analyzed as described below.
Quantification of DNA synthesis. Following a 4 hour co-culture period, bacteria were
removed and cells were washed with culture medium containing 10% FBS, 200 µg/ml
gentamicin and 100 µg/ml ciprofloxacin (GC-medium) to inhibit further bacterial growth.
Cells were pulsed for 20 hours in GC-medium containing 1 µCi/ml [methyl-3H]thymidine
(25 Ci mmol-1; Amersham, Arlington Heights, IL). DNA synthesis was quantified as
previously described (170) and is reported as the percent of [3H]thymidine incorporated
relative to that of non-bacterial treated control cells.
Analysis of cell viability. Cell viability was examined following a 3, 4.5 and 6 hour coculture period, after which bacteria were removed, and total cell viability was determined
by trypan blue exclusion immediately after removal of bacteria and following an
extended 20 hour culture period in GC medium.
Examination of cell morphology. To compare long-term effects of ExoS on cellular
morphology, cells were co-cultured with bacteria for 4 hours, bacteria were removed,
cells were washed with PBS and cultured in GC-medium for an additional 20 hours.
Morphological alterations were examined by phase contrast microscopy.
Analysis of eukaryotic cell adherence. The effects of ExoS producing bacteria on
eukaryotic cell adherence to matrix were assessed after a 2 to 6 hour co-culture period
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by quantifying adherent and non-adherent cells, using trypan blue exclusion, 20 or 40
hours after bacteria were removed. To assess the effects of ExoS on re-adherence,
cells were detached with trypsin-EDTA following co-culture with bacteria, washed,
resuspended in GC-medium, re-plated and allowed to re-adhere for 20 hours (HT-29,
NIH-3T3, Swiss-3T3 cells) or 48 hours (LNCaP cells). (LNCaP cells were previously
recognized to require a longer adherence time (98)). The number and viability of nonadherent and trypsinized, adherent cells were determined after this time based on
trypan blue exclusion. The percentage of viable and non-viable, adherent or nonadherent cells was calculated relative to total cell number.
Bacterial association with eukaryotic cells. To compare the adherence of bacteria to
different eukaryotic cell lines, cells were seeded in 24-well plates, as described above,
and co-cultured with bacteria at a MOI of approximately 200:1 for 4.5 hours (HT-29,
NIH-3T3, and Swiss-3T3 cells) or 3 hours (LNCaP cells). (The limited time of exposure
of LNCaP cells related to their increased sensitivity to bacterial effects on cell viability.)
Bacteria were removed, and 1 ml HEPES buffered saline (HBS) (137 mM NaCl, 4 mM
KCl, 10 mM Hepes pH 7.4, 11 mM glucose) was added to wells. Cells were detached by
scraping, transferred to microcentrifuge tubes, and washed three times with HBS,
centrifuging cells at 400 g for 4 minutes at 4°C between washes. Eukaryotic cells were
lysed in PBS containing 0.25% v/v Triton X-100 for 30 minutes on ice, and lysates were
diluted 1:1000 and plated on Luria broth (LB) agar plates. Bacterial colonies were
counted 16 hours later, and the number of bacteria associated per eukaryotic cell was
determined. Data were analyzed for statistical significance using one-way factorial
ANOVA (http://members.aol.com/johnp71/anova1sm.html).
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ADP-ribosylation of cellular substrates by bacterially translocated ExoS.
In vivo. In vivo ADP-ribosylation of LMWG-protein substrates by bacterially translocated
ExoS was assessed based on altered protein mobility by SDS-PAGE following coculture with bacteria for 4 or 6 hours, as previously described (64, 65, 153). To examine
Ras modification, cells were lysed in TBS-TDS (10 mM Tris, pH 7.4, 140 mM NaCl, 1%
v/v Triton X-100, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS), and cellular Ras was
immunoprecipitated using Y13-259 anti-pan Ras antibody, as previously described
(153). Precipitates were resolved by SDS-12.5% PAGE (129), transferred to PVDF
membranes (Millipore; Bedford, MA) (233), and Ras was detected using 100 ng/ml
LA045 pan-Ras antibody or 100 ng/ml LA069 H-Ras specific antibody (Quality Biotech;
Camden, NJ), followed by horseradish peroxidase (HRP)-conjugated anti-mouse IgG
(Jackson Immuno Research; West Grove, PA) and visualized by enhanced
chemiluminescence (ECL) (Amersham). RalA, Rab5, Rab7, Rab8, Rab11 and Rac1
modification was detected following lysis of cells with Laemmli electrophoresis sample
buffer, and lysates were resolved by SDS-12% PAGE and transferred to PVDF
membranes, as described above. Individual LMWG-proteins were detected using the
following antibodies: RalA, 50 ng/ml mouse anti-RalA monoclonal antibody
(Transduction Laboratories; Lexington, Kentucky); Rab5, 10 ng/ml rabbit anti-Rab5B (A20) polyclonal antibody (Santa Cruz Biotechnology; Santa Cruz, California); Rab7, 0.7
µg/ml goat anit-Rab7 (C-19) polyclonal antibody (Santa Cruz); Rab8, 250 ng/ml mouse
anti-Rab8 monoclonal antibody (Transduction Laboratories); Rab11, 250 ng/ml mouse
anti-Rab11 monoclonal antibody (Transduction Laboratories); and Rac1, 250 ng/ml
mouse anti-Rac1 monoclonal antibody (Transduction Laboratories). Immunoblots were
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developed with HRP-conjugated anti-mouse IgG (Sigma) or anti-rabbit IgG
(Transduction Laboratories), as appropriate, and visualized by ECL.
In vitro. In vitro ADP-ribosylation of fibroblastic RalA, Rab proteins, or Rac1 was
performed, as previously described (65), using 0.2 µM purified ExoS (153), 10 mM NAD
(Sigma) and 40 µl of NIH-3T3 or Swiss-3T3 fibroblast cell lysate (as a source of the
endogenous proteins and 14-3-3 cofactor) in a 100 µl reaction volume, which was
incubated for 30 minutes at room temperature. Reactions were stopped with 4x
Laemmli sample buffer and heating at 95ºC for 5 minutes. Fibroblast cell lysates were
prepared by incubating cells on ice for 30 minutes in lysis buffer containing 50 mM Tris,
0.1% Triton X-100, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1mM EDTA and 100 µM
PMSF. Lysates were cleared of nuclei and unbroken cells by centrifugation at 16,000 x
g for 5 minutes prior to use in reactions. Following the ADPRT reactions, proteins were
resolved by SDS-12% PAGE and immunoblotted for the specific proteins, as described
above.
Time course analysis of ExoS internalization. Substrate modification and the
internalization of ExoS ADPRT activity was assessed in fibroblastic and epithelial cells
seeded in 100 mm dishes and co-cultured with bacteria for 3, 4.5 or 6 hours. Following
removal of bacteria, cell monolayers were washed twice with PBS, and adherent cells
were detached with trypsin-EDTA. Cells were recovered from washes by centrifugation
at 400 g for 10 min and combined with trypsin-detached cells. The treatment of cells
with trypsin in these studies minimized the likelihood that extracellularly bound ExoS
would remain in cellular fractions. The cell pellet was resuspended in 100 µl of cell
permeabilization solution (0.2% w/v saponin, 100 mM NaCl, 250 mM sucrose, 5 mM

51

EDTA, 1 mM PMSF, 10 µg/ml, each, leupeptin and aprotinin (Sigma) and 100 µg/ml
ciprofloxacin) and lysed on ice for 30 minutes. Lysates were centrifuged at 16,000 g for
20 minutes at 4°C. The supernatant (cytosolic fraction) was removed, and the pellet was
resuspended in 100 µl of cell permeabilization solution containing 1% v/v Triton X-100
and vortexed for 15 seconds every 5 minutes four times to solubilize membrane
proteins. The solubolized pellets were centrifuged at 16,000 g for 10 minutes, and the
supernatant (membrane fraction) was removed. To analyze substrate modification in the
cytosolic and membrane fractions, a 50 µl aliquot of each sample was mixed with 4x
Laemmli sample buffer, and an equivalent volume of each fraction was resolved by
SDS-PAGE and immunoblotted for RalA, Rab proteins, or Rac1, as described above.
ExoS ADPRT activity in remaining portions of cytosolic and membrane fractions was
quantified, as previously described (54), and related to total protein concentrations in
the respective sample determined using the Sigma Diagnostics Lowry-based protein
assay (Sigma). Data were analyzed for statistical significance using one-way factorial
ANOVA, as described above.
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Results
Comparison of effects of ExoS on cell function. We previously found that effects
of T3S-T-ExoS on eukaryotic cell function could be assessed in a bacterial/eukaryotic
cell co-culture model of infection by comparing alterations caused by ExoS producing
strain 388 to that of the isogenic, non-ExoS producing strain 388∆S (169, 170). In
comparisons of different cell lines for the effects of T3S-T-ExoS, we recognized a
general increase in sensitivity of human epithelial cells to ExoS as compared to NIH3T3 and Swiss-3T3 fibroblastic cells. This difference in cell sensitivity to ExoS was
consistent with previous studies which found Detroit 532 fibroblasts to be sensitive to
effects of ExoS on DNA synthesis, but relatively resistant to effects of ExoS on cell
morphology (170). To gain a better understanding of cellular differences in the effects of
ExoS and the mechanisms associated with these differences, HT-29 and LNCaP
human epithelial cells and NIH-3T3 and Swiss-3T3 fibroblastic cells were used as
model cell lines to further explore differences in the effects of ExoS on cell function.
In examining effects of T3S-T-ExoS on DNA synthesis, HT-29 and LNCaP epithelial
cells were found to be more sensitive to effects of ExoS on DNA synthesis, showing a
51.6% ±0.5% and 88.6% ±1.0% inhibition of DNA synthesis, respectively, relative to that
of strain 388∆S. This compared to a 36.0% ±1.3% and 20.3% ±0.7% inhibition of DNA
synthesis caused by strain 388 in NIH-3T3 and Swiss-3T3 murine fibroblasts,
respectively, relative to strain 388∆S. In determining how effects of ExoS on cell viability
related to effects on DNA synthesis, cell viability was assayed, based on trypan blue
exclusion, under the same co-culture conditions and at the same time point as DNA
synthesis analyses. In these studies, LNCaP and NIH-3T3 cells exhibited a greater loss
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of viability (95.2% ± 0.4% and 44.6% ±0.9%, respectively). This compared to a minimal
6.1% ±0.9% and 6.8% ±0.2% loss of viability caused by bacterially translocated ExoS in
HT-29 and Swiss-3T3 cells, respectively. These studies found that human epithelial
cells were more sensitive than murine fibroblasts to effects of ExoS on DNA synthesis,
and that the effects on DNA synthesis did not necessarily correlate with effects of ExoS
on cell viability.
Previous studies from our laboratory found permanent, long-term effects of strain
388 on HT-29 epithelial cell rounding to be directly associated with ExoS ADPRT
activity (64, 169). This differed from transient effects on cell morphology caused by the
non-ExoS producing strain 388∆S, which were less severe and reversible upon removal
of bacteria. In comparing the effects of ExoS on the morphology of these four different
cell lines, severe cell rounding persisted in HT-29 and LNCaP epithelial cells 20 hours
after exposure to strain 388, while long-term rounding was limited in NIH-3T3 cells and
absent from Swiss-3T3 fibroblastic cells (Figure 10).
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Figure 10. Effects of T3S-T-ExoS on epithelial and fibroblastic cell morphology.
HT-29, LNCaP, NIH-3T3 and Swiss-3T3 cells were seeded at 1 x 105 cells/ ml in 48-well
plates, either 24 hours (fibroblasts) or 48 hours (epithelial) prior to the addition medium
containing no bacteria (0), or 107 cfu/ml of strain 388 or 388∆S (∆S) for 4 hours.
Bacteria were removed, cells were washed with PBS and cultured in GC-medium for an
additional 20 hours. Long-term effects on cell morphology were examined by phase
contrast microscopy at 20 hours, and images are representative of a minimum of three
independent experiments.
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The functional detachment and reattachment of epithelial and fibroblastic cells to
extracellular matrix is required for cell mobility and the maintenance of cellular barriers.
This function was previously found to be affected in HT-29 cells following treatment with
ExoS-expressing bacteria (169). In assessing whether differences exist in the sensitivity
of the four cell lines to the effects of ExoS on cellular adherence and re-adherence, it
was first noted that minimal direct loss of adherence occurred following the co-culture of
HT-29, NIH-3T3 and Swiss-3T3 cells with ExoS-producing bacteria for 4 to 5 hours. In
comparison, LNCaP cells were found to detach from the culture plate or become loosely
adherent within a 4 hour exposure to bacteria (data not shown). Effects of ExoS on the
reattachment processes were examined by detaching cells from plates with trypsin,
following exposure to bacteria, replating, and allowing cells to re-adhere for 20 or 48
hours. In these analyses, HT-29 cells began to lose the ability re-establish adherence to
matrix after a 2 to 3 hour exposure to strain 388 (Figure 11). LNCaP cells, which were
sensitive to direct effects of ExoS on cell adherence, displayed a generalized sensitivity
to bacterial effects on re-adherence, independently of ExoS production. NIH-3T3 cells
required a greater than 4 hour exposure to strain 388 before re-attachment processes
were lost, and Swiss-3T3 cells tolerated a greater than 6 hour exposure to strain 388
before loss of re-adherence. These studies found that bacterially translocated ExoS
interfered with re-adherence processes differently in each cell line, but that overall,
murine fibroblasts appeared more resistant to effects of ExoS on adherence processes.
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Figure 11. Effects of T3S-T-ExoS on epithelial and fibroblastic cell re-adherence.
HT-29, LNCaP, NIH-3T3 and Swiss-3T3 cells were seeded and cultured with no
bacteria (open triangle) or strain 388 (filled square) or 388∆S (open square) for 2 to 6
hours, as in Figure 1. Bacteria were removed, cells were washed, detached with trypsinEDTA, replated, and allowed to re-adhere for 20 hours (HT-29, NIH-3T3, Swiss-3T3) or
44 hours (LNCaP). The number and viability of non-adherent and trypsinized adherent
cells were determined after this time based on trypan blue exclusion. The percentage of
viable, adherent cells was calculated relative to total cell number. Results are expressed
as percent viable adherent cells following the indicated co-culture time. The mean and
SE of three to four independent experiments are represented.
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In summarizing comparisons of the effects of T3S-T-ExoS on these four cell lines, it
was found that the two human epithelial cells examined were, in general, more sensitive
than the murine fibroblastic cell lines to effects of ExoS on DNA synthesis, alterations in
morphology, and effects on re-adherence processes. However, individual cell line
variations in the effects of ExoS were also evident in these studies, highlighting the
ability of eukaryotic cells to modulate, or contribute to, the effects of ExoS on cell
function in a cell line-dependent manner.
Comparison of bacterial association to cellular sensitivity to ExoS. Contact
between bacteria and eukaryotic cells is required for the T3S-T of effector proteins
(102). To assess whether the differential sensitivity among the cell lines to ExoS might
relate to efficiency of bacterial adherence, bacterial association with the different cell
lines was quantified after a 3 or 4.5 hour exposure to bacteria. Bacterial adherence to
LNCaP cells was assayed after a shorter, 3 hour period since this cell line begins to
loose viability after a 4 hour co-culture period (refer to previous section). As shown in
Figure 12, an average of 2 bacteria associated with each HT-29 epithelial cell, with 5 to
6 bacteria associating with each LNCaP cell. In analysis of the NIH-3T3 and Swiss-3T3
fibroblastic cells, an average of 20 bacteria were associated per cell, which was
significantly greater (P < 0.006) than the number adhering to epithelial cells.
Comparisons of the size of epithelial and fibroblastic cells as cultured monolayers,
found fibroblasts to have about a 2.5 times greater surface area than epithelial cells,
making the association of bacteria per surface area still slightly greater for fibroblastic
than epithelial cells. Based on these analyses, and consistent with previous reports (58,
154), we were unable to relate the efficiency of bacterial association with cells to
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Figure 12. Bacterial association with HT-29, LNCaP, NIH-3T3 (NIH) and Swiss-3T3
(Swiss) cells.
Mammalian cells were seeded in 24-well plates as in Figure 1, and cultured with 388
(hatched bars) or 388∆S (open bars) bacteria (MOI, 200:1) for either 3 hours (LNCaP)
or 4.5 hours (HT-29, NIH-3T3 (NIH), Swiss-3T3 (Swiss)). A higher MOI. was used in
these studies to maximize bacterial association. Bacteria were removed, eukaryotic
cells were detached by scraping into HEPES buffered saline (HBS) and washed three
times in HBS. Eukaryotic cells were lysed in PBS containing 0.25% v/v Triton X-100,
and the lysate was diluted and plated on LB agar plates. Bacterial colonies were
counted after 16 hours. Assays were performed in quintuplicate, and the number of
associated bacteria per eukaryotic cells was calculated. The mean and SE of three to
four independent experiments are represented. A statistically significant difference was
detected between the association of strain 388 and strain 388∆S with epithelial and
fibroblastic cells, based on ANOVA; *, P = 0.307 in the comparison of adherence of
388∆S and 388 to NIH-3T3 cells, indicating that the differences noted were not
statistically significant.
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differences in cellular sensitivity to the effects of ExoS. Also evident in Figure 12, is the
lack of significant difference in the association of strain 388 or 388∆S bacteria with the
different cell lines, indicating no influence of ExoS production on bacterial adherence in
these studies.
ADP-ribosylation of cellular substrates by T3S-T-ExoS. Previous studies
confirmed the requirement of ExoS ADPRT activity for effects of T3S-T-ExoS on
epithelial cell DNA synthesis and morphology (64). To examine how differences in the
sensitivity of cell lines to ExoS might relate to cellular targets of ExoS ADPRT activity,
identified LMWG-protein substrates of T3S-T-ExoS (63, 65, 153) were examined for
modification in the different cell lines. Cellular substrates examined in these studies
included Ras, RalA, Rab5, Rab7, Rab8, Rab11 and Rac1, and modification was
determined based on a shift in molecular mass by SDS-PAGE, previously shown to
relate to ExoS ADP-ribosylation (63, 65, 153).
While Ras appeared to be modified similarly in the human epithelial and murine
fibroblasts, based on SDS-PAGE analyses, a difference was detected in the
modification of the other LMWG-proteins between the two cell types (Figure 13 A). Two
modified forms of RalA were detected in HT-29 and LNCaP cells, but only one modified
form of RalA was detected in NIH-3T3 or Swiss-3T3 fibroblastic cell lines. Comparisons
of the ADP-ribosylation of Rab proteins by T3S-T-ExoS, found Rab5, Rab7, Rab8 and
Rab11 to be modified in the human epithelial cell lines, but no modification of Rab
proteins was detected in murine fibroblasts. (Representative results of Rab5 and Rab8
are shown in Figure 13 A.) Also, Rac1 modification was detected in human epithelial but
not murine fibroblastic cells. The different number of modification bands observed in
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Figure 13. Cell line-related effect of substrate modification by T3S-T-ExoS.
(a) ADPRT substrate modification by T3S-T-ExoS: Cellular substrate modification was
examined following a 4 to 5 hour co-culture period with strain 388 or 388∆S (∆S), as in
Figure 1. To analyze Ras modification, cells were lysed in TBS-TDS, Ras was
immunoprecipitated using Y13-259 anti-pan Ras antibody, and immunoprecipitates
were resolved on SDS 12.5%-PAGE. Ras was detected by immunoblot analyses and
visualized using enhanced chemiluminescence (ECL). To analyze the modification of
RalA, Rab5, Rab8 and Rac1, cells were lysed in 1x Laemmli sample buffer and lysates
resolved by SDS 12%- PAGE. The individual LMWG-proteins were also detected by
immunoblot analyses (b) Substrate modification by ExoS in an in vitro ADPRT reaction:
ADP-ribosylation of fibroblastic RalA, Rab5 and Rab8 was examined in vitro using 0.2
µM purified ExoS, 10 mM NAD and 40 µl of NIH-3T3 or Swiss-3T3 fibroblast cell lysate
as a source of both the endogenous protein and the 14-3-3 cofactor, in a 100 µl reaction
volume. Reactions were incubated for 30 minutes at room temperature and stopped
with 4x Laemmli sample buffer and heating at 95ºC for 5 minutes. Proteins were
resolved by SDS-12% PAGE and immunoblotted. Positions of ADPRT modified (M) and
unmodified (U) proteins are indicated, and immunoblots are representative of a
minimum of 3 independent experiments.
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individual LMWG-proteins was previously shown to relate to the sequential addition of
ADP-ribose moieties (63, 65).
To assess whether differences in patterns of substrate modification in these cell
lines related to intrinsic protein differences or in situ cellular influences, RalA, Rab
proteins and Rac1 from fibroblast cell extracts were incubated with purified ExoS in an
in vitro ADPRT reaction. As shown in Figure 13 B, fibroblastic derived RalA, Rab5,
Rab8 (and Rac1, not shown) were able to be ADP-ribosylated by purified ExoS in vitro
as efficiently as their respective epithelial proteins were in vivo. Also, because ADPRT
reactions were performed using fibroblastic extracts as a source of eukaryotic cell
proteins, neither the absence of functional 14-3-3 eukaryotic co-factor, nor the presence
of endogenous ADPRT inhibitors appeared to be contributing to the limited ADPRT
substrate modification detected in murine fibroblasts.
Time-course analysis of T3S-T and substrate modification by ExoS ADPRT
activity. To further explore whether the limited substrate specificity of fibroblastic cells
related to less efficient T3S-T of ExoS into cells, LMWG-protein substrate modification
was monitored relative to the internalization of ExoS ADPRT activity into the eukaryotic
cell in a time-dependent study. In these experiments, cytosolic and TX-100 solubilized
membrane fractions of cells were analyzed for ExoS ADPRT activity and RalA, Rab5,
Rab8 and Rac1 modification following a 3, 4.5, or 6 hour exposure to bacteria. Our
studies examined ExoS ADPRT activity, rather than the ExoS protein, because of our
ability to quantify ExoS ADPRT activity precisely and because of previous difficulties in
detecting ExoS protein by immunoblot analyses (64).

62

Consistent with the studies shown in Figure 13 A, patterns of LMWG-protein
substrate modification in human epithelial and murine fibroblastic cells remained
distinctly different, even with increasing time of exposure to bacteria (Figure 14 A). The
difference in substrate modification was specifically recognized in the single
modification of RalA and absence of modification of Rab5, Rab8 or Rac1 in murine
fibroblastic cells, compared with two modifications of RalA, two modifications of Rab5
and a single modification of Rab8 and Rac1 detected in human epithelial cells. Analysis
of all cell lines was similar in that substrate modification was more efficient in the TX100 membrane fraction when compared with the cytosolic fraction. Also, while variations
in levels of individual LMWG-proteins were detected between the cytosolic and
membrane compartments, the relative distribution of these proteins was generally
consistent in all cell lines. For example, there was a general preferential localization of
RalA to the membrane fraction, Rab proteins were somewhat equally distributed in both
the cytosolic and membrane fractions, and Rac1 preferentially localized to the cytosolic
fraction. The lack of prominent differences in the cellular localization of LMWG-proteins
is supportive of this not being a factor in differences observed in patterns of ExoS
substrate modification in human epithelial and murine fibroblastic cells.
In time course analyses of ExoS ADPRT activity, increases in ADPRT activity were
found to closely parallel increases in the efficiency of cellular patterns of substrate
modification (Figure 14 B). ADPRT activity was significantly higher in the membrane
than cytosolic fraction (p < 0.009, except for data received for HT-29 cells at 3 hrs), and
progressively increased in both fractions with time in association with the increased
efficiency of substrate modification. Notable in comparisons of ExoS ADPRT activity
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Figure 14. Time course analysis of ExoS substrate modification and
internalization of ExoS ADPRT activity
(a) ADPRT substrate modification. Epithelial and fibroblastic cells were seeded in 100
mm dishes and co-cultured with strain 388∆S (∆) or 388 (S), as in Figure 1, for 3, 4.5, or
6 hours. Cell monolayers were washed twice with PBS, non-adherent cells were
recovered and combined with adherent, trypsin detached cells. The cells were washed
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with PBS, resuspended in 100 µl of cell permeabilization solution (defined in Methods)
and placed on ice for 10 min to release the cytosolic fraction. Permeabilized cells were
centrifuged at 16,000 g for 20 minutes at 4°C. The supernatant (cytosolic fraction) was
removed, and the pellet was resuspended in 100 µl of cell permeabilization solution
containing 1% v/v Triton X-100 and vortexed for 15 sec every 5 minutes, four times to
solubilize membrane proteins. The membrane TX-100 soluble protein fraction was
obtained by centrifugation at 16,000 g for 10 min. To analyze substrate modification in
the cytosolic and membrane fractions, 4x Laemmli sample buffer was added to a 40 µl
aliquot of each sample, and RalA, Rab5, Rab8 and Rac1 modification was examined as
described in Fig. 4. Positions of ADPRT modified (m) and unmodified (u) proteins are
indicated. (H) HT-29 cells; (L) LNCaP cells; (N) NIH-3T3 cells; (S) Swiss-3T3 cells; (*)
indicates a longer exposure to film, relative to the other samples, was required for the
ECL signal shown.
(b) Internalization of ExoS ADPRT activity. ExoS ADPRT activity was quantified in the
cytosolic and membrane fractions of HT-29, LNCaP, NIH-3T3 and Swiss-3T3 cells in a
1 hour in vitro ADP-ribosylation reaction, containing 1.2 µM [14C]NAD and 100 µM
soybean trypsin inhibitor (SBTI) as the ADP-ribose acceptor. ADPRT activity is reported
as fmol per min of ADP-ribose incorporated into SBTI per µg of cellular protein. ADPRT
assays were performed in duplicate and the mean and SD (not evident) of samples
represented in (a) are shown. The results are representative of 3 independent
experiments. Open squares, cytosol, strain 388∆S; open circles, cytosol, strain 388;
filled squares, membrane strain 388∆S; filled circles, membrane, strain 388.
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was the high level of activity detected in both the cytosolic and membrane fractions of
murine fibroblastic cells, even though more restricted patterns of substrate modification
were detected. The high levels of ExoS ADPRT activity detected in fibroblasts further
support the notion that ExoS activity is not tethered in murine fibroblasts by endogenous
ADPRT inhibitors. While levels of ExoS ADPRT activity were calculated relative to total
cellular protein concentration in Figure 14 B, higher levels of activity were also evident
in murine fibroblastic cells when related to total cell numbers (data not shown). In
addition, while studies represented in Figure 14 were performed at an MOI of 10, the
same pattern of substrate modification was detected in murine fibroblasts at a MOI
>250, highlighting the defined nature of murine fibroblastic cell substrate modification
pattern. We conclude from these studies that the limited substrate modification by
bacterially translocated ExoS in murine fibroblasts was not linked to the inefficient
internalization of ExoS ADPRT activity by the Pa T3S system, but rather reflected in situ
differences in ExoS function.
Patterns of ExoS substrate modification in different cell lines. To explore the
specificity of the ExoS ADPRT substrate modification pattern relative to cell type or
animal origin, we compared substrate modification by T3S-T-ExoS in fibroblasts,
epithelial and endothelial cell lines from rodents, monkeys and humans (Table 1; Figure
15). Rodent-derived CHO-K1 and TCMK-1 epithelial cells, and RHEC endothelial cells,
exhibited the same pattern of substrate modification as that of murine NIH-3T3 and
Swiss-3T3 cells; that is, showing more limited modification of RalA and no modification
of Rab proteins or Rac1. Simian-derived Cos-1 fibroblasts and Vero epithelial cells
showed a similar pattern of substrate modification as human HT-29 and LNCaP cell
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Figure 15. Patterns of LMWG-protein substrate modification by T3S-T-ExoS in
different cell lines.
Eukaryotic cells were seeded at 105 cells/ml in 6-well plates for 24 hours prior to coculture with 106 cfu/ml 388, 388∆S (∆S) (MOI 10-20:1), or no bacteria. After a 4.5 hour
co-culture period, bacteria were removed, cells were washed in PBS and lysed in 200 µl
1x Laemmli sample buffer. Lysates were resolved by SDS 12%-PAGE and
immunobloted for RalA, Rab5, Rab8 and Rac1, as described in Figure 4. ADPRTmodified (m) and unmodified (u) proteins are labeled. Immunoblots shown are
representative of at least 4 independent studies.
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lines, although modification was consistently less efficient. Human-derived HT-1080
fibrosarcoma and T24 transitional cell carcinoma cells also displayed the same pattern
of substrate modification as LNCaP and HT-29 cells. Since previous studies found
tumor derived cells to be highly sensitive to the effects of ExoS (154), we examined
whether oncogenic transformation or viral transformation of cell lines could influence
substrate specificity. When substrate modification in normal and SV40-transformed
human WI-38 fibroblasts (WI-38t) was compared, the pattern of substrate modification
of both cell lines was similar to that of other human cell lines, indicating that viral
transformation did not alter ExoS substrate modification. In addition, substrate
modification by T3S-T-ExoS in the WI-38t cells did not differ from that detected in the
HT-29, LNCaP, HT-1080 and T24 cells, indicating that neither viral nor oncogenic
transformation influenced the substrate specificity of ExoS. The one cell line exception
to the pattern of substrate modification observed for human cells was the Detroit 532
fibroblastic cells, which exhibited a more limited pattern of substrate modification, similar
to that of rodent cell lines.
We conclude from these studies that patterns of ExoS substrate modification are
linked more closely to the origin of the cell line, rather than cell type or state of cellular
transformation. However, as evident from Detroit 532 human fibroblasts, this
relationship is not absolute, and differences in individual cell lines can also alter ExoS
substrate-modification patterns.
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Discussion
The T3S system is thought to be evolutionarily derived from bacterial flagellar
machinery and was an adaptation that allowed the bacterium to directly translocate
effector proteins and manipulate the function of eukaryotic cells (102). The conservation
of the genetically complex T3S regulon among a broad range of Gram-negative
organisms implies its general importance to bacterial survival. While it has been
recognized that differences exist in the sensitivity of eukaryotic cells to T3S processes,
the cellular mechanism for these differences, and the contribution of the eukaryotic cell
to the T3S process remain largely unknown.
We have used the T3S-T of ExoS by Pa to explore how the host cell might influence
the translocation and cellular effect of T3S-effector proteins. Previous studies found that
macrophage and epithelial cell lines responded differently to the Pa T3S process, with
cell morphology being affected in epithelial cell lines and cell viability being affected in
macrophages (27). ExoS is the most extensively studied of the Pa T3S-effector
proteins, and comparisons of different epithelial cell lines identified differences in cell
sensitivity to T3S-T-ExoS (154). Notable in these comparisons was that epithelial cell
sensitivity to ExoS appeared to parallel the opportunistic nature of Pa infections,
implying a relationship between the T3S process and cells targeted by Pa. Since
studies supported that the host cell can influence the outcome of T3S-T events, we
reasoned that we might be able to gain insight into these eukaryotic cell influences by
comparing the cellular mechanism of ExoS in cell types that respond differently to T3ST-ExoS.
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We had previously observed differences in sensitivities of human carcinoma and
mouse fibroblastic cells to the effects of T3S-T-ExoS. Based on these observations, we
used HT-29 and LNCaP human epithelial cells and NIH-3T3 and Swiss-3T3 murine
fibroblasts to explore how the host cell might contribute to differences in the toxicity of
ExoS. Previously defined effects of ExoS on epithelial cells, which include inhibition of
DNA synthesis, long-term cell rounding and loss of re-adherence (169), were used as
criteria for functional comparisons of the toxicity of ExoS. Two strains of bacteria, 388
and 388∆S, were used to distinguish the effects of ExoS from other bacterial factors.
Studies performed in parallel using strain 388∆ExoT confirmed that the cellular effects
being monitored related to ExoS, and not ExoT, which is also expressed by strain 388
(data not shown). Our studies identified individual cell line variations in the effects of
ExoS on cell function, but overall, human epithelial cells examined were more sensitive
than murine fibroblastic cells to the effects of ExoS on DNA synthesis, morphology and
cellular adherence. Of these four cell lines, LNCaP epithelial cells were the most
sensitive to the effects of T3S-T-ExoS, and Swiss-3T3 fibroblasts were the most
resistant. We also found that decreased sensitivity to ExoS did not relate to decreased
bacterial association.
In defining the mechanism for the differential effects of ExoS on cell function, our
studies focused on ExoS ADPRT activity, rather than GAP activity, since previous
studies linked toxic effects of T3S-T-ExoS on epithelial cell morphology and DNA
synthesis to ExoS ADPRT activity (64). ExoS ADPRT activity was functionally evaluated
based on the efficiency of ADP-ribosylation of cellular substrates. T3S-T-ExoS has been
found to ADP-ribosylate multiple LMWG-proteins in HT-29 epithelial cells, with Ras and
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RalA modification detected first, followed by the modification of Rab proteins, then Rac1
(65). A different pattern of LMWG-protein substrate modification by T3S-T-ExoS was
detected in murine fibroblasts. Although no differences in Ras modification were evident
in the two cell types based on SDS-PAGE, differences were detected by twodimensional electrophoresis (2DE), with one modification of Ras detected in murine
fibroblasts (E. A. Rucks, unpublished results), while two or three sites of Ras
modification have been detected in human epithelial cells (64, 241). Differences in RalA
modification were also detected, with only one modification of RalA detected in murine
fibroblasts by SDS-PAGE, while two modifications were evident in human epithelial
cells. In analyses of Rab proteins, Rab5, Rab7, Rab8 and Rab11 were all modified in
human epithelial cells, while no modification of Rab proteins was detected in murine
fibroblastic cell lines. Consistent with previous reports identifying LMWG-protein targets
of ExoS ADPRT activity in NIH-3T3 fibroblast membranes (26), when murine fibroblastic
cell extracts were used as a source of endogenous LMWG-proteins in in vitro ADPRT
reactions using purified ExoS, RalA, Rab proteins and Rac1 were found to be modified
by ExoS as efficiently as that observed in human epithelial cells. These results support
the notion that the decreased efficiency of RalA, Rab, and Rac1 modification in murine
fibroblasts did not relate to intrinsic protein properties, but rather to in situ cellular
effects.
The decreased efficiency of LMWG-protein modification in murine fibroblasts
suggested that the T3S process functioned differently in murine fibroblastic and human
epithelial cells relative to either the efficiency of ExoS internalization or the action of
ExoS once it was T3S-translocated. In comparing the efficiency of ExoS internalization
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in the two cell types, ExoS was found to be translocated as (or slightly more) efficiently
in murine fibroblasts when compared to human epithelial cells, supporting that the T3S
apparatus was functional in murine fibroblasts. Consistent with the translocation of
ExoS through the membrane into cytosol via the T3S apparatus, levels of ExoS ADPRT
activity and the efficiency of substrate modification was higher in membrane than
cytoplasmic fractions of all cell lines, as has been previously recognized (64, 188). Our
analyses of ExoS internalization relied on quantification of ExoS ADPRT activity, rather
than ExoS protein, for we have had difficulty in detecting ADPRT-active ExoS within
cells by immunoblot analyses using antibodies against ExoS (64). The more limited
modification of LMWG-protein substrates in murine fibroblastic cells, in association with
efficient ExoS internalization, indicated that cellular factors, beyond membrane
translocation, were influencing the ADP-ribosylation of substrates by ExoS within the
cell.
Differences in substrate modification between human epithelial and murine
fibroblasts prompted us to examine how the pattern of ExoS substrate modification
related to cell type, the animal origin of the cells, or the state of viral or oncogenic
cellular transformation. In comparing ExoS substrate modification in murine, rat,
hamster, simian or human cells, of epithelial, endothelial and fibroblastic cell types, two
basic patterns of substrate modification were identified. One pattern showed more
restricted substrate ADP-ribosylation, detecting limited modification of RalA and no
modification of Rab proteins or Rac1. This pattern was common to rodent cell lines and
independent of cell type. The second pattern showed more extensive LMWG-protein
substrate ADP-ribosylation, with T3S-T-ExoS modifying RalA more efficiently and also
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modifying Rab proteins and Rac1. This pattern was apparent in human and simian cell
lines, but modification in simian cell lines appeared less efficient. Notably, one human
cell line, Detroit 532 fibroblasts, was found to have the more limited ExoS substrate
modification pattern seen in rodent cells. The mechanistic link between the restricted
ExoS ADPRT substrate pattern observed in Detroit fibroblasts is not known. In
assessing the role of viral or oncogenic transformation in ADPRT substrate modification,
no alterations in patterns were detected in any of the cell lines in association with
cellular transformation.
The cellular mechanism for the different patterns of ADPRT substrate modification
is not yet understood. Factors that could alter the substrate specificity of T3S-T-ExoS
include differences in the subcellular targeting or localization of ExoS within cells and/or
differences in co-localization of the ExoS eukaryotic cofactor, 14-3-3 protein. Relative to
the functional co-localization of the 14-3-3 cofactor, based on our in vitro ExoS ADPRT
reactions, we know that the cofactor is present and functional in murine fibroblastic cell
extracts which exhibit the more restricted cellular substrate-modification pattern. It has
also been found that 14-3-3 protein co-localizes to endosomes with Rab4 (15), although
Rab4 does not appear to be a substrate of ExoS when internalized by the T3S process
in either epithelial cells (65) or fibroblasts (E. A. Rucks, unpublished observation).
These data imply that co-localization of 14-3-3 co-factor by itself is not sufficient for
ExoS substrate ADP-ribosylation. An alternative, more likely explanation for altered
patterns of ExoS ADPRT substrate modification, based on current available data, is that
differences in targeting of ExoS within the cell affect its ADPRT substrate specificity.
Consistent with this hypothesis, both an N-terminal processing site and a membrane
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localization domain have been identified within the first 78 amino acids of ExoS (176,
177). These sites appear to influence the subcellular localization of ExoS and may also
prove to influence the substrate targeting specificity of ExoS ADPRT activity.
In relating substrate patterns of ADP-ribosylation by T3S-T-ExoS to effects of ExoS
on cell function, ExoS has previously been found to affect the function of several of its
LMWG-protein substrates. The ADP-ribosylation of Ras by ExoS is known to interfere
with guanine nucleotide exchange factor (GEF) catalyzed GDP to GTP exchange, and
the interaction of Ras with its downstream effector Raf-1 and activation of the MAPkinase, Erk-2 (73, 91, 241). In addition, the modification of Ras has been found to
correlate with the ExoS-dependent inhibition of DNA synthesis (153). RalA is involved in
signaling processes that affect cell proliferation, vesicular transport and cytoskeletal
structure (50, 158, 226, 229). Recent studies have shown that the ADP-ribosylation of
RalA by ExoS interferes with RalA interaction with its downstream effector, Ral binding
protein 1 (63). Rab proteins control distinct pathways in endocytosis and vesicular
trafficking which affect membrane recycling (194). In vitro analysis found the ADPribosylation of Rab5 by ExoS to interfere with its ability to bind early endosomal
autoantigen 1 (EEA1), which retarded endosome-endosome fusion (10), which, in turn,
could influence the regeneration of adherence procces. Together, these data implicate
the potential role for ExoS-associated alterations of Ras, RalA and Rab protein function
to contribute together to the cellular effects of T3S-T-ExoS.
Consistent with a functional relationship between substrate modification and effects
of T3S-T-ExoS on cell function, LMWG-protein ADP-ribosylation was more extensive in
human HT-29 and LNCaP epithelial cells, in association with their greater sensitivity to
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effects of ExoS on cell growth, morphology and re-adherence, when compared to
murine fibroblasts. However, while a direct relationship was observed between
efficiency of substrate modification and increased sensitivity to the effects of T3S-TExoS, an absolute link between patterns of substrate modification and specific cellular
effects of ExoS was not evident, based on analyses used in our studies. For example,
effects on DNA synthesis, cell rounding and re-adherence, which were associated with
human epithelial cell responsiveness to ExoS were also detectable in NIH-3T3 cells,
which had more limited ExoS substrate modification; albeit the responses of NIH-3T3 to
T3S-T-ExoS were less severe. We suspect that an inability to observe a direct
relationship between functional effects of ExoS and specific patterns of substrate
modification reflects the functional interrelationship of the LMWG-proteins targeted by
ExoS within the cell. The function of Ras, Ral, Rac and Rab proteins are all linked to
each other through a hierarchy of cellular network interactions. It therefore might be
predicted that a more limited pattern of Ras and Ral modification could equate to
cellular effects associated with more extensive patterns of substrate modification if
given more time or upon more prolonged exposure to ExoS. Such a dose-response
functional relationship of ExoS was evident in cellular re-adherence studies in which
NIH-3T3 cells required a longer exposure to ExoS-producing bacteria than HT-29 cells
to obtain a similar loss of adherence (Figure 11). While the complexity of cellular
signaling events might mask distinct relationships between ExoS substrate modification
and effects on cell function, what is clearly evident in comparisons of different cell lines
is that the host cell can influence the efficiency of the intracellular targeting of ExoS
ADPRT activity.
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We conclude from these studies that the cellular response to T3S-T-ExoS is
dictated to varying degrees by the host cell targeted by Pa. ADPRT substrate
modification by T3S-T-ExoS is more restricted in rodent cells, when compared to human
and simian cells, yet the T3S-T process appears equally efficient in these cells. It
becomes apparent from these studies that the host cell is not a passive recipient during
the bacterial driven T3S process, but rather cell properties are able to influence the
activity and targeting of T3S-effector proteins.
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Chapter 3: Characterization of an ExoS type III translocation-resistant cell line

Contents of this chapter were published as a Note in the January 2005 (Volume
73) issue of Infection and Immunity, pages 638-643, and appears with permission from
the American Society of Microbiology Press and with permission from the authors, E. A.
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Abstract
Pseudomonas aeruginosa (Pa) ExoS is a type III secreted (T3S), bifunctional
protein that inactivates eukaryotic cell function. The co-culture of Pa strains expressing
ExoS with HL-60 myeloid cells revealed the cell line to be resistant to the effects of T3ST-ExoS. Differentiation of HL-60 cells with phorbol 12-myristate 13-acetate (TPA)
rendered the cell line sensitive to ExoS. To understand the cellular basis for the
alteration in sensitivity, undifferentiated and TPA differentiated HL-60 cells were
compared for differences in bacterial adherence, T3S induction, and ExoS T3S-T.
These comparisons found that ExoS was translocated more efficiently in TPAdifferentiated HL-60 cells than in undifferentiated cells. The studies support the idea that
the eukaryotic cell has the ability to influence Pa T3S at the level of membrane
translocation.
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Introduction
The type III secretory (T3S) process allows the direct translocation of bacterial
effector proteins into eukaryotic cells and is associated with the virulence of many
Gram-negative bacteria (70, 102). Four virulence factors, ExoS, ExoT, ExoU and ExoY,
are known to be translocated into eukaryotic cells by Pa T3S (258, 260). Unlike many
Gram-negative bacteria, both clinical and environmental P. aeruginosa isolates maintain
the T3S system, implying the integral role of T3S to P. aeruginosa survival in general
(52, 54, 200). Also, consistent with its opportunistic life-style, normal, healthy epithelial
barriers and monolayers remain resistant to P. aeruginosa infection and T3S (59, 115,
154). The purpose of these studies is to further understand the cellular basis of host-cell
resistance to Pa T3S using the type III effector, ExoS, as a tool to monitor T3S.
In analysis of human epithelial cells, bacterially translocated ExoS (T3S-T-ExoS)
has been found to cause a general inactivation of host cell function, as recognized by
effects on cell growth, adherence, morphology and phagocytic processes (66, 169, 170,
193). ExoS affects eukaryotic cell function through a bi-functional mode of action. The
N-terminal region of ExoS includes a GTPase activating (GAP) activity (77), which can
affect eukaryotic cell morphology and phagocytosis (178, 193). The C-terminal region of
ExoS includes an ADP-ribosyltransferase (ADPRT) activity that targets specific cellular
proteins, including low molecular weight G- (LMWG-) proteins in the Ras superfamily
(30, 63, 65, 89, 153). The ADPRT activity of ExoS is required for the irreversible effects
of ExoS on cellular proliferation, re-adherence and morphology (64, 169).
This study focuses on the effects of T3S-T-ExoS on HL-60 myeloid cell function.
The HL-60 cell line originated from peripheral blood leukocytes of a patient with
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promyelocytic leukemia (32). When treated with specific compounds, HL-60 cells can be
induced to terminally differentiate into granulocytes or monocytes (33, 134). We found
HL-60 cells to be resistant to the toxic effects of ExoS in their undifferentiated form.
However, upon differentiation with TPA, HL-60 cells became sensitive to ExoS. The
identification of a T3S-T-resistant cell line that can be induced to become T3S-Tsensitive provides a model system for studying eukaryotic cell factors that influence the
establishment of a functional Pa T3S process.
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Materials and Methods
Bacterial strains and culture conditions. Pa strains used in this study include: i)
the prototype ExoS producing strain, 388 (106), ii) an isogenic ExoS mutant 388∆exoS
(388∆S) (126), iii) strain 388∆popD::Tc* (388∆PopD), which lacks production of the
PopD T3S translocation protein (236), and strain 388exs1::Tn1 (388-11), which contains
a Tn1 insertion in the pscC gene, predicted to encode an outer membrane component
of the Pa T3S process (60, 119, 258). All Pa strains were provided by Dara Frank
(Medical College of Wisconsin, Milwaukee, WI). Strain PA103∆exoU,exoT::Tc
(PA103∆UT), a derivative of strain PA103, which lacks production of T3S effectors,
ExoU, ExoS, ExoT and ExoY (235), served as the host strain for production and T3S
translocation of pUCP encoded hemagglutinin-tagged ExoS (ExoS-HA). ExoS-HA was
provided by Joseph Barbieri (Medical College of Wisconsin, Milwaukee, WI).
To allow induction and T3S-translocation of ExoS, P. aeruginosa were cultured in
T3S-induction medium (TSBD-N) (106) for 16 hours prior to co-culture with eukaryotic
cells. In preparation for co-culture, bacteria were diluted based on OD590 to 107 cfu/ml,
as previously described (170) in RPMI 1640 medium (Gibco-BRL, Gaithersburg, MD)
supplemented with 0.6% bovine serum albumin (Sigma, St. Louis, MO) (RPMI-BSA)
and were added to eukaryotic cells at a multiplicity of infection (MOI) of approximately
30:1, unless otherwise indicated.
Eukaryotic cell culture. The non-adherent HL-60 human leukemia cell line was
obtained from the American Type Culture Collection (ATCC, CCL 240, Manassas, VA)
and maintained in RPMI 1640 medium containing 10% or 20% fetal bovine serum and
100 U/ml penicillin and 100 µg/ml streptomycin (Gibco-BRL) (RPMI-FBS) at 37ºC in 5%
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CO2-95% air. In preparation for culture with bacteria, HL-60 cells were centrifuged for
10 min at 400 g and seeded at 5 x 105 cells/ml in either polystyrene tubes or tissue
culture plates, 48 hours prior to the addition of bacteria (Costar, Cambridge, MA). HL-60
cells were differentiated into mature monocytes by the addition of 20 ng/ml TPA
(phorbol 12-myristate 13-acetate) (Sigma) to cell culture medium and incubation for 48
hours (111) (TPA-HL-60). For co-culture studies, cell medium was replaced with RPMIBSA containing no bacteria or 107 cfu/ml bacteria, then cultured for 3 to 6 hours, as
indicated, and assayed for changes in cell function and internalization of ExoS, as
described below.
Effects of T3S-T-ExoS on cell function.
i) Quantification of DNA synthesis. Following a 3 to 4 hour co-culture period, cells
were washed with phosphate buffered saline (PBS) and pulsed for 20 hours with 1
µCi/ml of [methyl-3H]thymidine (25 mCi/mmol; Amersham Life Sciences, Arlington
Heights, IL) in RPMI-FBS containing 200 µg/ml gentamicin (Sigma) and 100 µg/ml of
ciprofloxacin (Bayer, West Haven, CT) (RPMI-FBS-GC). DNA synthesis was quantified
as previously described (170) and is reported as percent [3H]thymidine incorporation
relative to non-bacterial treated cells.
ii) Examination of cellular morphology by scanning electron microscopy
(SEM). Prior to co-culture with bacteria, HL-60 cells were seeded at 106 cells/ml on 12
mm-diameter glass Thermanox coverslips (Nalge Nunc, Naperville, IL) and cultured for
48 hours in 35 mm tissue culture dishes, in the presence or absence of TPA. Following
a 3.5 hour co-culture period, bacteria were removed; cells were fixed with 2%
cacodylate glutaraldehyde for 30 min as a primary fixative then with 2% acqueous
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osmium tetroxide for 30 min as a secondary fixative. Samples were rinsed with distilled
water, dehydrated with 100% ethanol and incubated with hexamethyldisilazane (Sigma)
until dry. The samples were then mounted and sputter-coated with gold palladium (20nm coating) and examined using a JEOL SEM-LV5410 scanning electron microscope.
ADP-ribosylation of LMWG-proteins by T3S-T-ExoS. ADP-ribosylation of
LMWG-proteins of undifferentiated or TPA-HL-60 cells was assessed based on altered
protein mobility following a 4 hour co-culture period with strain 388, 388∆S or no
bacteria, as previously described (63, 65, 153) (Chapter 2, Methods and Materials).
Bacterial association with HL-60 cells. Effects of TPA differentiation on bacterial
adherence to HL-60 cells were assessed after a 4 hour co-culture period of HL-60 or
TPA-HL-60 cells with strains 388 or 388∆S, at a high MOI (100:1) to optimize detection
of bacterial association. Bacteria were removed and cells were washed three times with
HEPES buffered saline (HBS) (137 mM NaCl; 4 mM KCl; 10 mM HEPES, pH 7.4; 11
mM glucose). Bacterial association was quantified by lysing cells in PBS containing
0.25% Triton X-100, diluting samples 1:1000 and plating 50 µl of lysate onto LB agar
plates. Bacterial colonies were counted 24 hours later and the number of bacteria per
eukaryotic cell was calculated.
Monitoring induction Pa T3S process. To assess T3S induction, strains 388 and
388∆PopD were cultured in a non-T3S induction medium (TSBD supplemented with 5
mM CaCl2) prior to co-culture with eukaryotic cells. Undifferentiated or TPA-HL-60 cells
were then co-cultured with or without bacteria for 4 hours, in Hanks Balanced Salt
Solution (Sigma), which was found to minimize background induction of PopD and
maintain eukaryotic and bacterial cell growth. After a 4 hour co-culture period, Laemmli
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sample buffer was added to co-culture wells, to harvest both, i) cell pellets containing
eukaryotic cells and associated bacteria, and ii) co-culture supernatants containing
bacteria and secreted proteins, within the same sample. Samples were heated at 95o C
for 5 min, resolved by SDS-PAGE, immunoblotted using an anti-PopD antibody
(provided by Dara Frank), and visualized by ECL. Comparable eukaryotic cell growth
and protein loading were confirmed by immunoblotting for the eukaryotic housekeeping
enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Chemicon International
Inc., Temecula, CA).
T3S-T of ExoS into HL-60 cells.
i) Detection of T3S-T-ExoS ADPRT activity. Undifferentiated and TPA-HL-60 cells
were co-cultured with strains 388 or 388∆S for 3, 4.5 or 6 hours, at a low MOI (<10:1) to
facilitate detection of differences in the efficiency of ExoS translocation. Bacteria were
removed, cells were washed, treated with 0.5% trypsin/0.53 mM EDTA (trypsin-EDTA)
(Gibco-BRL) to proteolyze extracellular ExoS, then were lysed in 0.2% saponin, 100
mM NaCl, 250 mM sucrose, 5 mM EDTA, containing the protease inhibitor, P8340
(Sigma). Cellular lysates were centrifuged at 16,000 g for 20 min to obtain the cytosolic
(supernatant) fraction. The TX-100 soluble membrane fraction was obtained by treating
cellular pellets with 1% TX-100 and vortexing for 15 sec every 5 min for 20 min, then
centrifuging at 16,000 g for 10 min. ExoS ADPRT activity was quantified in an in vitro
ADPRT reaction, using soybean trypsin inhibitor (SBTI) as substrate, as previously
described (54, 117, 186). ExoS ADPRT activity in cellular fractions was calculated
relative to total protein determined using the Sigma Diagnostics Lowry-based protein
assay (Sigma). To compare ExoS ADPRT activity to substrate modification, an aliquot
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of each fraction was analyzed by SDS-PAGE and immunoblotted for RalA, Rab5 and
Rac1, as described previously.
ii) Detection of T3S-T-ExoS protein. T3S-T-ExoS was detected using HA-tagged
ExoS (ExoS-HA). In these studies, undifferentiated and TPA-HL-60 cells were cocultured for 4 hours with strain PA103∆UT expressing ExoS-HA. Cells were washed
and lysed in a digitonin extraction buffer (0.01% digitonin, 10 mM Pipes, 300 mM
sucrose, 100 mM NaCl, 3 mM MgCl2, 5 mM EDTA) and separated into cytosolic and
membrane fractions by centrifugation at 16,000 g for 15 min at 4ºC. Cytosolic and
membrane fractions were equilibrated relative to volume in Laemmli sample buffer,
samples were resolved by SDS-PAGE, immunoblotted using 2 µg/ml anti-HA antibody
(Upstate Biotechnology, Lake Placid, NY) and visualized using ECL. Comparable
eukaryotic cell protein loading was assessed by immunoblotting for GAPDH.
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Results
Induction of HL-60 cell sensitivity to ExoS. As part of a series of experiments
examining the effects of T3S-T-ExoS on different cell types, the effects of ExoS on HL60 cell function were assessed in co-culture studies comparing Pa strain 388 and the
isogenic non-ExoS producing strain, 388∆S. Using [3H]thymidine incorporation as a
measure of cellular proliferation (170), exposure to Pa bacteria was found to cause an
approximate 45% inhibition of HL-60 DNA synthesis. However, no ExoS specific effect
on DNA synthesis was detected (strain 388 caused a 45.0% ± 2.0% and strain 388∆S
caused a 44.7% ± 2.0% inhibition). Unlike epithelial cells, HL-60 cells have a round
morphology, which precludes the use of cell rounding as a measure of the effects of
ExoS on cell morphology. Instead, scanning electron microscopy (SEM) was used to
examine whether ExoS alters cell surface structures. We previously detected that T3ST-ExoS caused microvilli effacement in HT-29 epithelial cells (169). After a 3.5 hour coculture period, no alteration in HL-60 cell surface structure was evident following
treatment with strain 388 (Figure 16 A). The lack of ExoS-specific effects on DNA
synthesis and cell morphology suggested that HL-60 cells were resistant to the effects
of T3S-T-ExoS.
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No Bacteria

388∆S

388

A.

B.

Figure 16. SEM analysis of the morphological effects of ExoS on HL-60 or TPAHL-60 cells.
HL-60 cells were seeded on glass cover slips in 35 mm tissue culture dishes and
cultured for 48 hours in the absence (A) or presence (B) of 20 ng/ml TPA. Cell
monolayers were washed and cultured with 388∆S, 388 or no bacteria for 3.5 hours.
Bacteria were removed and cells were fixed, sputter coated with gold, and examined
using a JOEL SEM-LV5410 scanning electron microscope. Noted in comparisons of
these images is the loss of microvilli in TPA-HL-60 cells upon exposure to ExoSproducing bacteria.
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To assess whether HL-60 cell-sensitivity to ExoS could be altered by treatments
that induce differentiation, cells were terminally differentiated into adherent monocytes
by treatment with TPA, then co-cultured with strains 388, 388∆S or no bacteria, as
above. Terminal differentiation of eukaryotic cells halts cellular proliferation, thereby
precluding the examination of effects of ExoS on the cellular proliferation of TPA-HL-60
cells. In SEM analyses, exposure of TPA-HL-60 cells to ExoS producing strain 388
resulted in an increased loss of cell surface microvilli, when compared with TPA-HL-60
cells exposed to 388∆S or no bacteria. The effect of strain 388 on cell-surface microvilli
provided an initial indication that TPA differentiation altered HL-60 cell sensitivity to
T3S-T-ExoS. Notably, cell membrane ruffling, which was induced in HL-60 cells by
TPA-treatment, was still evident following exposure to ExoS-producing bacteria. These
results support that TPA treatment induced alterations in HL-60 cell sensitivity to T3S-TExoS, but effects of ExoS on cell structure were preferentially targeted to microvilli
projections.
TPA-induced alterations in HL-60 cell sensitivity to T3S-T-ExoS were also
recognized at the level of ExoS ADPRT substrate modification. The ADP-ribosylation of
LMWG-proteins by ExoS has previously been found to be lead to alterations in protein
mobility, based on SDS-PAGE analyses (30, 63, 65, 89, 153). When TPA-HL-60 cells
were co-cultured with strain 388, 388∆S or no bacteria for 4 hours and analyzed for
ADP-ribosylation of LMWG-proteins, shifts in the mobility of Ras, RalA, Rab proteins
and Rac1 were apparent (Figure 17). In comparison, only a slight modification of Rab
proteins was detected in undifferentiated HL-60 cells co-cultured with strain 388.
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Figure 17. ExoS ADPRT substrate modification in HL-60 and TPA-HL-60 cells.
HL-60 cells were cultured for 48 hours in the presence or absence of TPA, prior
to co-culture with strain 388∆S (∆S) or 388 for 4 hours. Bacteria were removed, and
cells were processed and analyzed for ADP-ribosylation of the indicated LMWGproteins based on altered mobility by SDS-PAGE and immunoblot analyses. Results are
representative of at least 3 independent experiments. ADP-ribosylated (M) and
unmodified (U) proteins are labeled.
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The studies support that TPA differentiation induces HL-60 cell sensitivity to T3S-TExoS as evident in ExoS ADP-ribosylation of cellular proteins, which correlate with
alterations in microvilli structure.
Mechanisms of induction of ExoS sensitivity. Although ExoS is secreted by Pa
into culture supernatants, it is not toxic to eukaryotic cells in the absence of a T3S
appartus (170, 258). Possible mechanisms by which TPA could induce alterations in
sensitivity to ExoS include: i) indirect effects on T3S that facilitate bacterial adherence
or non-T3S mediated diffusion of ExoS into cells, or ii) through direct effects on T3S that
alter the induction or efficiency of the T3S-T process.
i) Indirect mechanisms. To examine whether TPA treatment induces cell surface
alterations that enhance Pa adherence, rendering HL-60 cells more sensitive to the
bacterial contact-mediated T3S process, bacterial association to non-differentiated and
TPA-HL 60 cells was assayed. In these studies, cells were co-cultured with strain 388 or
388∆S for 4 hours at a high MOI (100:1) to facilitate detection of bacterial association.
Using a plating assay to quantify bacterial association, 25.8 ± 2.6 bacteria were found to
associate per undifferentiated HL-60 cell, which compared with 8.5 ± 0.8 bacteria per
TPA-HL-60 cell. In similar comparisons of 388 and 388∆S, bacterial association to
eukaryotic cells was not significantly altered with ExoS expression (data not shown).
The results indicate that TPA treatment did not affect HL-60 membrane properties in a
manner that enhanced bacterial association with cells.
Another means by which TPA-treatment might indirectly affect ExoS internalization
is through alterations in membrane properties that allow direct diffusion of ExoS into
cells. To examine this possibility, TPA-HL-60 cells were cultured with soluble ExoS for

90

4.5 hours in the presence and absence of bacteria. In addition to strains 388 and
388∆S, these studies included the T3S mutant strains, 388-11 (a PscC mutant defective
in T3S-mediated secretion and translocation (258)) and 388∆PopD (a PopD mutant
defective in T3S-mediated translocation, but not secretion (236)) to assess ExoS
diffusion independently of a functional T3S-process. Previous studies have shown that
in the absence of PscC and PopD, ExoS is unable to exert toxic effects on eukaryotic
cell function (169, 236). To allow an endogenous form of ExoS to be evaluated in these
studies, strain 388 culture supernatant (500 µl) containing 1.1 µg of ExoS in the
presence of other Pa secreted factors, served as the source of ExoS. Using ExoS ADPribosylation of cellular substrates to detect ExoS internalization, no substrate
modification was detected in TPA-HL-60 cells cultured with soluble ExoS in the
presence of strain 388∆S, 388-11 or 388∆PopD (data not shown). In addition, no
enhancement of ExoS substrate modification was detected when soluble ExoS was
added to TPA-HL-60 cells co-cultured with strain 388. The results support that TPA
treatment does not alter HL-60 membrane integrity in a manner that allows ExoS
internalization independently of the TTS process.
ii) Direct mechanisms. Differences in the sensitivity of undifferentiated and TPAHL-60 cells to ExoS might also relate to alterations in cellular properties that affect hostcell induction of the T3S process. Prior to coculture, strains 388 and 388∆PopD were
cultured in medium that does not allow T3S induction (TSBD supplemented with 5 mM
CaCl2). Bacteria were then co-cultured with HL-60 or TPA-HL-60 cells for 4 hours in
Hanks balanced salt solution (Sigma). Total PopD was examined by adding 4X Laemmli
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Figure 18. Analysis of PopD induction by HL-60 and TPA-HL-60 cells.
HL-60 cells were cultured in the presence or absence of TPA for 48 hours prior to
co-culture with strains 388 or 388∆PopD (∆D) for 4 hours, then processed and resolved
by SDS-PAGE and immunoblotted for PopD and GAPDH. Bacterial supernatant
obtained from strain 388 cultured in inducing medium was used as a positive control
(SN). Results are representative of at least three independent experiments. (–) HL-60,
bacterial strains cultured in co-culture medium for 4 hours in the absence of eukaryotic
cells.
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sample buffer (129) to tissue culture wells, which allowed the combined harvest of
eukaryotic cells, bacteria and co-culture supernatants. Cells treated with strain
388∆PopD, no bacteria or bacteria cultured in the absence of eukaryotic cells served as
negative controls in these experiments. As shown in Figure 18, the induction of PopD by
HL-60 cells closely corresponded to that of TPA-differentiated HL-60 cells. These
results confirm that undifferentiated HL-60 cells are effective in inducing T3S
components, which mediate T3S-T.
Collectively, these data point to the likelihood that the increased sensitivity of TPAHL-60 cells to ExoS relates to an increased efficiency of ExoS T3S-T. To assess the
efficiency of ExoS translocation in HL-60 and TPA-HL-60 cells, time-course, co-culture
studies were performed, examining ExoS ADPRT activity in cytosolic and Triton X-100
membrane soluble fractions. In these analyses, ExoS ADPRT activity was found to be
5-6 fold higher in both the cytosolic and TX-100 membrane fractions of TPA- HL-60
cells, as compared to that of undifferentiated HL-60 cells (Figure 19 A). The efficiency of
ExoS ADPRT internalization was also found to directly correlate with the degree of
ExoS ADPRT substrate modification (Figure 19 B). ADP-ribosylation of RalA, Rab5 and
Rac1 was most efficient in the TX-100 membrane fractions of TPA-HL-60 cells, in
association with the highest levels of ExoS ADPRT activity. Rab5 modification was less
efficient and Rac1 was not modified in the cytosolic fraction of TPA-HL-60 cells in
association with lower levels of ExoS ADPRT activity in these fractions. RalA
modification could not be assessed since it was not detected in the cytosolic fraction.
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Figure 19. Time-course analysis of T3S-T-ExoS ADPRT activity and substrate
modification.
HL-60 and TPA-HL-60 cells were co-cultured with strain 388 or 388∆S for 3, 4.5
or 6 hours. Bacteria were removed, cells were washed, and cytosolic and Triton X-100
(membrane soluble) fractions were obtained, as described in Materials and Methods. A.
Internalized ExoS ADPRT activity. ADPRT activity is reported as fmol per min of ADPribose incorporated into the artificial substrate (SBTI) per µg of cellular protein, and the
mean and standard deviation of assays performed in duplicate are shown. B. ExoS
ADPRT substrate modification. Cell fractions in (A) were examined for ExoS ADPribosylation of eukaryotic LMWG-proteins by resolution by SDS-12% PAGE and
immunoblot analysis using RalA, Rab5 and Rac1 antibodies. ADP-ribosylated (m) and
unmodified proteins (u) are labeled. The results are representative of 3 independent
experiments.
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Minimal substrate modification was detected in the membrane fractions of
undifferentiated HL-60 cells, as would be predicted based the limited ExoS ADPRT
activity detected in these samples. Only a slight modification of Rab5 was detected after
a 4.5 hour co-culture time. No ADP-ribosylation of cellular substrates was detected in
the cytosolic fraction of undifferentiated HL-60 cells.
To further assess intracellular ExoS, undifferentiated HL-60 cells and TPA-HL-60
cells were co-cultured with Pa strain PA103∆UT expressing ExoS-HA (176). We have
previously been unable to detect T3S-T-ExoS protein in eukaryotic cells by Western blot
analysis (64, 197). However, the addition of the HA-tag to ExoS allowed detection of
T3S-T-ExoS in eukaryotic cell extracts, without reported effects on ExoS function (176).
Consistent with studies quantifying the internalization of ExoS ADPRT activity, ExoS
protein was found predominately in the membrane fraction of TPA-HL-60 cells (Figure
20 A). Confirming TPA-HL-60 internalization of ExoS, the T3S-T-ExoS was detected in
the cytosolic fraction of TPA-HL-60 cells. As shown in Figure 20 B, levels of T3S-TExoS correlate with the efficiency of Rab5 ADP-ribosylation in the respective fractions.
These results are consistent with the resistance of HL-60 cells to ExoS relating to the
less efficient ExoS translocation, and that TPA differentiation induces cellular changes
that allow a functional T3S apparatus to form and translocate ExoS.
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Figure 20. T3S-T of ExoS protein into HL-60 and TPA-HL-60 cells.
Cytosolic (C) and membrane (M) fractions of undifferentiated HL-60 or TPA-HL-60
cells were obtained by digitonin extraction and centrifugation. Fractions were resolved
by SDS-PAGE and immunoblotted with (A) anti-HA antibody to detect ExoS-HA and (B)
anti-Rab5 antibody to detect ExoS ADPRT substrate modification. Modified (M) and
unmodified (U) Rab5 proteins are labeled. ExoS-HA, obtained from T3S-induced
bacterial culture supernatants (SN), was included as a positive control.
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Discussion
It has become evident from studies of different cell lines that the host cell can
influence the effectiveness of Pa T3S. Polarized confluent epithelial monolayers remain
resistant to Pa infection and T3S, but become sensitive to both when the epithelial layer
is compromised (58, 154, 182). The host cell can also influence the toxicity and
substrate targeting of T3S effectors, as evident in decreased ExoS toxicity, in
association with alterations in LMWG-protein substrate modification patterns (192, 197).
In studying the effects of ExoS on the promyelocytic HL-60 cell line function, we
identified another cell line that was resistant to Pa T3S. A notable finding relative to HL60 cells was that sensitivity to T3S-T-ExoS could be induced by treatment with the
phorbol ester, TPA.
Treatment of spherical, non-adherent HL-60 cells with TPA induces their
differentiation into mature adherent monocytes that exhibit microvilli, pseudopodia and
lamellipodia on their cell surface. Induction of HL-60 T3S-T-sensitivity by TPA treatment
was initially recognized morphologically, by a loss of microvilli, with little or no change in
expression of pseudopodia or lamellipodia following exposure to T3S-T-ExoS. Previous
studies have linked effacement of microvilli to toxic effects of T3S-T-ExoS on actin
cytoskeleton structure in epithelial cells and macrophages (66, 169, 192). Functional
effects of T3S-T-ExoS on microvilli structure in TPA-HL-60 cells correlated with the
increased internalization of ExoS-HA and increased ExoS ADP-ribosylation of LMWGproteins. Our studies support that HL-60 resistance to T3S-T-ExoS relates to the lack of
efficient ExoS translocation and corresponding ExoS ADPRT substrate modification,
which can be induced by treatment with TPA.
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Several mechanisms were tested to explain the higher levels of T3S-T-ExoS in
TPA-HL-60 vs. HL-60 cells. These included: i) alterations in the efficiency of bacterial
adherence to HL-60 cells, which is required for T3S-T, ii) alterations in host cell
induction of T3S proteins, or iii) TPA-induced membrane alterations that allow direct
internalization of ExoS, independently of the T3S apparatus. None of these
mechanisms accounted for the differences in the effects of ExoS on cell function and
ADP-ribosylation of substrates in HL-60 and TPA-HL-60 cells. Another possible
mechanism that might explain the decreased levels of T3S-T-ExoS in HL-60 cells is an
increased rate of ExoS degradation. Studies examining this possibly also provided
negative results. In in vitro ExoS ADPRT reactions, purified ExoS was found to
efficiently ADP-ribosylate LMWG-proteins in HL-60 cell lysates, as previously reported
(30), and ExoS was not degraded or its activity inhibited by endogenous HL-60 proteins
(data not shown). Similarly, treatment of HL-60 cells or TPA-HL-60 cells with the
irreversible proteasome inhibitor MG132 (Sigma) or protease inhibitors did not enhance
T3S-T-ExoS ADPRT substrate modification in either cell line (data not shown).
Alternatively, in support of HL-60 cell resistance to T3S-T-ExoS occurring at the level of
membrane translocation, time course analyses revealed only a minimal increase in
ExoS ADPRT activity in the membrane fraction of HL-60 cells with time, and no activity
was detected within the cytosol. In comparison, a linear increase in ExoS ADPRT
activity was detected in the membrane fraction of TPA-HL-60 cells with time, and
detectable but smaller amounts translocated into the cytosol. Similar results were
obtained from tracking bacterial translocation of ExoS-HA. Combined, these data
indicate that the differential sensitivity of HL-60 and TPA-HL-60 cells to ExoS reflect
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cellular influences on the Pa T3S-T, rather than cellular properties that affect membrane
permeability, bacterial adherence, T3S-T-induction or ExoS degradation.
While these studies provided evidence that TPA differentiation of HL-60 cells
altered cell line responsiveness to T3S-T-ExoS, the mechanism for this transition
remains unknown. TPA induces HL-60 cells to differentiate into mature macrophages by
activating protein kinase C (PKC) signaling pathways (232) and increasing protease
activity (14). A hallmark of TPA differentiation is the ability of the cells to adhere to one
another and to tissue culture substrates. This suggests the potential for TPA to induce
alterations in HL-60 cell surface components that might affect T3S-responsiveness.
Several receptors for Pa have been identified, including the cystic fibrosis
transmembrane regulator (CFTR) (75, 180), asialo-GM1 (34, 41, 87, 123) and β1
integrins (182, 195). However, the identity of the eukaryotic receptor that is required for
Pa T3S-eukaryotic host cell interaction remains unknown. Interestingly, bacterial
association with TPA-HL-60 cells decreases when compared to that of HL-60 cells,
which might seem contradictory to the increased T3S-sensitivity of TPA-HL-60 cells.
However, this could also be an indication that Pa adherence to TPA-HL-60 cells is more
T3S-specific. Of note, candidate T3S-interactive proteins, such as α5β1 integrins and
intracellular adhesion molecules-1 (ICAM-1) show enhanced expression and avidity,
respectively, in response to TPA differentiation (14, 131, 195). Together, these draw
attention to the potential use of comparisons of HL-60 and TPA-HL-60 cells to identify
T3S-specific eukaryotic cell interactive components.
Currently, little is known about the host cell contribution to Pa T3S. Studies
described here identify a link between HL-60 cell resistance to T3S-T-ExoS to host cell
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properties that prohibit the establishment of a functional T3S apparatus. While the
mechanism for this T3S-resistance is not known, it appears to be reversed by
treatments that affect cell dynamics and motility. Also of particular relevance to these
studies is the identification of a T3S-resistant HL-60 cell line, which can be induced to
become T3S-sensitive, and in so doing provides a model system to study eukaryotic cell
mechanisms associated with alterations in Pa T3S-sensitivity.
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Chapter 4: Contribution of the host cell to the molecular targeting of type III
translocated ExoS
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Abstract
Both the GTPase activating activity (GAP) and the ADP-ribosyltransferase activity
(ADPRT) of bacterially translocated ExoS (T3S-T-ExoS) target low molecular weight Gproteins (LMWG-proteins) within the eukaryotic cell, which leads to interference of host
cell function. We have identified differences in host cell responsiveness to ExoS, which
now allows ExoS to be used as a tool to elucidate mechanisms by which the host cell
can modulate Pa T3S effector function. Previous studies defined two main patterns of
ExoS ADP-ribosylation: 1) a more restrictive pattern common to rodent cell lines,
recognized as a less efficient modification of Ras and RalA, and 2) a more extensive
pattern common to simian and human cell lines, recognized as a more efficient
modification of Ras, RalA, Rabs 5, 7, 8 and 11, and Rac1. Residues 51-72 of ExoS
define a membrane localization domain (MLD), which targets T3S-T-ExoS to eukaryotic
membranes. Deletion of the MLD resulted in relocalization of ExoS to the cytosolic
fraction. To examine the molecular basis for differences in ExoS substrate patterns,
ExoS with mutations in its MLD (∆MLD), GAP (R146) and ADPRT (E379, E381)
activities were examined for their influence on intracellular targeting of ExoS ADPRT
activity. T3S-T-ExoS∆MLD and T3S-T-ExoS-E381A produced a restrictive pattern of
substrate modification in human cell lines, but the mutations did not severely alter the
targeting of T3S-T-ExoS ADPRT activity in rodent cell lines. In comparison, T3S-TExoS-E379A was unable to ADP-ribosylate eukaryotic proteins. Mutation in the GAP
region resulted in increased intracellular levels of T3S-T-ExoS, indicating the role of this
region on translocation or clearance of ExoS. Together these studies identify molecular
signals within ExoS that influence the targeting of its ADPRT activity and find that these
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signals are interpreted differently in human and rodent cell lines. To understand the
mechanism for the differential targeting of ExoS ADPRT activity within human and
rodent cell lines, T3S-T-ExoS was co-immunoprecipitated from human and rodent cells.
Differences in T3S-T-ExoS protein interactions were observed, providing a means to
understanding differences in T3S-T-ExoS intracellular trafficking mechanisms.
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Introduction
Pa utilizes the type III secretion (T3S) system to translocate the virulence factor,
ExoS, into eukaryotic cells (258). T3S-translocation (T3S-T) of ExoS escalates tissue
damage in an acute lung infection model (212) and inactivates cell function in a tissue
culture model of infection (169). Specifically, in analysis of human epithelial cells, T3ST-ExoS inhibits cell growth and adherence and causes permanent cell rounding (66,
169). In J774 macrophages, T3S-T-ExoS protects Pa from phagocytosis (192). The
complex, suppressive effects of T3S-T-ExoS on cell function are attributed to its
bifunctional mode of action. The N-terminal portion of ExoS includes a GAP activity,
which targets Rho, Rac and Cdc42, (77) and is required for the T3S-T-ExoS
antiphagocytic phenotype (192). The C-terminal region of the molecule includes the
ADPRT activity (117), which preferentially targets LMWG-proteins within eukaryotic
cells (63, 65, 89), and is required for the effects of T3S-T-ExoS on DNA synthesis,
adherence and permanent cell rounding (64).
Subsequent studies have identified two main patterns of T3S-T-ExoS substrate
ADP-ribosylation (197). The first, more restrictive, pattern is observed when ExoS is
bacterially translocated into cells of rodent origin, which results in limited ADPribosylation of Ras and RalA. The second, more extensive, pattern is observed when
ExoS is bacterially translocated into cells of human or simian origin, which results in
more efficient ADP-ribosylation of Ras, RalA, in addition to ADP-ribosylation of Rab5,
Rab8, Rab11, Rab7 and Rac1. These findings suggest that the eukaryotic cell
influences the intracellular targeting of T3S-T-ExoS ADPRT activity.
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Integral to understanding the molecular mechanism of action of T3S-effector
proteins is linking their functional activity to intracellular localization. To date little is
known or understood about how T3S-T-ExoS is trafficked within the eukaryotic cell.
Previous studies reported that T3S-T-ExoS ADP-ribosylates Rab proteins in a time
course dependent manner (65). However, Rab proteins are not targeted in rodent cell
lines, suggesting a link between assessiblity to vesicular trafficking mechanisms and the
targeting of ExoS ADPRT activity. Other studies have indicated that transfected,
enzymatically inactive ExoS is trafficked to the perinuclear region of eukaryotic cells
(177). Recently, a membrane localization domain (MLD) was identified in the N-terminal
region of ExoS, between amino acids 51 and 72. This region targets T3S-T-ExoS to
eukaryotic membranes (176). The effect of this domain on ExoS subcellular localization
is consistent with studies, which found that T3S-T-ExoS ADPRT is enhanced in
membrane fractions of eukaryotic cells (64, 188, 197).
In order to ADP-ribosylate substrates, ExoS requires a eukaryotic factor, a member
of the14-3-3 family of proteins (68). 14-3-3 proteins are ubiquitously expressed in all
eukaryotes and are responsible for the subcellular localization, stability and molecular
activity of over 100 target proteins (46). While it is unknown with which 14-3-3 isoform(s)
T3S-T-ExoS interacts within the eukaryotic cell, all isoforms are capable of stimulating
ExoS ADPRT in vitro (268). Differences in substrate modification patterns in rodent
versus human cells may be linked to potential host cell influences on T3S-T-ExoS
subcellular localization and differential trafficking patterns, either through the vesicular
network or 14-3-3 interactions. The goal of these studies is to characterize differences
in intracellular targeting of T3S-T-ExoS.

105

We were able to explore the mechanism by which the host cell influences the
intracellular activity of T3S-T-ExoS using MLD, GAP or ADPRT mutant forms of ExoS.
Studies, which compare rodent and human cell lines, highlight the role of 1) the MLD in
ExoS localization and substrate modification, 2) the GAP domain on T3S-T of ExoS, 3)
the E379, E381 catalytic residues in ADPRT function, and 4) differences in protein
interactions with T3S-T-ExoS in rodent and human cell lines.
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Materials and Methods
Bacterial strains and culture conditions.

Strain

T3S

388

+

388∆S

T3S-

ExoS

ExoT

ExoU

ExoY

Reference

+

+

+

-

+

(106)

+

+

-

+

-

+

(126)

388∆PopD

+

-

+

+

-

+

(235)

38811

-

-

+

+

-

+

(258)

PA103∆UT

+

+

-

-

-

-

(235)

T

Table 2. Pa strain phenotypes
The + and – symbols indicate the presence or absence of the indicated phenotype, T3S,
T3S-T or expression of the indicated T3S effector.
Pa strains used were cultured as described in Chapters 2 and 3. Bacteria were
added to eukaryotic cells at an MOI of 50-100. The phenotypes of the strains used in
these studies are shown in Table 1. PA103∆UT strains expressing pUCP plasmid
encoded ExoS and ExoS with mutations in the GAP (R146A) and/or ADPRT (E379A or
E381A) were constructed as previously described (64, 141, 235).
Construction of ExoS-HA mutants
To assess how catalytic regions of ExoS affect its T3S-T, mutants of ExoS GAP
and/or ADPRT activities were constructed using the pUCPExoS-HA template. pUCP
vectors (211) encoding ExoS with an hemagglutinin tag (ExoS-HA) and ExoS with a
deletion in the membrane localization domain (MLD) (residues 51-72) (ExoS∆MLD-HA)
were kindly provided by Joseph Barbieri (Medical College of Wisconsin, Milwaukee, WI)
(176). The pUCPExoS-HA encodes a PstI-BamHI fragment of ExoS cloned from strain
388 (126, 258). When pUCPExoS-HA is expressed in strain PA103∆UT, it allows the
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T3S-T of ExoS in the absence of other known T3S effectors. The addition of the HA tag
to ExoS allows T3S-T-ExoS to be detected within eukaryotic cells by Western blot
analysis, without affecting ExoS function (176). The R146A GAP mutation was
introduced to pUCPExoS-HA (pUCPExoS-R146A-HA), essentially as previously
described (64), using the QuikChange PCR-based site-directed mutagenesis system
(Stratagene, La Jolla, CA). The primers used to introduce the mutation (indicated in
bold) and an NheI restriction site (underlined) were as follows: forward, 5’CGGAGATGGGGCGCTAGCTTCGCTGAGCACCG-3’, and reverse, 5’CGGTGCTCAGCGAAGCTAGCGCCCCATCTCCG-3’. PCR reaction mixtures
contained 200 ng of plasmid DNA, 25 µM primers, 625 µM mixture of deoxynucleotide
triphosphate (dNTP’s), 5 µl Pfu reaction buffer and 2.5 U of Pfu DNA polymerase
(Stratagene). The reaction mixtures were subjected to one denaturing cycle of 2
minutes at 95ºC, and then 18 cycles under the following conditions: 30 sec denaturing
cycle at 95ºC, 30 sec annealing cycle at 63ºC and a 12 minute extension cycle at 72ºC,
and completed by a 1 hour extension cycle at 72ºC. The PCR product was digested with
DpnI, then purified using an ethanol precipitation protocol. The entire precipitate was
then electroporated into electrocompetent Escherichia coli DH5α electrocompetent cells
(24).
The E379A mutation was introduced into the pUCPExoS-HA vector to produce
pUCPExoS-E379A-HA using the PCR-based GeneTailor Site Directed Mutagenesis
system (Invitrogen, Carlsbad, CA). The primers used to introduce the mutation (bold)
and an BsmI site (underlined) were as follows: forward, 5’GGGATATCGAACTACAAGAATGCAAAAGAGA-3’, and reverse, 5’-
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CATTCTTGTAGTTCGATATCCCGCTGA-3’. The E381A mutation was introduced into
both pUCPExoS-HA and pUCPExoS-R146A-HA using the GeneTailor Site Directed
Mutagenesis system, resulting in the construction of pUCPExoS-E381A-HA and
pUCPExoS-R146A/E381A-HA. The following primers were used to introduce the E381A
mutation (bold) and a BsrG1 site (underlined): forward, 5’CAAGAATGAAAAAGCGATTCTGTACAACAAAGAAAC-3’, and reverse, 5’CTTTTTCATTCTTGTAGTTCGATATCC-3’. To construct a pUCPExoS-E379A/E381AHA mutant, an E381A mutation was introduced to the pUCPExoS-E379A-HA template
using the following primers: forward, 5’CTACAAGAATGCAAAAGCGATTCTGTACAACAAAGAAAC-3’, and reverse, 5’TTTTGCATTCTTGTAGTTCGATATCC-3’.
For all mutants created by the GeneTailor Site-Directed Mutagenesis system, prior
to PCR reactions 100 ng of template DNA were methylated using 4 units of CpG
Methylase (M.Sss I) (New England Biolabs, Beverly, MA). PCR reaction mixtures
contained 12.5 ng methylated DNA, 300 µM dNTP’s, 10 µM primers, 1 mM MgSO4,
High Fidelity PCR buffer, and 1.5 units of Platinum Taq High Fidelity enzyme
(Invitrogen). The reaction mixtures were subjected to one 2 minute denaturing cycle at
94ºC, followed by 35 cycles: 30 sec denaturing cycle at 94ºC, a 30 sec annealing cycle
at 55ºC and a 8 minute extension cycle at 68ºC, and completed by a final 10 minute
extension cycle at 68º. The PCR reaction (4µl) was then transformed into One-Shot
Max Efficiency DH5α-T1R (Invitrogen), using a heat-shock method (13).
pUCPExoS-R146A/E379A-HA and pUCPExoS-R146A/E379A/E381A-HA were
constructed by digesting plasmids, pUCPExoS-R146A-HA, pUCPExoS-E379A-HA and
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pUCPExoS-E379A/E381A-HA with enzymes EagI (which cuts in the middle of exoS)
and BamHI (which cuts outside the C-terminal region of exoS). EagI-BamHI fragments
from pUCPExoS-E379A-HA and pUCPExoS-E381A-HA were gel purified using the
Wizard SV Gel and PCR Clean-Up system (Promega, Madison, WI) and ligated into the
digested pUCPExoS-R146A-HA plasmid (100 ng vector; 115 ng insert) using T4 DNA
ligase (Promega). The ligation reaction (5 µl) was transformed into One-Shot Max
Efficiency DH5α-T1R (Invitrogen).
Mutants were selected by plating transformed E. coli strains onto LB agar plates
containing 100 µg/ml ampicillin. Clones were initially screened using restriction digests
for added sites. ExoS mutations were confirmed by sequencing (Biotech Core, Inc.,
Sunnyvale, CA). pUCP vectors (150 ng) encoding mutant forms of ExoS-HA were
electroporated into electrocompentent PA103∆UT (43). Transformed bacteria were
selected on LB agar containing 400 µg/ml carbenicillin. Positive clones were tested for
ExoS expression by growing cells in TSBD-N medium, harvesting cells and fractionating
them into secreted supernatants and whole cell pellets. Samples were processed for
SDS-PAGE and immunoblotted with anti-ExoS and anti-HA-tag antibodies (Covance,
Berkeley, CA). To confirm that the transformed Pa contained the correct ExoS
construct, plasmid was re-isolated from Pa using the Holmes and Quigley
phenol/chloroform extraction protocol (97), transformed into DH5α, and subjected to
restriction digest analysis.
Eukaryotic cell culture
Eukaryotic cells were cultured as described in Chapters 2 and 3.
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Monitoring ADP-ribosylation of eukaryotic substrates
In vitro analysis.
Eukaryotic cells were grown to confluency, washed twice with Dulbecco’s
phosphate buffered saline (DPBS) and lysed for 30 minutes on ice in a buffer containing
0.03 M HEPES (pH 7.5), 1% Triton X-100, 10 mM NaCl, 10% glycerol, 1 mM EGTA, 25
mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate and supplemented with Protease
Cocktail III (Calbiochem), proteosome inhibitor MG-132 (Sigma) and benzamidine, then
stored at -70ºC. Before the in vitro ADPRT reaction, lysates were thawed at room
temperature, and unbroken cells and nuclei were cleared by centrifugation at 16,000 x g
for 5 minutes at 4ºC. To monitor ExoS ADP-ribosylation of eukaryotic substrates,
supernatants, which were the sources of ExoS and mutant ExoS, from T3S-induced
bacterial cultures (~1.7 µg of total protein) and 100 nM NAD were added to the
aliquoted cleared lysates. Mixtures were incubated for 1 hour at room temperature, and
reactions were stopped by the addition of 4X Laemmli sample buffer (129), and heating
at 95ºC for 5 minutes. Samples were resolved by SDS-12% PAGE and immunoblotted
for the appropriate proteins, as outlined in Chapters 2 and 3.
In vivo analysis
T3S-T-ExoS and T3S-mutant ExoS was determined as described in Chapters 2 and 3.
Intracellular localization of T3S-T-ExoS
i) Co-culture
With the ability to detect intracellular ExoS through immunoblot analysis, several
cellular fractionation techniques were developed to track T3S-T-ExoS’s cytosolic or
membrane localization. To determine the intracellular localization of T3S-T-ExoS,
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eukaryotic cells were seeded in 100 mm dishes at 105 cells/ml and grown to 60-80%
confluency. Cells were co-cultured with Pa strains, expressing pUCPExoS-HA (MOI of
20:1), for 5 hours. At the end of the co-culture period, cells were washed twice with
DPBS, and detached with 2 ml 0.025% Tryspin-EDTA (GibcoBRL, Gaithersburg, MD).
The trypsin served to both detach eukaryotic cells and proteolyze extracellular ExoS
(non-T3S-T-ExoS). After 12 minutes, cells were removed from the dishes and the
trypsin was neutralized with cell medium containing FBS.
ii) Ultracentrifugation method
The membrane or cytosolic localization of T3S-T-ExoS was initially determined by
subjecting co-cultured eukaryotic cells to ultracentrifugation. Washed and trypsinized
cells were pelleted by low-speed centrifugation and resuspended in 650 µl of HBII buffer
(3 mM Imidazole, pH 7.4, 250 mM sucrose and protease inhibitors). Lysates were
obtained by passaging cells through a 5/8 inch 27 gauge needle 14 times. Unbroken
cells and nuclei were cleared by centrifugation at 800 x g for 5 minutes at 4ºC. Lysates
were further fractionated into cytosolic (S100) and membrane (P100) fractions by
ultracentrifugation at 116,140 x g for 40 minutes at 4ºC. The P100 fraction was
equilibrated to the volume of the S100 fraction, and 4X Laemmli sample buffer was
added to an aliquot of sample, which was processed for SDS-PAGE and immunoblotted
for ExoS using an anti-HA antibody (Upstate, Lake Placid, NY). Additional aliquots of
the same samples were examined for T3S-T-ExoS ADP-ribosylation of eukaryotic
substrates, and ExoS ADPRT activity, as previously described in Chapters 2 and 3
(197, 198).
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iii) Digitonin extraction
As a means to track T3S-T-ExoS ADPRT activity, the subcellular localization of
substrates ADP-ribosylated by ExoS was determined by digitonin extraction. After the
co-culture period, cells were lysed in 750 µl (60 mm dish) or 1 ml (100 mm dish) with
digitonin extraction buffer (0.01% digitonin, 10 mM Pipes, 300 mM sucrose, 100 mM
NaCl, 3 mM MgCl2, 5 mM EDTA; pH buffer to 6.8) for 20 minutes on ice. Cells were
scraped into microfuge tubes and separated into cytosolic (supernatant) and membrane
(pellet) fractions by centrifugation at 16,000 x g for 15 minutes at 4ºC. The volumes of
supernatants and pellets were equilibrated with sample buffer and processed as
previously described for SDS-PAGE and immunoblot analysis.
iv) Modified digitonin extraction
A limitation of the ultracentrifugation method was that only 6 samples could be
processed at one time. To increase the throughput of the fractionation analysis, a
modified-digitonin extraction method was developed. Washed and trypsinized
eukaryotic cells (described above) were pelleted by low-speed centrifugation and
resuspended in 750 µl modified digitonin extraction buffer (10 mM Imidizole, pH 7.4, 250
mM sucrose, 3 mM MgCl2, 5 mM EDTA, 0.01% digitonin). (The new buffer recipe
combined components of HBII and digitonin extraction buffers (both defined above) to
maximize the detection of ExoS-HA in cellular fractions.) Cells were then processed,
essentially as described by the digitonin extraction protocol. After the lysates were
centrifuged at 16,000 x g for 15 mintues at 4ºC, the pellet (membrane fraction) was
resuspended in 750 µl of HBII buffer containing 0.1% Triton X-100. Protein
concentrations of cytosolic and membrane fractions were determined using the BCA
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Protein Assay Kit (Pierce, Rockford, IL). Laemmli sample buffer was added to the
remaining fraction volumes and samples were heated at 95ºC for 5 minutes. Equal
amounts of protein were resolved by SDS-PAGE, and localization of T3S-T-ExoS to
cytosolic or membrane fractions was determined by immunoblot analysis using an antiHA antibody (Covance). To monitor protein loading, immunoblots were probed with an
antibody against heat shock protein 70, anti-HSP70, which is known to localize to
mitochondrial, endoplasmic reticulum, nuclear and cytosolic fractions (BD Transduction
Laboratories). The densities of protein bands were determined using Tiffany software
(Humphrey Gardner, Scripps Institute, La Jolla, CA).
Examination of T3S-T-ExoS intracellular processing
i) Effect of protease inhibitors on T3S-T-ExoS ADPRT activity
To determine if T3S-T-ExoS is processed by a eukaryotic protease, eukaryotic cells
were treated with diffusible protease inhibitors, and cell lysates were examined for ADPribosylation of eukaryotic proteins. In these studies, HL-60 cells were seeded and TPAdifferentiated as described in Chapter 3. One hour prior to co-culture with Pa strain 388,
TPA-HL-60 cells were pretreated with a 1:500 dilution of a protease inhibitor cocktail
(PIC), P8340, (Sigma), as well as, the appropriate concentrations of the individual
protease inhibitor-components of the PIC. The 1:500 dilution of the PIC contains 208
µM AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride) (serine PI), 160 nM aprotinin
(serine PI), 4 µM leupeptin (serine and cysteine PI), 8 µM bestatin (aminopeptidase
inhibitor), 3 µM pepstatin A (acid PI), and 2.8 µM E-64 (N-(trans-Epoxysuccinyl)-Lleucine 4-guanidinobutylamide) (cysteine PI). The 1:500 PIC dilution was found to have
an effect on ExoS ADP-ribosylation, without affecting bacterial growth. Pretreatment of
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eukaryotic cells with PI solvents, including dH20 (AEBSF, aprotinin, leupeptin), DMSO
(PIC, bestatin, E-64) and 10% acetic acid in methanol (pepstatin A), served as controls.
After a 4 hour co-culture period with strain 388 or no bacteria, eukaryotic cells were
lysed in Laemmli sample buffer, heated at 95ºC for 5 minutes, resolved by SDS-PAGE
and examined by immunoblot analysis, as previously described.
ii) Effect of PIC on Pa T3S
To determine if the PIC and AEBSF had an effect on Pa T3S, strains 388, 388∆S,
388∆PopD, and 38811 were cultured with the drugs and then monitored for the
production of PopD, a protein required for T3S-T. In these studies, bacteria from frozen
stock were initially cultured overnight in LB, then cultured for an additional 14 hours in
dialyzed tryptic soy broth supplemented with 5 mM CaCl2 (to suppress T3S). For the
experiment, 208 µM AEBSF, 1:500 dilution of PIC, and appropriate diluent controls
(dH2O and DMSO) were added to 3 ml of dialyzed tryptic soy broth supplemented with 5
mM EGTA (to induce T3S). The medium was then inoculated with 107 bacteria/ml and
incubated for 4 hours in a 37ºC shaking water bath. At the end of the culture period, 300
µl of the bacterial culture was removed and 100 µl of 4X Laemmli sample buffer was
added to the sample. The samples contained bacteria and secretion products. The
samples were processed for and resolved by SDS-PAGE and immunoblotted with an
anti-PopD antibody (Dara Frank, Medical College of Wisconsin).
Co-immunoprecipitation of T3S-T-ExoS
To understand a mechanism associated with differences in T3S-T-ExoS substrate
specificity between rodent and human cell lines, a co-immunoprecipitation (Co-IP)
procedure was developed, which would allow for the purification of T3S-T-ExoS and
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ExoS-associated proteins. In initial studies, Co-IP reactions were performed using
ExoS-HA and anti-HA antibodies and protein A-sepharose beads to IP the protein
complexes. However, several complications were associated with this approach: 1)
significant background was caused by the heavy chain of IgG (which resolves similarly
to ExoS by SDS-PAGE) and Protein A breakdown products, 2) the HA tag is a small
epitope, limiting the specificity of the reaction, which made it difficult to identify unique
T3S-T-ExoS interacting proteins. To address these problems, we were given an
enzymatically inactive ExoS mutant constructed with a C-terminal triple FLAG tag
(Sigma) by Joe Barbieri (Medical College of Wisconsin), which is encode on the pUCP
plasmid and expressed by PA103∆UT (PA103∆UTpUCPExoS-R146K/E379D/E381D3XFLAG). The triple FLAG epitope is approximately 22 amino acids in length and
includes two additional FLAG epitopes for recognition by the M2 anti-FLAG tag antibody
(Sigma).
T24, human epithelial cells, and TCMK-1, mouse epithelial cells, were seeded in
100 mm dishes, as previously described, and grown to 70-95% confluencey. Eukaryotic
cells were co-cultured with 107 PA103∆UTpUCP or PA103∆UTpUCPExoS-R146KE379D/E381D-3XFLAG for 4.5 hours. Cells were then washed twice with DPBS and
detached with 0.25% trypsin-EDTA (HyClone, Logan, UT) for 10 minutes. Trypsinized
cells were removed from the dishes, and dishes were washed an additional time with
DPBS (to maximize harvest of eukaryotic cells). The trypsin was neutralized with the
addition of 1 ml fetal bovine serum (CellGro, Mediatech, Inc. Herdon, VA). Eukaryotic
cells were pelleted by low-speed centrifugation and then resuspended in 800 µl of HBII
buffer (defined above). Cells were lysed by passage 20 times through a 27 gauge

116

needle or by passage 15 times through a 28 gauge needle. Unbroken cells and nuclei
were pelleted by centrifugation at 16,000 x g for 5 minutes at 4ºC. A 24 µl volume of 5 M
NaCl was added to lysates to obtain a final concentration of 150 mM NaCl. Protein
concentrations in lysates were determined using a BCA Protein Assay (Pierce). Prior to
the co-immunoprecipitation reaction, 30 µl of anti-FLAG M2-Agarose affinity resin
(Sigma) was washed 3 times in HBII, pelleting the resin by centrifugation at 8,200 x g
for 30 seconds at 4ºC between washes. Equal amounts of protein were added to the
washed resin, and reactions were rotated at 4ºC for 2 hours. Resin was washed 5 times
in Tris buffered saline (TBS, 50 mM Tris, 150 mM NaCl, pH 7.4 supplemented with 1%
EDTA and PIC) centrifuging at 8,200 xg for 30 seconds at 4ºC between washes. To
elute the co-immunoprecipitate, resin was resuspended in 100 µl of TBS containing 150
ng of 3X FLAG peptide (Sigma) and rotated overnight at 4ºC. The supernatant
containing the co-immunoprecipitate was obtained by pelleting the resin by
centrifugation at 8,200 x g for 30 seconds at 4ºC. 4X Laemmli sample buffer was added
to the supernatant and heated at 95ºC for 5 minutes. An aliquot of the sample was
analyzed by SDS-PAGE and immunoblot analysis with the M2 anti-FLAG antibody
(Sigma). The remainder of the sample was resolved by SDS-10% PAGE on an 13.0 cm
X 14.5 cm gel, and protein was visualized by Imperial Protein Stain (Pierce), Gel Code
Color Silver Stain Kit (Pierce) or SilverSNAP Stain for Mass Spectrometry (Pierce).
Seven samples were excised from the gel and sent to James Carroll (Department of
Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine,
Pittsburgh, PA) for tryptic digestion, and MALDI-MS (matrix-assisted laser
desorption/inonization mass spectrometry) analysis using an ABI 4700 TOF-TOF
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Proteomic analyzer (Applied Biosystems, Foster City, CA) located in the Genomics and
Proteomics Core Laboratories at the University of Pittsburgh. As a negative control, a
portion of the gel, which lacked discernible protein bands, was excised and processed.
Results were analyzed using Prospector software, v 4.0.5 (Mass Spectrometry Facility,
University of California at San Francisco, San Francisco, CA).
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Results
Effects of MLD, GAP and ADPRT mutations on T3S-T-ExoS eukaryotic substrate
modification
ExoS is a biglutamic ADP-ribosyltransferase, with E379 conferring the transfer of
the ADP-ribose to target proteins and E381 conferring the action of cleaving the ADPribose from NAD molecules (Figure 1A) (141, 186). Previous in vitro analyses indicated
that an E381 ExoS mutant would not be able to ADP-ribosylate substrates (141). To
corroborate previous studies and determine which residues were required for in vitro
ExoS ADPRT, equal amounts of supernatant from T3S-induced Pa cultures that
expressed wild-type or mutant ExoS were incubated with lysates from eukaryotic cells
for 1 hour at room temperature. Mutation of either E379 or E381 resulted in lack of
ADP-ribosylation of RalA or Rac1 in both rodent (TCMK-1) and human (T24) cell lysates
(Figure 1B). These results were consistent with the previously observed lack of ExoS
ADP-ribosylation of Ras in vitro by E379A and/or E381A ExoS mutants (64, 186).
Previously it was shown that the eukaryotic cell influences which substrates T3S-TExoS targets (65, 197). To better understand how the host cell specifically influences
T3S-T-ExoS restrictive or extensive patterns of ADP-ribosylation, rodent (TCMK-1 or
Swiss-3T3) and human (T24) cells were co-cultured with Pa strain PA103∆UT which
expressed a pUCP plasmid encoding a wild type or mutant-form of ExoS (Figure 1C).
Interestingly, T3S-T-ExoS-E381A was able to modify both Ras and RalA within
eukaryotic cells, albeit to a more limited extent than ExoS. However, it was unable to
ADP-ribosylate cellular Rabs and Rac1 (Figure 1B and Figure 2). The E381A mutation
did not alter how T3S-T-ExoS targets substrates within rodent cell lines.
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Figure 21. Effect of MLD, GAP and ADPRT mutations on ExoS ADP-ribosylation of
cellular substrates.
A. Linear model of ExoS showing the location of the MLD (residues 52-71) (176),
GAP domain (residues 72-253) (77), ADPRT domain (residues 253-453) (117, 141,
186), and the 14-3-3 binding domain (residues 420-429) (90). The location of the HA
epitope tag (176) or the 3XFLAG epitope tag (J. Barbieri, personal communication) are
also indicated. A detailed description of the linear map is included in Figure 6. B. In vitro
analysis. Wild type or the indicated mutant ExoS, obtained from bacterial culture
supernatants, was incubated with NAD and cell lysates for 1 hour at room temp, as
previously described. Reactions were stopped with the addition of 4X Laemmli sample
buffer, heated to 95ºC for minutes, and resolved by SDS-PAGE. The indicated proteins
were immunoblotted with specific antibodies and developed by ECL. C. In vivo analysis.
Eukaryotic cells were co-cultured with bacteria expressing wild type or mutant ExoS,
harvested, and examined as described in B. ADP-ribosylated (M) and unmodified (U)
proteins are indicated. M1 and M2 refer to the first and second modifications of RalA by
T3S-T-ExoS. Cell lines with restrictive and extensive T3S-T-ExoS ADPRT-modification
patterns are indicated.
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Also evident in these studies was the lack of substrate modification by the E379A
mutant, indicating the absolute requirement for the E379 residue for T3S-T-ExoS
substrate ADP-ribosylation in vivo (Figure 21C).
It was clear that the E379A and E381A affected how ExoS ADPRT activity was
targeted within the cell, however, the mechanism for these differences were not clear.
To help understand the cellular mechanism associated with the effects of E381 and/or
E379 mutations on T3S-T-ExoS substrate specificity, patterns of T3S-T-ExoS ADPribosylation or T3S-T-ExoS localization were monitored in cell lines exhibiting the
restrictive (CHO, NIH-3T3, Swiss-3T3) or extensive pattern (Vero, T24, Wi38-SV40t).
Cell fractionation was previously found to facilitate detection of subtle differences in
ExoS ADPRT substrate ADP-ribosylation. For example, modification of Cdc42 was
undetectable in whole HT-29 cell lysates, but became evident upon fractionation (65). In
these studies, cells were fractionated by digitonin extraction after co-culture with Pa
strains producing wild type or mutant ExoS constructs, and the resultant cytosolic and
membrane fractions were examined for substrate modification of RalA, Rac1 and Rab5.
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Figure 22. Digitonin extraction of eukaryotic cells treated with Pa expressing wild
type or mutant ExoS.
After a 5 hour co-culture period with PA103∆UT expressing the indicated ExoS
mutants or empty vector pUCP, eukaryotic cells were fractionated into cytosolic (C) and
membrane (Mb) fractions. Samples were resolved by SDS-PAGE, followed by Western
blot of the indicated proteins, and visualized using ECL. Cells lines belonging to the
extensive or restrictive pattern of substrate modification are indicated. Rab5
modification is shown only for cell lines having an extensive ADPRT substrate pattern
(Vero, T24, and Wi38t). ADP-ribosylated (M) and unADP-ribosylated (U) proteins are
indicated.
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As evident in Figure 22, RalA remains predominately in the membrane fraction,
Rac1 remained predominately in the cytosolic fraction, and Rab5 was equally
distributed between the two fractions in cells treated with PA103∆UTpUCP. Elimination
of ExoS GAP activity by mutation of the arginine at position 146 to an alanine
(ExoSR146A) did not affect ExoS substrate specificity when it was bacterially
translocated into eukaryotic cells (Figure 21 C and Figure 22). However, in cells with an
extensive ADPRT substrate modification pattern, ADP-ribosylation of RalA and/or Rab5
was more efficient in association with T3S-T of ExoSR146A, as compared to T3S-T of
wild type ExoS. Consistent with analysis of whole cell lysates, T3S-T-ExoSE381A
resulted in a single modification of RalA in both rodent and human cell lines and E379
was absolutely required for T3S-T-ExoS ADP-ribosylation of substrates. Also, both the
E379 and E381 residues were found to be required for T3S-T-ExoS ADP-ribosylation of
Rab proteins and Rac1, and the more efficient ADP-ribosylation of Ras and RalA.
These studies identified a role of the E381 residue in the extensive ADPRT substrate
pattern observed in human and simian cell lines, but not for ADP-ribosylation in rodent
cell lines. Differences observed in substrate modification by the R146A and E381A
mutants in human and rodent cell lines further highlight eukaryotic cell influences on the
targeting of T3S-T-ExoS ADPRT activity.
Recently, a MLD has been identified to reside within amino acids 51-72 of ExoS and
it functions to target ExoS to eukaryotic membranes (176). ExoS ADPRT activity has
been found mainly within the membrane fraction, indicating that intracellular localization
is important to T3S-T-ExoS ADPRT activity (64, 188). With the availability of the
PA103∆UT strain to express the ExoS∆MLD-HA mutant, we asked how the
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Figure 23. Effect of MLD on intracellular targeting and localization of T3S-T-ExoS
ADPRT activity
A. Effect of MLD on T3S-T-ExoS substrate modification. Eukaryotic cells of
restrictive or extensive patterns of substrate modification were co-cultured with
PA103∆UT expressing wild type ExoS-HA (ExoS) or ExoS∆MLD-HA (MLD) or, pUCP
(pU) vector, for 4 to 5 hours, and harvested and examined for the indicated proteins by
Western blot analysis, as previously described. ADP-ribosylated (M) and unmodified (U)
proteins are indicated. B. Effect of MLD on T3S-T-ExoS intracellular localization. After
co-culture with PA103∆UT expressing either ExoS∆MLD-HA (MLD) or ExoS-HA (S),
cell lines were harvested and fractionated by ultracentrifugation (refer to Methods and
Materials), to produce cytosolic S100 (S) and membrane P100 (P) fractions. Fraction
volumes were equilibrated and samples were resolved and immunoblotted using an
anti-HA tag antibody, as previously described. ExoS (S) and ExoS∆MLD proteins have
different mobilities by SDS-PAGE, as indicated. The cytosolic ADPRT activity, which is
measured in fmol/µg min and corresponds to the data points displayed in Figure 3B, for

124

T3S-T-ExoS∆MLD-HA versus T3S-T-ExoS-HA are as follows: CHO, 116.305 ± 5.8 vs.
31.69 ± 0.206; NIH-3T3, 61.78 ± 3.3 vs. 5.90 ± 0.187; Cos-1, 80.9 ± 0.233 vs. 17 ± 0.28;
T24, 37.7 ± 2.1 vs. 1.68 ± 0.07. Restrictive pattern cell lines: CHO-K1 (CHO), NIH-3T3
(NIH); Extensive pattern cell lines: Cos-1, T24.
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MLD influenced the targeting of ExoS to eukaryotic substrates. In examining
ExoS∆MLD in an in vitro analysis, using T3S-induced Pa supernatant as a source of
ExoS and ExoS∆MLD, and eukaryotic lysates as a source of 14-3-3 and substrates,
ExoS∆MLD-HA ADP-ribosylated proteins similarly to wild type ExoS (refer to Figure 21
A). When we compared the ADP-ribosylation of ExoS substrates in rodent (CHO) or
human (T24) cell lines after co-culture with Pa expressing ExoS-HA or ExoS∆MLD-HA
(Figure 21 and Figure 23 A), T3S-T-ExoS∆MLD-HA reduced the efficiency of ExoS
ADPRT substrate modification. In rodent cells, Ras and RalA were modified by T3SExoS∆MLD, but much less efficiently than that observed in vitro (compare Swiss-3T3,
Figure 21 C and CHO, Ras and RalA, Figure 23 A). In T24 human epithelial cells, T3ST-ExoS∆MLD-HA ADP-ribosylated substrates in a manner similar to that of wild type
T3S-T-ExoS-HA in rodent cell lines. This was evident in the modification of Ras, a
single modification of RalA, and no modification of Rabs 5 and 8 or Rac1 (Figure 21B
and Figure 23 A). In addition, T3S-T-ExoS∆MLD-HA did not redirect ExoS to cellular
targets, which are not normally ADP-ribosylated by T3S-T-ExoS-HA, such as Rab4 and
Rho (Figure 23 A). These results indicate that the MLD may play a greater role in
targeting ExoS to eukaryotic proteins in human cells, than in rodent cells.
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ExoS ADPr pattern
Substrate Intracellular Extensive Restrictive

Mutant ExoS ADPr
E381A

∆MLD

localization
Ras

PM

+*

+

+

+

RalA

PM

+*

+

+

+

Rab5

CCV, EE

+

-

-

-

Rab8

tG, SG

+

-

-

-

Rab7

LE

+

-

-

-

Rab11

pnRE, pgRE

+

-

-

-

Rac1

Cyto/PM

+

-

-

-

Table 3. Summary of ExoS ADP-ribosylation patterns and subcellular localization
of target proteins
Summary of targets of ExoS ADP-ribosylation within the eukaryotic cell. Extensive
(human and simian cell lines) and restrictive (rodent cell lines) patterns are defined. The
effect of E381A and ∆MLD mutations on substrate targeting in human cells is shown.
The E381A and the ∆MLD mutations do not affect T3S-T ExoS targeting of substrates
in rodent cell lines. + or – indicates whether proteins are ADP-ribosylated or not by
ExoS. +* indicates a protein is more efficiently modified in human and simian cell lines,
as compared to rodent cell lines. ADPr, ADP-ribosylation; PM, plasma membrane; CCV,
clathrin coated vesicles; early endosomes, EE; trans-Golgi region, tG; secretory
granules, SG; late endosomes, LE; perinuclear recycling endosomes, pnRE; perigolgi
recycling endosomes, pgRE; cytosol, Cyto.
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To further explore the mechanism for diminished ADP-ribosylation by the
ExoS∆MLD mutant within eukaryotic cells, cytosolic and membrane fractions were
compared for the presence of ExoS∆MLD-HA and ExoS-HA, by Western blot analysis
(Figure 23 B) and by quantification of ExoS ADPRT within cytosolic and membrane
fractions. T3S-T-ExoS∆MLD-HA localized to the cytosolic fraction, while wild type T3ST-ExoS-HA localized mainly to the membrane fraction of both rodent and human cell
lines. These results correlated with the greater amount of ExoS ADPRT activity
detected in cytosolic fractions of cells treated with PA103∆UT-pUCPExoS∆MLD-HA, as
compared to the cytosolic fractions of cells treated with PA103∆UT-pUCPExoS-HA.
Also evident from these results was that the decreased ADP-ribosylation of substrates
by ExoS∆MLD-HA did not relate to a defect in the T3S-T of ExoS∆MLD-HA. In general,
greater total amounts of T3S-T-ExoS∆MLD-HA were detected in total lysates of all cell
lines (data not shown); however, bacteria also secreted ExoS∆MLD-HA more efficiently
than ExoS-HA (data not shown), indicating that this domain may be important for T3S of
ExoS, as well as, intracellular targeting of T3S-T-ExoS. Most importantly, these results
indicate that without localization to the membrane fraction, T3S-T-ExoS can not
efficiently ADP-ribosylate substrates.
Examining intracellular processing of T3S-T-ExoS
While examining the intracellular localization of ExoS, we often noticed multiple
forms of ExoS in total lysates of cells treated with ExoS-HA producing bacteria (Figure
24 A). Although the heterogeneity in molecular mass and charge of ExoS had been
noted previously (151), the function of these different forms of ExoS within eukaryotic
cells remains unclear. In our studies we have observed three forms of T3S-T-ExoS by
SDS-PAGE followed by Western blot analysis: a form which has a lower mobility than
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T3S-secreted ExoS, a form which has a similar mobility to T3S-secreted ExoS, a form
which has a higher mobility than T3S-secreted ExoS (Figure 24 A and Figure 25). ExoS
has been reported to have a processing site within the first 78 amino acids (177) and to
ADP-ribosylate itself (auto-ADP-ribosylated) within the cell (189). Hence, we
hypothesized that the lower mobility form of T3S-T-ExoS to be a processed form, and
the higher mobility form to be the auto-ADP-ribosylated form. The processed form and
the ADP-ribosylated form of T3S-T-ExoS have never been observed within the same
sample. The ADP-ribosylated form is also more commonly observed than the processed
form, suggesting that the lower mobility form may be an intermediate state or unstable
form that precedes the self-ADP-ribosylated form of T3S-T-ExoS (personal
observation). In addition, T3S-T-ExoS auto-ADP-ribosylation has been observed in both
rodent and human cells, but was not observed when E379A and/or E381A mutants
were bacterially translocated into the host cell, indicating that this event requires both
glutamic acid residues (Figure 5).
To better understand the processed, intermediate form of T3S-T-ExoS, eukaryotic
cells were treated with membrane permeable protease inhibitors and then co-cultured
with ExoS producing bacteria. Initial results indicated that a 1:500 dilution of the
protease inhibitor cocktail (PIC), eliminated ADP-ribosylation of Rab5 (Figure 24 B). The
1:500 dilution of the PIC did not have an effect on eukaryotic cell viability or bacterial
cell growth (data not shown). In examining the individual components of the PIC, 208
µM AEBSF, which is a serine protease inhibitor, was the component which was
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Figure 24. Effect of protease inhibitors on the intracellular targeting and T3S-T of
ExoS ADPRT activity.
A. Cellular processing of T3S-T-ExoS. Eukaryotic cell lysates (TL) were prepared from
the indicated cell lines and resolved by SDS-PAGE and immunoblotted for ExoS, using
the anti-HA tag antibody. The asterisk denotes the lower, processed form of ExoS
observed in TL but not in bacterial supernatants (Pa sup). B. Effect of components of
the PIC on ExoS ADP-ribosylation of Rab5. TPA-HL-60 cells were treated with
individual components of the PIC, prior to incubation with Pa strain 388. Samples were
resolved by SDS-PAGE, followed by Western blot analysis for Rab5 and visualized by
ECL. ADP-ribosylated (M) and unmodified (U) forms of Rab5 are indicated. No drug,
ND; AEBSF, A; Aprotinin, Ap; Leupeptin, L; Bestatin, B; Pepstatin A, P; E-64, E;
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Protease inhibitor cocktail, PIC; DMSO, DM; 10% Acetic acid, Ac; dH2O, dH. C. Effect of
PIC and AEBSF on production of PopD. Pa strain 388 was incubated with no drug, PIC,
AEBSF or carrier controls for 4 hours, prior to the combined harvest of bacterial cells
and bacterial supernatants. Samples were resolved by SDS-PAGE, followed by
Coomasie staining or immunoblot analysis for PopD (shown). To ensure equal protein
loading, densitometry analysis was performed on the Coomasie stained gel and raw
densitometry values for total bacterial supernatant are as follows: ND, 24.56; A, 25.31;
PIC, 26.28; DM, 27.73; dH, 28.04. D. Effect of AEBSF and PIC on T3S-Tof ExoS. After
treatment with the indicated drugs or controls, T24 cells were trypsinized and processed
for SDS-PAGE and immunoblot analysis. Membranes were incubated simultaneously
with antibodies against heat shock protein 70 (HSP70), HA tag, RalA and Rac1, and
visualized by ECL. ADP-ribosylated (M) and unmodified (U) proteins are indicated. No
bacteria, NB.
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responsible for the inhibition of ADP-ribosylation of Rab5 in TPA-differentiated HL-60
cells (Figure 24 B). As a control, bacterial cells were cultured in the absence of
eukaryotic cells and examined for production of a protein required for Pa T3S, PopD.
Unexpectedly, AEBSF and the PIC, lessened bacterial production of PopD (Figure 24
C). These data suggested that the drugs affected the assembly/production of the
bacterial T3S apparatus. Unexpectedly, T3S-T-ExoS was more evident in cells treated
with either AEBSF or PIC, than control cells treated with carrier compounds or no drug.
Despite greater amounts of T3S-T-ExoS, modification of RalA or Rac1 or ExoS autoADP-ribosylation was not evident (Figure 24 D). Also, despite a less robust production
of PopD in AEBSF-treated Pa strains, there was enough PopD produced to allow T3ST. These results could indicate that only a minimal amount of PopD is required for T3ST or that another Pa T3S protein can substitute for function. Overall, these results
indicate that AEBSF interfered with both Pa PopD production, and with T3S-T-ExoS
ADPRT activity.
Role of the R146 GAP residue in T3S-T of ExoS
Seven ExoS-HA tagged mutants, which included single or combination mutations in
the GAP (R146) and ADPRT (E379, E381) activities of ExoS, were constructed using
the pUCP-ExoS-HA construct provided by Joe Barbieri (Medical College of Wisconsin,
Milwaukee, WI). These mutants allowed further exploration of mechanisms associated
with their recognized differences in substrate specificity (refer to Figures 21 C and 22),
and also to examine the effects of the mutations on the T3S-T of ExoS. For these
studies, eukaryotic cells were co-cultured with PA103∆UT expressing wild-type or
mutant forms of ExoS-HA. Following the co-culture, eukaryotic cells were harvested and
fractionated into cytosolic and membrane fractions.
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HSP70
ExoS-HA

HSP70
ExoS-HA

Figure 25. Effect of GAP and ADPRT mutations on the T3S-T of ExoS.
Membrane fractions were obtained by the digitonin extraction method (described in the
Methods and Materials) from eukaryotic cells after co-culture with PA103∆UT
expressing wild type ExoS (wtS), the indicated mutant ExoS, or empty vector control,
pUCP (pU). Samples were resolved by SDS-PAGE and immunoblotted for loading
control, HSP70, and ExoS-HA. Auto-ADP-ribosylated forms of ExoS are indicated by an
asterisk.
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T3S-T-ExoS was predominately found in the membrane fraction. In examining, the T3Stranslocation of ADPRT mutants, both E379 and E381 mutants were T3S-T into
membrane fractions similarly to wild type ExoS in both rodent and human cell lines
(Figure 25). These results indicated that the limited or lack of ADP-ribosylation of
substrates by the E381A and E379A ExoS mutants, respectively, was not due to the
lack of T3S-T. Interestingly, auto-ADP-ribosylated forms of ExoS were detected only for
wild-type T3S-T-ExoS and T3S-T-ExoSR146A (asterisks, Figure 25). Mutation of
R146A, in the absence or in combination with E379A and/or E381A mutations, resulted
in more efficient T3S-T of ExoS as compared to wild type ExoS (Figure 25). Results for
the T3S-T of R146A/E379A were consistent with R146 contributing to increased T3S-T
of ExoS (data not shown). These results support a role of the R146 residue in either
regulation of T3S-T or in signals that mark T3S-T-ExoS for degradation.
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Figure 26. Immunoprecipitation of T3S-T-ExoS.
T24 (extensive pattern) or TCMK-1 (restrictive pattern) cells were co-cultured with
PA103∆UT expressing empty vector pUCP (pU) or pUCP-ExoS-R146K-E379/81D3XFLAG (S). A. Cells were harvested and T3S-T-ExoS was immunoprecipitated with
M2 FLAG antibody immobilized to resin (Sigma) as described in the Methods and
Materials. As a negative control, the IP procedure was performed using lysis buffer only
(Blank, Bl). Eluates from the IP reaction were resolved by SDS-PAGE, followed by
Western blot analysis using the M2 FLAG mouse monoclonal antibody (Sigma) and
anti-HSP70 antibody (BD Transduction Labs) (followed by anti-mouse IgG::HRP) or
only, anti-mouse IgG, conjugated to HRP. B. Total lysates samples were resolved by
SDS-PAGE and immunoblotted with M2 anti-FLAG tag (Sigma) and anti-HSP70 (BD
Transduction Labs).
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T3S-T-ExoS protein interactions within rodent and human cell lines
An important objective of these studies was to identify a mechanism for the
differential targeting of T3S-T-ExoS ADPRT activity in rodent and human cell lines.
Initially we attempted to localize T3S-T-ExoS-HA within the eukaryotic cell by
immunofluorescence and flow cytometry, but the high background precluded meaningful
interpretations of results. We next performed co-immunoprecipitation (Co-IP) assays to
identify proteins that interact with T3S-T-ExoS, as a means to understand how
intracellular ExoS ADPRT activity is targeted.
Originally, Co-IP studies were attempted with ExoS-HA constructs, but there were
difficulties in interpreting the results due to high background from immunoglobulin G
(IgG) heavy and light chains, and protein A as well as limited T3S-T of wild type ExoSHA (refer to Figure 25). Given these limitations, we chose to use an enzymatically
inactive construct of ExoS, with mutations in the GAP and ADPRT regions (R146K,
E379D, E381D) that included a C-terminal triple FLAG tag (ExoS-KDD-3XFLAG) (gift
from Joe Barbieri, Medical College of Wisconsin) for these studies. Mutation of R146
has been shown to facilitate T3S-T of ExoS (refer to Figure 25). The use of the 3X
FLAG epitope in combination with the M2 FLAG antibody immobilized to resin for the
Co-IP reaction, eliminated the background from Protein A and reduced background from
IgG. However, using an enzymatically inactive form of ExoS, potentially compromised
the detection of protein interactions directed by key catalytic residues in ExoS.
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Figure 27. Silver stain analysis of T3S-T-ExoS IP eluates.
IP eluates were obtained from T24 (extensive pattern) and TCMK-1 (restrictive pattern)
cells co-cultured with PA103∆UT expressing pUCP or pUCP-ExoS-R146K-E379/81D3XFLAG (ExoSi). As a negative control (Bl), lysis buffer alone was added to the M2
FLAG antibody-immobilized resin. Samples were resolved by SDS-10% PAGE and gels
were silver stained using A. the Gel Code Color Silver Stain Kit (Pierce) and B.
SilverSNAP Stain for Mass Spectrometry (Pierce). Molecular weights of standards are
indicated. A single asterisk indicates proteins identified in IP eluates from both ExoSi
treated cell lines. A double asterisk indicates proteins found in either T24 or TCMK-1
cells treated with ExoSi producing bacteria. All astericked proteins in B. were excised
for MALDI-MS analysis. The SilverSNAP Stain for Mass Spectrometry was found to
lightly stain gels, but unique proteins in T24-ExoSi (40 and 45 kDa) and TCMK-1-ExoSi
(70 and 85 kDa) IP eluates were more easily identifiable.
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Figure 28. T3S-T ExoS co-immunoprecipitates with 14-3-3.
As previously described, total lysates and Co-IP eluates were obtained from T24 and
HT-29 cells (extensive pattern), and TCMK-1 and Swiss-3T3 (Swiss) cells (restrictive
pattern) after co-culture with PA103∆UT expressing empty vector pUCP (p) or pUCPExoS-R146K-E379/81D-3XFLAG (S). Samples were resolved by SDS-12% PAGE,
followed by Western blot analysis using an anti-14-3-3 rabbit polyclonal antibody
(Upstate Biotechnology), which recognizes ζ, γ, and η 14-3-3 isoforms.

138

We co-cultured rodent and human cell lines with PA103∆UT expressing ExoS-KDD3XFLAG and T3S-T-ExoS and interacting proteins were extracted in a CoIP reaction.
Samples were resolved by SDS-PAGE and either processed for Western blot analysis
or silver stain analysis. Western blot analysis revealed that ExoS was successfully
being immunoprecipitated from eukaryotic cells, albeit in the presence of a minimal IgG
background (Figure 26). As a negative control, Co-IP eluates were immunoblotted for
HSP70, which was not evident (data not shown). In comparison of Co-IP samples from
rodent and human cell lines, two bands, which were approximately 27 and 30 kDa in
size, were present in both samples treated with ExoS-KDD-3XFLAG expressing
bacteria (Figure 27). The 30 kDa protein was identified by MALDI-MS to be the ε
isoform of the 14-3-3 protein family by matching 13 out of 214 peptides, with 50%
coverage and a MOWSE score of 5.065e + 05 (J. Carroll, personal communication).
The 27 kDa protein was tentatively identified as a 14-3-3 protein (ζ, γ, or η isoform) by
Western blot analysis (Figure 28). The identification of 14-3-3 proteins in Co-IP eluates
from cells treated with ExoS-KDD-3XFLAG expressing bacteria served as a positive
control. Additionally it is currently unknown which 14-3-3 isoform(s) interact with T3S-TExoS. ExoS also purified with 40 kDa and a 45 kDa human protein, and a 70 kDa and
an 85 kDa rodent protein. The identification of different T3S-T-ExoS interactive proteins
in rodent and human cells supports the hypothesis that the differential targeting of T3ST-ExoS ADPRT activity within human and rodent cell lines is due to differential protein
interactions.
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Discussion
To further explore the mechanism underlying the differential targeting of T3S-TExoS to substrates in rodent and human cell lines (197), we designed studies to: 1)
further characterize the differences in substrate specificity, and 2) identify mechanisms
responsible for the differences in substrate specificity. All of these studies were based
on the perspective that the host cell contributes to Pa T3S process. An example of host
cell influence on the targeting of ExoS ADPRT activity is in the comparison of the
repertoire of proteins that ExoS ADP-ribosylated in rodent cell extracts in vitro, including
Ras, RalA, Rab proteins and Rac1, to the limited proteins that T3S-T-ExoS ADPribosylated in the cell, including only Ras and RalA (197).
Analysis of substrates targeted by wild type or mutant ExoS in vitro revealed that
mutation of either glutamic acid, 379 or 381, resulted in a lack of substrate modification
and lack of auto-ADP-ribosylation of ExoS (personal observation) in both rodent and
human cell extracts. These results confirmed previous in vitro studies, which
characterized E381 as the critical residue for ExoS ADPRT activity (141). Unexpectedly,
T3S-T-ExoSE381A ADP-ribosylated Ras and RalA in both rodent and human cell lines,
but did not target Rab proteins or Rac1 in human cells. An auto-ADP-ribosylated form of
ExoS-E381A-HA also was not observed in either rodent or human cell lines. These
results indicated that the ExoS-E381A mutant exhibited ADPRT activity only after T3S-T
into eukaryotic cells. These results were consistent with previous studies that indicated
that the host cell could limit and influence the molecular targeting of T3S-T-ExoS
ADPRT activity (65, 193, 197), which led to the examination of the influence of
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intracellular localization and protein interactions on the targeting of ExoS ADPRT
activity in rodent and human cells.
It was observed that ExoS ADPRT activity is found mainly in the membrane fraction
of eukaryotic cells (64, 188). Concordantly, a membrane localization domain (MLD) was
found to reside within residues 51-72 of ExoS and to localize T3S-T-ExoS to eukaryotic
membranes. Loss of the MLD caused T3S-T-ExoS to localize to the cytosolic fraction of
eukaryotic cells (176). The restrictive pattern of substrate modification was observed in
human cells following T3S-T of ExoS∆MLD, and there was a modest decrease in the
ability of T3S-T-ExoS to ADP-ribosylate proteins in rodent cells, which intrinsically
exhibit the restrictive pattern of substrate modification. The ability of ExoS∆MLD to
ADP-ribosylate target proteins was similar to results observed upon T3S-T of the ExoSE381A mutant, which resulted in a restrictive substrate modification pattern in human
cells, but did not alter the substrate modification pattern observed in rodent cells. The
decreased ability of ExoS∆MLD to ADP-ribosylate cellular proteins was linked to the
inappropriate localization of ExoS to the cytosol. In contrast, T3S-T-ExoS-E381A
localized to membrane fractions similarly to wild type ExoS in both rodent and human
cell lines. These data indicated that inappropriate intracellular localization or
handicapped ADPRT activity can lead to similar restrictive patterns of substrate
modification, which suggests that there may be more than one mechanism affecting the
intracellular targeting of ExoS ADPRT activity.
As mentioned previously, the functional role of T3S-T-ExoS auto-ADP-ribosylation,
observed both in vitro and within the cell, has not yet been described (189). Auto-ADPribosylation by other bacterial ADPRT toxins, such as E. coli heat labile enterotoxin
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(LTA), has been noted to occur in in vitro reactions, but not within the cell and
seemingly without any functional consequence to the toxin (223). In contrast, studies
examining mammalian ADPRT’s have found that auto-ADP-ribosylation affects enzyme
function. For example, auto-ADP-ribosylation of ADP-ribosyltransferase 5 (ART5) was
shown to decrease NADase activity, while increasing ADPRT activity of the molecule,
implicating a role of auto-ADP-ribosylation in the regulation of the enzyme’s function
(244). ExoS has been shown to closely resemble mammalian ADP-ribosyltransferases,
as evident in: 1). the sequence homology between the catalytic domain of ExoS and
domains of vertebrate ADPRTs, 2) both ExoS and eukaryotic ADPRT’s ADP-ribosylate
cellular proteins at more than one site, and 3). ExoS, like eukaryotic ADPRTs, targets
multiple proteins (72). These similarities suggest that ExoS auto-ADP-ribosylation may
regulate ExoS ADPRT activity.
Initial studies indicated that the purpose of ExoS auto-ADP-ribosylation was to down
regulate ExoS GAP activity by auto-ADP-ribosylating the R146 residue (189). However,
the GAP activity of ExoS was hard to discern in non-macrophage, mammalian cell lines
(64, 192, 193), and the recorded effect of ExoS auto-ADP-ribosylation of the GAP
region was unimpressive (189). In these studies, auto-ADP-ribosylation was observed
to occur with ExoS-R146A GAP mutant, confirming that the R146 residue was not the
only potential arginine target of auto-ADP-ribosylation. ExoS auto-ADP-ribosylation was
observed following the T3S-T of wild type or R146A mutant ExoS in rodent and human
cells, and appeared to require both E379 and E381 residues. Linking these results to
previous observations about the role of E381 in the intracellular targeting of ExoS
ADPRT activity indicate that the E381 residue of ExoS may contribute to ExoS auto-
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ADP-ribosylation in all cells lines, the extensive pattern of ExoS substrate modification
in human and simian cell lines, but not to ExoS substrate ADP-ribosylation in rodent cell
lines. Therefore, upon T3S-T of ExoS into rodent cells, the activity of E381 may be
limited to auto-ADP-ribosylation only, without influencing ExoS substrate ADPribosylation.
The observation that the T3S-T-ExoS-R146A mutant seemingly ADP-ribosylated
substrates more efficiently than wild type T3S-T-ExoS, prompted studies which
examined the T3S-T of ExoS-R146A mutants into eukaryotic host cells. These studies
found that mutation of R146 (alone or in combination with ADPRT mutations) resulted in
increased T3S-T of ExoS into both restrictive and extensive pattern cell lines. These
data indicated that ExoS GAP activity may play a role in regulation of bacterial
translocation or overall stability of the protein. Previous studies, which explored the
T3S-T of YopE, found that the GAP activity of YopE (the GAP domain of YopE has
sequence homology to that of ExoS (259)) acted in part to prevent actin polymerization,
by downregulating RhoGTPase activity, to prevent the T3S apparatus from forming
pores in the eukaryotic cell membrane (240). This was evident in that mutation of the
GAP activity in YopE resulted in cell lysis by the pores formed by the T3S-apparatus. In
our studies, mutation of the GAP activity did not result in cell lysis or death (data not
shown). However, we wished to determine if the integrity of the eukaryotic cell
cytoskeleton influenced the T3S-T of ExoS. To examine if the GAP region of ExoS
functioned similarly to YopE by altering the status of the cytoskeleton, we treated T24,
human epithelial, cells with cytochalasin D, which inhibited actin polymerization, and
colchicine A, which inhibited microtubule polymerization, prior to co-culture with ExoS-
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HA or ExoS146-HA bacteria. Interestingly, both drugs influenced the T3S-T of wild type
ExoS-HA, but not ExoS-R146A-HA. These results indicate that potentially both actin
and microtubule components play a role in the T3S-T of ExoS. These results also
suggest that the GAP activity controls the amount of ExoS which is T3S-T into
eukaryotic cells, independently of the cytoskeleton. However, these results do not rule
out the possibility that proper intracellular degradation of T3S-T-ExoS might rely on a
functional actin or microtubule cytoskeleton.
Results obtained by examining the T3S-T of both the R146A mutant and E381A
mutant highlighted areas of the T3S-T process about which very little is known, but in
which the host cell likely plays a role. These include: 1) the post T3S-translocation
processing/folding procedure that must occur to form a functional T3S effector, 2) T3ST-ExoS turnover, and 3) intracellular trafficking of T3S-T-ExoS. Given the 2-3 nm
diameter of the needle apparatus (18, 76, 94, 110), it has been hypothesized that all
T3S-effectors remain in a partially unfolded state to be translocated through the T3Sapparatus (220). This necessitates that the final folding of the T3S-effector occurs within
the eukaryotic host cell.
It has been hypothesized that ExoS is processed within the eukaryotic cell upon
T3S-T (177), and what appears to be a processed form of T3S-T-ExoS has been
observed in our studies. To better understand this process, we pretreated eukaryotic
cells with cell permeable protease inhibitors prior to co-culture with ExoS producing
bacteria. These studies identified the general serine protease inhibitor, AEBSF, as a
drug that negatively affected production of PopD, yet seemingly enhanced the T3S-T of
ExoS, but inhibited ExoS ADPRT activity. While these studies are curious, it is unclear if
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AEBSF inhibits transcription, translation or secretion of PopD. It is unlikely that AEBSF
acts as a global Pa T3S inhibitor, given that ExoS is produced and bacterially
translocated. This data supports the notion that the T3S-apparatus is formed after
treatment with AEBSF; however, the composition of the apparatus may be altered.
Previous studies found that in addition to PopD, PcrV and PopB were required for Pa
T3S-T, and that deletion of any one of the proteins inhibited T3S-T (67, 80, 81, 208,
235). The stability and solubility of PopD and PopB required a chaperone protein, PcrH
(210). Deletion of PcrH also resulted in inhibition of T3S-T (21). Since T3S-T of ExoS
was still observed in cells treated with AEBSF, it is unlikely that the drug caused
complete depletion of PopB, PcrV or PcrH. However it remains unknown if AEBSF
affects the production of these proteins in a manner that would deregulate T3S-T of
effectors. These studies were limited by the lack of examination of how AEBSF affected
the T3S-T of other Pa effectors.
The negative effect of AEBSF on T3S-T-ExoS ADPRT activity suggested that
AEBSF interfered with the serine protease responsible for T3S-T-ExoS processing.
AEBSF is a general serine protease inhibitor, which has been found to act as an
inhibitor of eukaryotic cell differentiation (14), a caspase inhibitor (42), a tumor
angiogenesis inhibitor (184), and lysosome associated protein cleavage disregulator
(39). Therefore, the negative effects of AEBSF on T3S-T-ExoS ADPRT activity may be
due to a wide-range of indirect effects, unrelated to T3S-T-ExoS intracellular
processing. Interestingly, aprotinin and leupeptin, which are components of the PIC and
serine protease inhibitors, did not affect T3S-T-ExoS translocation or ADPRT activity,
indicating that there may be specificity in the action of AEBSF.
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Critical to understanding how the host cell modulates T3S-T-ExoS ADPRT activity is
gaining insight into how T3S-T-ExoS is trafficked within rodent and human cell lines.
Previous studies found that T3S-T-ExoS ADP-ribosylated Rab proteins in a distinct
order (65), providing a clue that T3S-T-ExoS may be trafficked via vesicles in human
cells. Attempts at tracking T3S-T-ExoS by both immunofluorescence and flow cytometry
did not yield meaningful data due to the high amounts of background staining in both
assays. Subcellular fractionation of cells treated with ExoS-HA-producing bacteria has
not been attempted. While these studies would be beneficial to understanding the
intracellular localization of T3S-T-ExoS, very little wild type ExoS-HA could be
visualized in cells fractionated into cytosolic and membrane fractions, indicating a
potential difficulty in identifying T3S-T-ExoS within specific cellular compartments.
Therefore, a proteomics approach was designed, which involved co-culturing eukaryotic
cells with ExoS-producing bacteria and then co-immunoprecipitating ExoS with
interacting proteins. The identification of T3S-T-ExoS-interacting proteins was
hypothesized to lead to the identification of the intracellular location of ExoS. In
comparisons of co-immunoprecipitates from human and rodent cell lines, different T3ST-ExoS-interacting proteins were isolated in both human and rodent cell lines.
Preliminary results from MALDI-TOF indicate that the human ExoS-interacting proteins
may be involved in lysosomal trafficking (J. Carroll, personal communication). These
results support the hypothesis that T3S-T-ExoS ADP-ribosylates distinct eukaryotic
proteins in a restrictive and extensive pattern cell lines, in part, because of differences in
interacting proteins or intracellular location.
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Two similar proteins co-immunoprecipitated with T3S-T-ExoS from rodent and
human cells, and are thought to be 14-3-3 isoforms (J. Carroll, personal
communication). There are seven different isoforms of 14-3-3 found in mammalian cells:
ζ, ε, γ, β, σ,η, τ (1); all of which are capable of stimulating ExoS ADPRT activity in vitro
(268). Little is known about which 14-3-3, isoform interacts with T3S-T-ExoS within
cells. Since, 14-3-3 proteins regulate subcellular localization, stability and molecular
activity of their target proteins (46), characterizing the interaction of 14-3-3 with T3S-TExoS may be the key to understanding the intracellular targeting of ExoS ADPRT
activity. Comparisons of the amino acid sequences of Homo sapiens and Mus musculus
14-3-3 isoforms, found the ζ and ε isoforms to be identical, while all other isoforms
displayed differences in one or more amino acids (personal observation). Differences in
conserved proteins among mammals have previously been found to affect the outcome
of infectious agents. One such example is the single residue difference between the
human and mouse E-cadherin, which resulted in an abrogated infectivity of Listeria in
mice (132).
Further analysis of Co-IP samples by MALDI-TOF should reveal potential
differences in T3S-T-ExoS-14-3-3 interactions as well as positive identification of the
unique proteins which interact with T3S-T-ExoS in rodent or human cell lines. It is
currently unclear if ExoS interacting with different proteins in rodent and human cells
would have a direct affect on the intracellular targeting of ExoS ADPRT activity, but the
identification of ExoS-interacting proteins is expected to reveal the intracellular location
of ExoS in rodent and human cell lines. Defining the differences in how T3S-T-ExoS
ADPRT activity is targeted within rodent and human cell lines will provide a better
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understanding of how the host cell influences the T3S-T process and directs effector
activity.
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Chapter 5: Discussion
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The bacterial T3S system allows the microbe to hijack host cell function to its
advantage. In general, discussions and studies about T3S focus on the bacterial side of
the process. Many elegant studies have shown that bacterial T3S effector proteins
ingeniously mimic the function of eukaryotic proteins to manipulate the host cell (221).
Currently, there is very little known about the eukaryotic cell contribution to the T3S
process. Given the intimate nature of the bacterial-eukaryotic cell association required
for T3S to occur, it is bold to assume that the eukaryotic cell is a passive participant in
this process. However, in most studies, the role of the host cell in the T3S process is
eclipsed by the overt pathogenicity of most Gram-negative organisms. An advantage to
studying Pa is that this organism will only cause disease if the host is compromised. By
nature, Pa colonization and infection of the host is a negotiation rather than a hostile
takeover. Early studies of Pa T3S revealed that subconfluent monolayers of eukaryotic
cells were sensitive to Pa T3S-T of ExoS, while confluent cells were less sensitive (58,
115, 154). These were the first studies indicating that the status of the host cell
influences T3S, corresponding to the opportunistic nature of Pa infections.
In 1978, ExoS was characterized as a Pa ADPRT toxin distinct from exotoxin A
(ETA) (106). In mouse models of infection, ExoS was noted to contribute to Pa
dissemination (162, 163), but curiously, ExoS was nontoxic by itself to tissue culture
cells and animals (25, 162, 170). The inability to assign a cellular effect to the ExoS
prompted genetic analysis of its regulation and transcription. These studies led to the
recognition that Pa harbors a T3S system, homologous to the Yersinia T3S system
(258, 260). There are four known Pa T3S effector proteins (ExoS, ExoT, ExoU and
ExoY), but ExoS is the best characterized effector.
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ExoS is a bifunctional protein and serves both as a GAP targeting Rho, Rac and
Cdc42 in vitro (77), and an ADPRT targeting mainly low molecular weight G-proteins in
vitro (30, 63, 65). The broad range of target substrates of ExoS ADPRT activity
differentiates ExoS from other bacterial ADP-ribosyltransferase toxins, which are highly
specific. Transfer of an ADP-ribose moiety to a target protein typically alters or destroys
the function of that protein. For example, ETA ADP-ribosylation of elongation factor-2
(EF-2) inhibits protein synthesis in the eukaryotic cell (105). Endogenous eukaryotic
ADPRTs have also been identified that regulate cellular processes. Coordinate to a
eukaryotic ADPRT, a cognate ADP-ribose hydrolase may reverse the addition of ADPribose moieties to target proteins. For instance, polymerization of a muscle cell
cytoskeletal component, desmin, has been found to be controlled in part by ADPribosylation. ADP-ribosylation of desmin results in the inability of desmin to form
filaments, and the cognate ADP-ribosyl hydrolase allows desmin to re-form filaments
(100, 101). EF-2, which is a target of Pa ETA and diphtheria toxin (DT) ADPRT activity
(31, 105), has been found to be ADP-ribosylated by endogenous eukaryotic ADPRTs
(35, 53). While this reaction has not been fully characterized, the eukaryotic ADPRT
was found to ADP-ribosylate a subset of total cellular EF-2 and the ADPRT reaction
was found to be reversible (53). These studies suggest that bacterial toxins mimic the
actions of eukaryotic ADP-ribosyltransferases, but the lack of a cognate ADP-ribose
hydrolase that renders the bacterial ADP-ribosylation permanent and consequently
detrimental to eukaryotic cell function.
In studies characterizing the functional effects of T3S-T-ExoS, the ADPRT activity of
ExoS was found to be required for ExoS-specific inhibition of DNA synthesis, permanent
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cell rounding, and inhibition of adherence processes (64). Notably, the effects of ExoS
on cell function have not thus far been linked to the ADP-ribosylation of a particular
substrate. Current theories suggest that T3S-T-ExoS effectively inactivates host cell
function by the collective ADP-ribosylation of eukaryotic proteins. While ExoS targets
multiple proteins, recent studies have found that the eukaryotic cell environment limits
the substrates targeted by T3S-T-ExoS ADPRT activity (65, 89, 193, 197). Previous
studies in our laboratory using the HT-29 human epithelial cell line, identified Ras, RalA,
Rabs 5, 7, 8, 11, Rac1 and Cdc42 as targets of T3S-T-ExoS (63, 65). Importantly, Rab4
or Rap proteins were identified as targets of ExoS ADPRT in vitro, but not within
eukaryotic cells (30, 63, 65). In time-course co-culture studies, T3S-T-ExoS was found
to ADP-ribosylate proteins in a specific order; Ras, RalA and Rab5 were targeted first,
followed by ADP-ribosylation of Rabs 8 and 11, and lastly, Rab7 and Rac1 (65).
Combined, these studies indicated that the host cell limits and specifies the substrates
targeted by T3S-T-ExoS ADPRT activity.
During studies of the cellular effects of ExoS ADPRT, further understanding of how
the host cell contributes to and influences T3S-T-ExoS ADPRT activity began emerging.
The goal of my studies was to characterize the role of the host cell in the Pa T3S-T of
ExoS. Specifically, these studies have: 1) shown that cell origin influences T3S-T-ExoS
ADPRT substrate specificity, 2) determined that the host cell influences Pa T3S at the
level of membrane translocation, and 3) provided evidence that T3S-T-ExoS protein
interactions might influence ExoS ADPRT intracellular trafficking.
In studying the effects of T3S-T-ExoS on rodent fibroblasts and human epithelial
cell function, it was found that the rodent fibroblasts were typically less sensitive than
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human epithelial cells to the effects of ExoS on DNA synthesis, permanent
morphological alterations and readherence. These results correlate with the
identification of two patterns of T3S-T-ExoS ADP-ribosylation of substrates: 1) a
restrictive pattern, showing a single modification of Ras and RalA; 2) an extensive
pattern, recognized as more efficient modification of Ras and RalA and modification of
Rabs 5, 7, 8, 11 and Rac1. The pattern of T3S-T-ExoS substrate modification was not
linked to cell type or efficiency of T3S-T of ExoS, but to the species of origin, with rodent
cell lines exhibiting the restrictive pattern of ADP-ribosylation, and simian and human
cell lines exhibiting the extensive pattern of ADP-ribosylation (197).
Previous studies identified another instance in which human and rodent cell lines
displayed differential sensitivities to a bacterial ADP-ribosyltransferase. Studies which
examined cellular sensitivity to DT found that cells of monkey origin were the most
sensitive to DT, followed by human and hamster cells, while cells of mouse and rat
origin being resistant (157). Further examination showed that mouse and rat cells lack
the receptor required for DT fragment B binding and subsequent translocation of DT
fragment A (48, 222). In contrast to DT, ExoS was T3S-T equally well taken up by cells
of rodent origin, even though the end result was a restrictive pattern of substrate ADPribosylation (197). With regard to T3S-T-ExoS cytotoxicity, the limiting factor does not
appear to be bacterial binding or T3S-T of the effector protein, but instead related to
how the toxin is targeted by the mammalian cell.
The importance of the finding that T3S-T-ExoS targets proteins differently in rodent
and human cells is the identification of a model system to study factors that determine
intracellular T3S-effector targeting and may ultimately provide clues to understanding
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eukaryotic cellular trafficking mechanisms. The rodent cell lines (NIH-3T3 and Swiss3T3) used in our studies were found to be less sensitive than the human cell lines (HT29 and LNCaP) to the effects of ExoS. Subsequent studies examining the effects of
T3S-T-ExoS on morphological alterations found other rodent cell lines (TCMK-1, CHOK1) to be just as sensitive as HT-29 or LNCaP human cell lines to T3S-T-ExoS-induced
cell rounding, and simian and human cell lines (Cos-1, Vero, WI-38) to show similar
rounding patterns as NIH-3T3 and Swiss-3T3 cells (personal observation). Despite the
differences in sensitivity of individual cell lines to the morphological effects of T3S-TExoS, the patterns of ExoS ADP-ribosylation remained consistent within rodent
(restrictive) and human and simian (extensive) cell lines. These qualitative comparisons
highlight the notion that while cellular reactions to T3S-T-ExoS vary, ExoS substrate
targeting remains constant and dependent on mammalian origin.
In examining the effects of T3S-T-ExoS on different cell lines, HL-60 myeloid cells
were found to be resistant to the effects of ExoS on cell function, which corresponded
with a lack of ADP-ribosylation of eukaryotic proteins. Differentiation of HL-60 cells with
a phorbol ester, TPA, induced HL-60 cell sensitivity to effects of ExoS on cell
morphology and ExoS ADP-ribosylation of substrates. Studies examining mechanisms
of resistance, including bacterial adherence, induction of Pa T3S and Pa T3S-T,
revealed that the resistance and TPA-induced sensitivity to ExoS related to Pa T3S-T of
ExoS (198). More bacteria were able to adhere to HL-60 cells than to TPA-HL-60 cells,
and HL-60 cells were able to induce the production of PopD, a protein required for T3ST. The inability to detect intracellular ExoS-HA in HL-60 cells, which nevertheless bound
Pa and induced PopD, indicated that an HL-60 cell property interfered with T3S-T of
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ExoS. It remains unknown if a functional Pa T3S apparatus is formed when Pa is in
contact with HL-60 cells.
Previous discussion of HL-60 cell resistance focused on cell surface features that
might be altered with TPA-differentiation (Chapter 3). Other studies examining
pharmaceutical induction of Pa T3S sensitivity or resistance showed that treatment of
HL-60 cells with colchicine A, which disrupts microtubules, prior to co-culture with ExoS
producing bacteria, allowed ADP-ribosylation of Rab5 and RalA (E. Rucks, unpublished
data). Treatment of cells with colchicine A did not affect normal cellular distribution of
either Rab5 or RalA, as assessed by cell fractionation studies. In addition, treatment of
T24 cells with colchicine A also resulted in increased T3S-T of ExoS, compared to
untreated cells. Combined, these data suggest that a possible mechanism affecting
T3S-T-resistance or sensitivity relates to the cytoskeletal structure of eukaryotic cells
interacting with Pa. Polarized epithelial cells, like HL-60 cells, are resistant to Pa T3S-T
(34, 58, 115, 154), and both cell types can be induced to become T3S-T-sensitive,
through non-polarization or TPA-differentiation, respectively. Polarized epithelial
monolayers exhibit an asymmetrical microtubule arrangement with the minus ends of
microtubules being anchored at apical surface and plus ends being at the basal surface
(9). In contrast, undifferentiated HL-60 cells exhibit a concentrically symmetrical
microtubule organization, with microtubules radiating from a central location (136). Upon
conversion to T3S-T-sensitivity, non-polarized epithelial monolayers exhibit properties of
both symmetrical and asymmetrical microtubule organization, with microtubules
radiating from the centrosome and Golgi complex (9, 160). Upon TPA differentiation and
induction of T3S-T-sensitivity in HL-60 cells, the microtubule network stretches into
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pseudopodia from the centriolar region, in association with a loss of symmetrical
arrangement (112). While no obvious microtubule commonality is recognized in T3S-Tresistant cells, alterations in microtubule symmetry may be a feature common to the
induction of T3S-T-sensitivity by increasing the efficiency of the T3S-T process.
Recent studies have drawn attention to possible modulatory influences the
eukaryotic cell can have on ExoS function. Notably, T3S-T-ExoS ADPRT activity was
found to be enhanced in the membrane compartment of epithelial cells (64, 188). The
enhancement of ExoS ADPRT activity within the cell was further evident in the detection
of Ras and RalA modification upon T3S-T of an ExoS ADPRT E381A mutant, which
was unable to modify either protein in vitro (64) (Chapter 4). Correlating with these
findings was the identification of ExoS having a membrane localization domain (MLD) in
ExoS (176). T3S-T of ExoS∆MLD lacking this domain results in cytosolic ExoS
localization and decreased ADP-ribosylation of euakaryotic substrates (176). These
studies indicate the importance of ExoS membrane localization for ADPRT activity,
which supports the hypothesis that ExoS membrane localization optimizes interaction of
ExoS with eukaryotic cofactor required for ExoS ADPRT activity.
Studies examining the cellular effects of an ExoS GAP R146A mutant also provided
evidence that ExoS GAP activity modulates ADPRT function within the eukaryotic cell
(64). The complex interactions of the domains is illustrated with Rac1, a LMWG-protein,
which has been identified as a target of both ExoS GAP and ADPRT activities (65, 77,
193). Rac1 regulates multiple cellular processes, including phagocytosis and cell
motility, partly by controlling cytoskeleton dynamics. It is a primarily cytosolic protein,
but upon activation, GTP-bound Rac1 localizes to the membrane where it interacts with
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downstream effector PAK (229). After T3S-T of ExoS into human epithelial cells, ExoS
was found to ADP-ribosylate Rac1, leading to Rac1 activation and membrane
association, as indicated by ADP-ribosylated Rac1 interaction with PAK and cellular
fractionation analysis, respectively (65, 193). In contrast, in macrophages, Rac1 was
found to be a target of T3S-T-ExoS GAP, rather than ADPRT, activity, which resulted in
inactivation of Rac1 and prevention of phagocytosis (192). Recent studies found that
T3S-T-ExoS targeted Rac1 by either GAP or ADPRT activities, but not both, and that
these differences in ExoS targeting correlated with subtle differences in Rac1
subcellular localization within human epithelial and murine macrophage cells (193).
Combined, these data indicate that the GAP and ADPRT domains of ExoS are
modulated within the context of the host cell.
A role of R146A in the GAP domain in the effectiveness of T3S-T of ExoS has also
been identified. Mutation of R146A resulted in increased levels of T3S-T-ExoS in
eukaryotic membrane and cytosolic fractions. The more efficient translocation of R146A
ExoS did not lead to alteration of the substrate modification pattern of T3S-T-ExoS.
These data indicate that R146A may have a regulatory role at the level of T3S-T of
ExoS and/or subsequent ADPRT activity. Previous studies indicated that R146 was the
preferential site of ExoS auto-ADP-ribosylation, but loss of this site does not completely
abrogate auto-ADP-ribosylation activities in vitro (189). In our studies we found that the
R146A mutant was still efficiently auto-ADP-ribosylated within the eukaryotic cell. It has
been reported in eukaryotic ADPRT proteins, auto-ADP-ribosylation serves as a means
of regulating enzymatic function (244). Therefore, with mutation of R146, T3S-T-ExoS
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may be auto-ADP-ribosylating at an alternative site that results in disregulation of a
feedback mechanism controling the amounts of ExoS that is T3S-T or ADPRT active.
If R146 controls the amount of ExoS that is bacterially translocated, its mutation
could have an effect on the translocation of other Pa T3S effector proteins. The R146A
mutation does not result in greater bacterial secretion of mutant ExoS compared to wild
type ExoS in eukaryotic cell-free bacterial cultures, suggesting that a host cell process
influences altered amounts of T3S-T-ExoS-R146A. This abberation can be studied by
monitoring the T3S-T of ExoT or ExoY in strains expressing ExoS-R146A-HA. If ExoSR146 serves as a general regulator of Pa T3S-T, an increase in the translocation of
ExoT or ExoY would be expected in strains expressing ExoS-R146A, as compared to
wild type ExoS. Interestingly, ExoT also harbors a GAP domain (114, 122), which could
function similarly to that of ExoS. If ExoS GAP activity, in combination with a host cell
process, regulated intracellular amounts of T3S-T-ExoS, then translocation of wild type
ExoT or transfection of the ExoS GAP domain would be expected to result in normal
intracellular levels of T3S-T-ExoS R146A GAP mutant relative to intracellular levels of
wild type ExoS. In summary, current studies suggest that specific ExoS residues, in
combination with host cell processes, influence the translocation and intracellular
targeting of ExoS activity.
Current data indicate that T3S-T-ExoS interacts with different proteins, in
association with its different ADPRT substrate modification patterns in human and
rodent cell lines. Using a Co-IP approach to identify ExoS-associated proteins within
eukaryotic cells, ExoS was found to associate with 14-3-3 proteins in both rodent and
human cell lines. This finding is consistent with the known interaction of Exos with its
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14-3-3 cofactor in vitro and confirmed the utility of this Co-IP approach to identify ExoS
interactive proteins. In addition, ExoS was found to interact with 40 and 45 kDa proteins
in human cells and 70 and 85 kDa proteins in rodent cell lines. While the identity of
these proteins has not been confirmed, it is expected that their identification will provide
insight into the differential subcellular localization of T3S-T-ExoS within rodent and
human cells.
The identification of these proteins could also elucidate intracellular trafficking
mechanisms of ExoS. In human cell lines, ExoS has been found to ADP-ribosylate Rab
proteins, which are located in different subcellular compartments, in a distinct order: first
Rab5, then Rabs 8 and 11, and lastly Rab7 (65). Rab5 resides in clathrin coated
vesicles and early endosomes; Rab8 resides within the trans-Golgi region and on
secretory granules; Rab11 is found within the perinuclear recycling endosomes and
recycling endosomes from the Golgi apparatus; and Rab7 is found on late endosomes
(267). The timing of ExoS ADP-ribosylation of these Rab proteins supports the notion
that ExoS has sequential access to these subcellular locations. Interestingly, Rab4,
which was not found to be a target of T3S-T-ExoS ADPRT activity, has been found
associated with early sorting endosomes, and is also present on vesicles with Rab5
(early sorting endosomes) and Rab11 (perinuclear recycling endosomes) (217, 267).
Previous studies indicated that Rab4 is central to early endosomal pathways in the
ability to facilitate the trafficking of Rab5 associated vesicles to Rab11 (217). It was also
reported that ExoS ADP-ribosylation of Rab5 interfered with protein function, implicating
a functional role of ExoS ADP-ribosylation in the targeting of Rab proteins (10). These
observations, in combination with lack of ExoS ADP-ribosylation of Rab4, support the
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notion that within human cells ExoS selectively targets Rab proteins in a manner that
facilitates intracellular effector transport.
It is currently unknown why ExoS ADPRT activity targeted Rab proteins in human
and simian cell lines but not in rodent cell lines. The identification of ExoS-interacting
proteins may be the first step to understanding a mechanism of these differences. ExoS
requires interaction with the cofactor 14-3-3. These studies have confirmed the
interaction of ExoS with 14-3-3 in both rodent and human cell lines, the specific
isoforms have not yet been identified. The significance of this would be to determine if
ExoS interacts with the same or different 14-3-3 isoforms in rodent and human cell
lines. As mentioned previously, only two out of seven 14-3-3 isoforms have identical
amino acid sequences in comparison of rodent and human. Any difference in ExoS-143-3 interactions in rodent and human cells might result in different protein interactions
and intracellular localization of ExoS. Therefore, understanding these differences would
determine a mechanism for different intracellular trafficking of ExoS ADPRT in rodent
and human cell lines.
As mentioned previously, T3S-T-ExoS caused eukaryotic cell rounding within 3 to 4
hours of co-culture (170). Initial cell rounding is thought to be caused by ExoS GAP
activity disrupting actin filaments (178), while permanent cell rounding has been linked
to ExoS ADPRT activity (64). When considering T3S-T-ExoS intracellular trafficking
patterns, they must be considered in the context of a modified actin cytoskeleton.
Treatment of eukaryotic cells with colchicine A, which disrupts microtubules, enhanced
T3S-T of ExoS, similar to the effect of the R146A mutation on T3S-T of ExoS.
Unexpectedly, in human epithelial cells that have been treated with colchicine A and co-
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cultured with ExoS producing bacteria, ADP-ribosylation of RalA, Rab5 and Rab7 was
observed, indicating that ExoS could still gain access to these subcellular
compartments. Recent advances in understanding vesicular trafficking have shown that
Rab proteins, through interaction with kinesin-like motor proteins, direct the motility of
vesicles and organelles by a microtubule-dependent mechanism (47, 167, 168, 209).
Critical to linking T3S-T-ExoS intracellular trafficking to the microtubule cytoskeleton is
further characterization of the effects of colchicine A on ExoS substrate targeting and
pharmacological abrogation of vesicular trafficking mechanisms through the use of such
agents as brefeldin A. It is my current hypothesis that ExoS specifically alters the actin
cytoskeleton to allow for intracellular trafficking via a modified microtubule cytoskeleton,
and that multiple Rab proteins are ADP-ribosylated in human cells leaving only a subset
of Rab vesicles navigable. The subtle role of the host cell in this process is evident in
the modulation of ExoS activity via interaction with 14-3-3 and subsequent protein
interactions, which results in the restriction (rodent cell lines) or extension (simian and
human cell lines) of ExoS intracellular trafficking (Figure 29).
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Figure 29. Model of differential targeting of T3S-T-ExoS ADPRT activity
The restrictive pattern characteristic of rodent cells, ExoS is sequestered from vesicles
by interaction with a 70 kDa (unkp70) or 85 kDa (not depicted) protein. The extensive
pattern, seen in simian or human cells, ExoS interaction with a 40 kDa (unkp40) or 45
kDa (not depicted) protein aids in targeting ExoS to vesicles, which are then trafficked
on microtubule filaments (light yellow cylinders) from the plasma membrane to other
intracellular organelles, such as the trans Golgi region. ExoS ADP-ribosylation of itself
and eukaryotic proteins is indicated in orange stars. EE, early endosome; SE sorting
endosome; RE, recycling endosome.
An recent review written by Marino Zerial and Heidi McBride summarized the function of
Rab proteins, which provided the foundation required to relate ExoS ADP-ribosylation
patterns to eukaryotic intracellular trafficking mechanisms (267).
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In conclusion, studies described in this dissertation have recognized that the host
cell can influence the Pa T3S-T of ExoS by: 1) determination of ExoS ADPRT-substrate
restrictive or extensive modification pattern, 2) allowing of membrane translocation, and
3) targeting intracellular ExoS GAP or ADPRT activity potentially through protein
interactions or intracellular trafficking mechanisms.
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